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ABSTRACT 
Chronic conditions are on the rise due to an ageing and increasing global population.  
Medication adherence to treat chronic conditions is low, with good adherence on 
average ≤ 50% across a wide range of chronic conditions. Poor adherence is estimated 
to cost between $100 and $300 billion of avoidable health care costs annually in the 
US alone. One was to tackle this issue is the use of implants, which provide sustained 
release of drug over a long time period, removing the reliance on daily oral medication. 
In situ forming implants are particularly of interest as they can be injected through a 
standard gauge needle, reducing pain and discomfort for the patient. They are injected 
as a liquid and then solidify at the injection site.   
Three different solidification methods were explored to allow a dispersion of 
poly(N-isopropylacrylamide) nanogels to act as an in situ forming implant for drug 
delivery. Two of these solidification methods were based on the modification of 
existing methods and utilised the modification of the nanogel behaviour with the 
incorporation of comonomers of acrylic acid and allylamine. The stabiliser 
polyvinylpyrrolidone (PVP) was included in the synthesis of these nanogels to attempt 
to aid nanogel dispersion and formulation with a drug payload. A third novel method 
of solidification was found to work successfully and so was developed and investigated 
further. This was based on the aggregation of poly(N-isopropylacrylamide) nanogels 
to rapidly form a drug depot at an injection site in response to both physiological 
temperature and ionic strength, giving a new in situ forming implant. Nanogels without 
surfactant, with sodium dodecyl sulphate (SDS), and with PVP were synthesised to 
determine if this would effect the suitability of the nanogels to undergo triggered 
aggregation under the correct conditions. 
The system was found to be easy to inject, and could be used to deliver hydrophobic 
drug or hydrophobic drug formulated into solid drug nanoparticles. Unlike the majority 
of in situ forming implants, a low burst release of drug payload was achievable, 
< 3.4 wt%, and sustained release was possible for over 120 days. The rate of release 
could also be tuned by altering the ratio of two different nanogels used to create the 
depot formulation which has not previously been demonstrated. One of these nanogels 
contained the comonomer allylamine alongside the monomer N-isopropylacrylamide. 
This gave a depot with a higher water content and more porosity. Release was also 
shown to occur through Fickian diffusion. The nanogels were also found not to exhibit 
any cytotoxicity. Nanogels of different sizes were also synthesised, and it was found 
that these exhibited different phase behaviour and rheological properties. The rate of 
drug release from the depot could also be tuned by the size of the nanogel used, which 
has not previously been demonstrated. Finally nanogels were synthesised with the 
degradable cross-linking agent N,N’-bis(acryloyl)cystamine (BAC). This allows a 
depot to degrade into polymeric fragments once it has served its purpose. Alongside 
BAC, the comonomer N-isopropylmethacrylamide (NIPMAM) was utilised to reduce 
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non-degradable cross-linking formation. The NIPAM and NIPMAM monomers were 
used to create core-shell nanogels. The ratio of each monomer used gave nanogels with 
a tuneable aggregation temperature. The nanogels were shown to be fully degradable 
into polymeric fragments beyond the lower detection limit of dynamic light scattering 
when the count rate of the nanogel dispersion was monitored using DLS. The 
degradation rate was also very sensitive to temperature, with degradation shown to 
take place at a much slower rate as temperature increased from 25 °C up to 40 °C, 
where the nanogels are deswollen and more hydrophobic in nature. This could 
potentially allow a depot to degrade slowly over a period of months, allowing it to 
provide a sustained release of drug over this time period, whilst also being fully 
degradable into polymeric fragments when subjected to an average body temperature 
of 37 °C. 
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CHAPTER 1 
1.1. The Rise of Chronic Conditions 
One of mankind’s greatest, and often overlooked achievements is the development of 
modern healthcare. This has been a big contributor to life expectancy, which has risen 
consistently for over a century, giving us all the gift of a longer life.1 In the record 
holding country (Japan), female life expectancy has risen at a rate of 3 months per year 
for the last 160 years.1 This trend is mirrored in other industrialised nations, and is 
predicted to carry on well into the future.2 However, this rise in life expectancy 
presents another set of challenges for scientist to address, that is the rise in chronic 
diseases as people live longer. Chronic diseases are defined and summarised by the 
U.S. National Center for Health Statistics as lasting 3 months or more, generally not 
being curable by medication, nor simply disappearing over time.3 Chronic diseases 
become more prevalent in a population with age, so as life expectancy rises, so does 
chronic disease.4 Over 50% of people over the age of 65 have more than one chronic 
disease, compared to a much lower rate for younger people.4 With the median age of 
the entire world’s population predicted to rise far into the future,5 the number of people 
living with chronic diseases will also carry on rising. This rise is enhanced not only by 
people living longer, but also by the fact that the world’s population is continually 
growing,6 further accelerating this problem in the future if it is not addressed.  
1.2. Adherence 
Many chronic diseases are managed through patient self-medication, where a patient 
must take medication appropriately without direct professional medical assistance to 
achieve the best therapeutic outcome.7 This most frequently takes the form of oral 
medication, taken once or multiple times a day, for the remainder of that patients 
lifetime, because of its simplicity and convenience over other administration routes.7 
The measure of a patients ability to adhere to medical advice in regards to their 
self-medication regime is termed medication adherence.8 If medication dosages are 
missed by the patient, they are considered to be less adherent than 100% adherence, 
where a patient takes their medication exactly as prescribed, also known as 
non-adherent.9 Adherence itself is much broader that simply adherence to medication. 
It can also be a measure of ability to seek medical attention, fill prescriptions, obtain 
immunisations, attending follow-up appointments and execute behavioural changes.10 
Adherence can be understood better with as example: in Europe, only 28% of patients 
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CHAPTER 1 
being treated for diabetes achieve good glycaemic control. However this figure is a 
combination of adherence measurements. These include adherence to a good diet 
(behavioural adherence), as well as medication adherence, which for diabetes still only 
lies at 67.5%11, despite diabetes being a potentially fatal condition.12 The focus of this 
thesis lies on medication adherence rather than adherence as a whole, and so from now 
on adherence refers specifically to medication adherence, which is generally the most 
widely researched and important of the forms adherence can take. 
1.2.1. Medication Adherence 
Medication adherence is vital in the treatment of many chronic conditions such as HIV, 
diabetes, cancer, hypertension, coronary heart disease, depression, and mental 
conditions, however mean patient adherence rates range anywhere from poor to near 
complete adherence depending on the disease, geographical location and a number of 
other factors. Surprisingly, in developed countries, good adherence in patients with 
chronic diseases is measured to average only 40-50% across a range of conditions,13,14 
and although the accuracy of these generalised adherence averages for all chronic 
conditions has been questioned,15 adherence is still clearly much lower than desired. 
The highest mean adherence in a review of 508 studies into 17 diseases was found to 
lie at 88.3% for HIV.11 The seriousness of this value is difficult to comprehend until 
taking into consideration that successful management of HIV requires adherence 
> 95%, and so good adherence is critical.16 Medication adherence is also important in 
many other chronic conditions such as diabetes, where poor adherence leads to 
increased morbidity and mortality.17 Rates of adherence are also found to be much 
lower in chronic conditions than acute ones, dropping most dramatically after the first 
6 months of therapy.18,19 Likewise medication adherence drops dramatically when 
patients are required to take an increasing number of daily medication doses. With 
over half of patients not intentionally missing doses, this effect is mainly down to the 
difficulty of remembering to take multiple doses at different times in the day, every 
day, for long periods.20 There are also many other factors which have an effect on 
medication adherence which can be broadly grouped into external, provider and patient 
factors. In patient factors alone lies demographical, sociocultural and behavioural 
reasons. Just a few interesting examples of the many barriers to adherence include 
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stress, cognitive function, health literacy, age, sex, employment status and income of 
the patient.21,22 
1.2.2. The Impact of Poor Adherence 
Patients need to be adherent to their medication regimen for a number of reasons. The 
most obvious and important being the increase in morbidity and mortality with poor 
adherence.23 There is also the avoidable healthcare cost burden placed on the 
healthcare system from increased service utilisation, such as increased hospital 
admissions.24 In the US alone this is estimated to total $100 and $300 billion of 
avoidable health care costs annually to due poor adherence.25 We can also consider 
why adherence is important therapeutically on a physiological level, which requires a 
little more detail to understand as a concept, and is the underlying reason for increased 
morbidity, mortality and healthcare cost.  
1.2.3. Therapeutic Effect of Poor Adherence 
When a patient is required to take repeated doses of medication at set intervals of time, 
it is because a steady state of drug at a certain plasma concentration is required in the 
body.26 When a patient takes their first dose of medication orally, this will lead to a 
spike of maximum drug plasma concentration (Cmax) at time (tmax), figure 1.1 (i).
27 The 
concentration of drug then decreases over time and is quantified by the elimination 
half-life (t1/2).
28 This then reaches a trough known as (Cmin), which is the minimum 
concentration reached before the next dose is administered, figure 1.1 (ii). Upon 
subsequent doses Cmax and Cmin are greater, and continue to increase until a steady 
state is reached, usually at 4 to 5 times the t1/2 of the drug, figure 1.1 (iii).
29 To maintain 
this steady state the patient must maintain the correct dosage amount and interval.  
The steady state concentration required is determined by the therapeutic index of the 
drug. The therapeutic index is the ratio of the lethal concentration to the therapeutic 
concentration of a particular drug in the body.30 Hence safer drugs have a higher index. 
The most effective drug dose and frequency to reach the steady state concentration 
required can be simulated through pharmacokinetic (PBPK) models,31,32 and is based 
on a large set of parameters, which include solubility, potency and bioavailability of a 
drug, metabolism rate, formulation of the drug and administration route.33 The actual 
steady state concentration can also be determined from patient blood samples.34 The 
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CHAPTER 1 
steady state concentration should fall in a concentration range known as the therapeutic 
window. This is bound by a maximum and minimum concentration, known as the 
minimum toxic concentration (MTC) and minimum effective concentrations (MEC) 
respectively, (figure 1.1).35 This window gives a range where drug is considered to act 
therapeutically; Cmax and Cmin should ideally fall within this window. 
An example using a hypothetical ‘Patient X’ (who is suffering from a chronic illness 
and taking a daily oral medication) can be used to demonstrate the importance of 
medication adherence for chronic conditions in terms of the therapeutic window. If 
patient X misses or delays medication doses, then the drug concentration will fall 
below the MEC and out of therapeutic window into the sub therapeutic range, figure 
1.1 (iv), particularly for drugs with a narrow therapeutic index.36 Other than halting 
the therapeutic action of the drug, this can also have more profound consequences for 
some conditions. An example of this is in the treatment of HIV, where drug resistance 
to highly active antiretroviral therapy (HAART) can develop in the sub therapeutic 
range, leading to failure of the treatment, and limiting options available for future 
treatments each time a treatment fails.37,38 There is also the potential for a patient to 
overdose on medication, which is caused by factors such as poor health literacy,21 
where medication adherence is then classed as > 100%. (i.e. the patient takes more 
than the prescribed dose).39 Using patient X’s poor health literacy as an example, they 
may think “I missed my last pill, I’ll take two pills this time to catch up”. 
Unfortunately, in this case, patient X doesn’t realise it, but the effect is to take the drug 
concentration over the MTC, and above the therapeutic window, figure 1.1 (v). 
Hopefully patient X avoids a dose great enough to cause death, however they now 
experience unwanted side effects as the drug reaches a toxic level.40 This causes patient 
X to decide to stop taking their medication because it’s making them feel much worse 
than the chronic condition they are suffering from, figure 1.1 (vi). This could result in 
an expensive hospital admission to stabilise the patient.41 Achieving good medication 
adherence avoids these issues. 
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Figure 1.1 Illustration of drug concentration over time with repeated oral dosage of medication 
for complete medication adherence: (i) first dose, (ii) second dose, (iii) point at which a steady 
stated of drug concentration is reached, and irregular medication adherence of patient X: (iv) 
deviation of drug concentration into sub therapeutic region with missed dose, (v) deviation of 
drug concentration into toxic range, (vi) drug clearance from body as patient ceases to follow 
drug regimen. 
1.2.4. Solutions to Poor Medication Adherence 
Over the decades there have been a wide range of strategies to improve medication 
adherence, which all have the aim of maintaining a drug concentration within the 
therapeutic window. Some more pragmatic approaches include simplifying the 
patients medicine regimen, medication aids, Short Message Service (SMS) reminders, 
and introducing a collaborative approach at the level of prescribing.9,42 Some easily 
overlooked solutions also include simply proving better transport and pharmacy 
parking for patients. Mail order pharmacy removes the influences of collecting 
medication prescriptions on adherence from the equation. Hence it has been shown to 
give a reduction in emergency department visits in the treatment of conditions such as 
diabetes over more traditional pharmacy routes.43 Interventions involving pharmacists, 
behavioural specialists, and nursing staff have also been utilised to try to improve 
medication adherence rates.44,45 These can take the form of behavioural, educational, 
integrated care, self-management and risk communication interventions.46,47 Simple 
interventions  somewhat increase adherence for short term treatments, however even 
when interventions were more complex, they were found to be much less effective in 
dealing with chronic conditions, with little perceived improvement across a range of 
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studies.43 Successful methods for improving medication adherence are generally 
complex, labour intensive, and single approaches are not suitable for all patients or 
conditions, leaving room for new innovative strategies.48 These strategies potentially 
come in the form of new technological approaches to improving adherence, this 
includes a concerted effort to leverage big data and the internet of things (IOT) to 
utilise devices such smartphones (mHealth) and virtual assistants (e.g. Amazon Alexa 
and Google Assistant).14,49 A technological approach has also been taken towards mail 
order pharmacy, incorporating it into a system of blockchain technology, which can 
utilise data sharing to create “adherence profiles”, cryptocurrency incentives, and 
customised reminders for patients to improve adherence.50 These new approaches are 
either still in development, or have only recently been employed, so they have not yet 
been studied and scrutinised to an appropriate level to make any claims as to their 
effectiveness. 
1.3. Long Acting Release 
One way to improve medication adherence is to remove the reliance on the patient to 
take either daily or more frequent medication doses. This has been shown to improve 
adherence by avoiding issues such as ‘pill fatigue’ and missed doses.51,52 This is 
achieved through long acting drug delivery systems, where dosing can be as infrequent 
as monthly, quarterly or yearly. This is also referred to as controlled release, because 
the controlled rate of release of drug gives a plasma concentration which remains 
constant or slowly decreases within the therapeutic window in comparison to the peaks 
and troughs of frequent oral dosing, figure 1.2.53,54 Ideally, release is zero order, to 
maintain a constant rate of release, although other release kinetics can still provide 
viable long acting release.55 Development of long acting drug release began with 
implantable drug delivery systems in the 1930’s for veterinary use,56 however the 
technology did not reach mainstream development for human use, and 
commercialisation, until the 1960’s and 1970’s respectively with the inception of 
companies dedicated to controlled release such as Alza and Elan. Early devices were 
macroscopic, non-injectable and non-degradable,57 which along with subcutaneous 
implants also took the form of mucosal inserts and topical patches.57  Whilst 
reasonably practical for mucosal and topical usage, they required invasive 
microsurgery to locate and remove from a subcutaneous site. Drug delivery devices 
have since become increasingly more sophisticated, and are now available in the form 
of injectable and biodegradable formulations;58 these include polymeric implants,59 
microspheres/particles,60,61 hydrogels,62 and oils.58 
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Commercially available implantable systems include Vitrasert® which was approved 
by the FDA in 1996 for the treatment of AIDS-related cytomegalovirus (CMV) 
retinitis. This consists of a reservoir of the drug ganciclovir coated in polyvinyl alcohol 
(PVA) and ethylene vinyl acetate (EVA) and located intravitreally. Delivery of drug 
is possible for 5-8 months with zero-order release,63 and replaces weekly injections.64 
This was shown to limit the progression of CMV retinitis three times longer than 
intravenous injection.65 However this requires invasive surgery for implantation and 
removal. Another example of a commercially available implant is a Lupron depot®, 
which is a microparticle depot used to treat cancer and other conditions via 
intramuscular injection.66 The leuprolide hormone is encapsulated in 
poly(lactic-co-glycolic acid) microspheres, with long acting release  allowing the 
frequency of injections to be lowered.67 
Overall implantable systems can be significantly more convenient for the patient, 
reduce morbidity and mortality, and also reduce healthcare costs by avoiding the 
effects of poor adherence such as hospital admissions. Long acting release has also 
proved particularly effective for patients with psychological dysfunctions, where oral 
medication compliance can be less than 40%,68 or patients with drug addictions where 
a large stock of tablets cannot be provided.69,70 
 
Figure 1.2 Illustrative comparison of drug concentration over time with repeated daily oral 
dosage of medication (black line) and a long acting injectable formulation (green line). 
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1.3.1. Routes of Administration of Long Acting Systems  
Long acting systems are most commonly administered through intravenous, 
intramuscular and subcutaneous routes,71 although oral, nasal and transdermal delivery 
is also possible with certain limitations.72  For example controlled release medications 
using the convenience of the oral administration route are available,73 however they 
are not truly long acting, because they still require frequent dosage. This is because 
the majority of a drug is absorbed in the small intestine, where the length of transit 
time is on average only eight hours.74 Hence an orally administered drug can only be 
employed for a short time as it migrates through the gastrointestinal tract. Long acting 
release will ideally therefore use an alternative method for drug delivery, where a 
longer release period can be obtained. For example intravenous injections are able to 
provide extended drug release during systemic circulation of a drug carrier.75,76 
Alternatively, the long acting system can be administered intramuscularly or 
subcutaneously, to form a drug delivery depot, which allows delivery on a prolonged 
timescale from weeks to years.77 A drug depot is a site where a localized mass of drug 
is stored and released at a controlled rate usually from a subcutaneous, intradermal or 
intramuscular site; replacing many doses with one dose for a given period of time. This 
allows the concentration of drug in the body to remain within the therapeutic window 
for a prolonged period of time. This is achieved by tuning the release rate from the 
drug depot to counter the rate of elimination of the drug from the body.78  
1.3.2. Subcutaneous and Intramuscular Administration Considerations  
There are a number of important considerations for long acting systems which are 
administered intramuscularly or subcutaneously. First of all, the biocompatibility of 
biomaterials used in this way is multifaceted. They must be chemically inert, 
noncarcinogenic, hypoallergenic, and avoid a large inflammatory response.79 
Otherwise issues such as platelet adhesion, tissue damage, or infection are all 
possible.54,80 Inflammatory response can also have an effect on drug release rate, for 
example the formation of a fibrous capsule of collagen fibrils around the depot can 
modify the in vivo release rate.81,82 Even without an inflammatory response the release 
rate observed in vitro and in vivo, for example in subcutaneous tissue, can differ due 
to the local in vivo environment.83 Hence it is important to consider the impact of the 
local environment on the in vitro – in vivo release rate correlation. This correlation is 
very difficult to predict, and although predictions can be made for specific depot 
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formulations of drug, often animal models are used to determine in vivo release rates.84 
The in vivo release rate at a subcutaneous or intramuscular site also effects the 
pharmacokinetics (distribution and fate) of a drug delivered from a depot. The 
pharmacokinetics are dependent on the release rate of drug as well as many other 
factors such as free drug in the surrounding tissue, metabolites, drug degradation, drug 
bound to tissue and proteins, and absorption via blood or the lymphatic system into 
systemic circulation.85 However this can be simplified in the categorisation by 
Washington et al. when the pharmacokinetics are controlled by the depot when drug 
release from the depot is slow (Type I), and release rate is limited by the 
pharmacokinetic absorption rate when depot drug release is fast (Type II).86 Drug 
release from a depot can also occur by different mechanisms depending on the 
chemistry of the biomaterials used to form the depot. This includes diffusion 
controlled, chemically controlled, solvent-activated and modulated-release, where 
drug release is controlled by stimuli such as pH, ionic strength or temperature.87 
1.3.3. Criteria for a Successful Long Acting System   
Alongside the above considerations, a long acting release injection or implant must 
meet a large set of criteria to be viable. Criterion that a delivery technology can prove 
inadequate against include: a) the length of the release period/release rate of drug, 
b) the amount of burst release that occurs, c) the percentage drug loading that can be 
achieved, d) mechanical stability, e) ease of administration, f) cytotoxicity and 
inflammation response, g) drug stability, and h) cost of the technology.88–90 It is 
important to assess long acting delivery technologies against this criteria during 
development. There is also no single solution which is suitable for the entire long 
acting release market; the treatment of different conditions for example requires a 
different rate of drug delivery to achieve a therapeutic dose. Some examples of how 
depots can be modified in development to achieve each of the above desired criteria 
include: a) changing the viscosity of an oil used in a drug loaded oil depot to change 
the release rate of drug from the depot,91,92 b) performing surface coating, or surface 
drug extraction on a depot to prevent burst release,90 c) changing the size of 
poly(lactic-co-glycolic acid) (PLGA) microspheres used in long acting drug delivery 
to increase drug loading,93 d) the inclusion of a second material, such as the addition 
of chitosan to bovine serum albumin based hydrogels to increase the mechanical 
stability of the depot,94 e) adding a rheological modifier, such as the addition of 
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N-methyl pyrrolidone to l-alanine based implants, to reduce the viscosity and allow 
easier administration of an injectable depot,95 f) using a depot coating such as a layer 
of poly(N-isopropylacrylamide) (polyNIPAM) nanogels to reduce inflammation 
response to a depot,96 g) including stabilising agents such as small sugars to increase 
the stability of biopharmaceutical drugs within a depot,97 and finally h) using low cost 
materials and a simple manufacturing process such as in systems based on sucrose 
acetate isobutyrate to reduce the overall cost of the technology.98 Therefore, although 
a drug delivery technology may not be appropriate for clinical usage after initial 
development due to a large set of criteria it must meet, there are usually many 
opportunities to continue the development of a promising long acting injection or 
implant to improve its performance. 
1.4. In Situ Forming Implants (ISFIs) 
One delivery system of current interest is in situ forming implants (ISFIs).99 An ISFI 
consists of an injectable low viscosity solution which once inside the body is able to 
transform into a gel or solid depot, (figure 1.3).98 The main advantage of an ISFI over 
other long acting implants is its comparatively less invasive and less painful 
administration, due to the ability of being able to inject a low viscosity liquid through 
a standard gauge needle, so that local anaesthesia and surgical intervention are not 
required.99 Due to the less invasive administration, it is also useful for the ISFI to be 
degradable, as then the depot does not have to be surgically removed after having 
served its purpose. Kang et al. were able to demonstrate a degradable depot which was 
also biocompatible, formed from the thermo gelation of a diblock copolymer 
consisting of polyethylene glycol block, and a random copolymer block of 
polycaprolactone (PCL) and poly-L-lactic acid (PLLA).100 By changing the ratio of 
PCL to PLLA, the rate of degradation could be tuned, with in vivo studies showing 
degradation of the depot to be tuneable from a range of weeks  to months.100 ISFI 
systems also provide a relatively extensive period of sustained release, compatibility 
with a wide range of drugs and relatively simplified manufacturing and low production 
cost.98 For the drug leuprolide (used to treat prostate cancer, breast cancer, 
endometriosis, uterine fibroids, and early puberty), an ISFI has been demonstrated 
clinically to be effective for a 6 month time span, meaning only 2 injections a year are 
required, allowing patients to improve their medication adherence.101 Many other 
drugs have also been successfully released from ISFIs,102 and they also show 
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suitability in the delivery of fragile drugs, biopharmaceuticals, and drugs with short 
half-lives.97 Amiram et al. showed that a glucagon-like peptide used in the treatment 
of diabetes could be fused to a thermally sensitive elastin-like polypeptide which forms 
a depot at body temperature. This allowed a 120 fold increase in therapeutic effect 
duration, in which blood glucose level was reduced.103 ISFIs are also useful where 
localised drug delivery is required.104 Kilicarslan et al. showed that mucoadhesive 
sodium carboxymethyl cellulose and carbopol polymers could be combined with 
poly(lactide-co-glycolide) (PLGA) to give an ISFI capable of releasing the drug 
metronidazole locally to treat periodontal pockets. The depot was also degradable, and 
the rate of drug release could also be tuned depending upon the composition of the 
depot.105 Compared to other delivery technologies, ISFIs can however also suffer from 
various issues. These include a large burst release of drug,106 potential toxicity of 
materials,107 cytotoxicity and inflammation response,54 long-term stability of the 
drugs,108 and finally variation in the shape of the implant formed, which leads to a 
variation in the amount of drug released.98 However these issues can be avoided in 
ISFIs. Shikanov et al. synthesised the polyesteranhydride poly(sebacic-co-ricinoleic 
acid), which solidified when in contact with water. Minimal burst release of the drug 
paclitaxel was observed from this depot material, whilst it was also degradable, and 
showed minimal inflammation response.109 
 
Figure 1.3 Illustration of an in situ forming implant (ISFI). (i) a low viscosity liquid is injected 
through a standard hypodermic needle into a subcutaneous or intramuscular site, (ii) a trigger 
causes the liquid to solidify, forming a depot which can give a sustained release of drug over 
time. 
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1.4.1. Solidification triggers used in ISFIs  
A range of ISFI systems have been developed, which achieve in situ gelation or 
solidification by different triggers. Some of these triggers include in situ physical or 
chemical cross-linking,107,108 solidifying organogels,110,111 and in situ phase separation 
via pH, solvent exchange or temperature.89  
In situ physical cross-linking occurs via hydrogen bonds or charge interactions. As an 
example, Balakrishnan and Jayakrishnan demonstrated that the gelation of alginates 
can occur in the presence of borax to provide the basis for an ISFI which was both 
biodegradable and biocompatible, with the system also being used to demonstrate the 
encapsulation of hepatocyte cells.112 Mekhail et al. used guanosine 5′-diphosphate as 
an anionic cross-linking agent to trigger the gelation of chitosan in 1.6 seconds using 
electrostatic attractions,113 which is much faster that the gelation of other chitosan 
system, which can require over 30 minutes to gelate,114 allowing potential burst release 
and flow to surrounding tissues.  
In situ chemical cross-linking can be achieved with cross linking agents in situ. An 
example of this is the in situ polymerisation of poly(propylene fumarate)-diacrylate 
with the initiator benzoyl peroxide, where the formation of chemical cross-linking in 
situ allows solidification.115 However like many in situ polymerisations, there are 
potential toxicity issues due to the reactive nature of the polymerisation species. In the 
case of the reactive initiator benzoyl peroxide, there is the potential to promote tumour 
growth.116 There are, however, non-cytotoxic methods to induce in situ chemical 
cross-linking, such as the use of cross-linking agents which are activated by biological 
triggers. For example, Saeed et al. showed that non-cytotoxic chemical cross-linking 
using di-sulphide bonds and vinyl groups could be triggered by the biological reductant 
glutathione. It is also possible to trigger chemical cross-linking via photo-initiation. 
Ono et al. modified chitosan to contain lactose and azide moieties. UV light could then 
be used to trigger photoreactive azide groups to undergo cross-linking, forming a 
hydrogel within 30 to 60 seconds. The hydrogel also acted as a tissue adhesive.117 This 
was then demonstrated to inhibit tumour growth in mice when the antitumour drug 
paclitaxel was incorporated.118 One potential drawback for photo cross-linked systems 
is the low penetration depth possible with irradiated light,98 and the potential 
modification of some drugs by high energy radiation.119 
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Another way to trigger solidification is in the use of organogels, which are able to 
self-assemble and hence gelate through intermolecular interactions, such as hydrogen 
bonding, π-π stacking, and electrostatic interactions.111 Gelation can be triggered by 
heating the organogel and then allowing it to cool at the injection site, or through 
solvent exchange.111 Example of the two triggers can be demonstrated with the 
organogelator N-stearoyl L-alanine methyl ester. Vintiloiu et al. showed that as the 
organogelator cools it gelates via the self-assembly driven by Van der Waals 
interactions and hydrogen bonding.120 Plourde et al. showed that solvent exchange in 
the same gelator allowed it to self-assemble into a fibre like structure. This allowed 
the release of therapeutic peptide for 14 to 25 days.95 
Finally a range of ISFIs which phase separate based on various different triggers have 
been demonstrated. A change in pH can be used to trigger solidification, as 
demonstrated by Chenite et al. in the formation of a gel like precipitate for chitosan 
based implants, due to chitosan being a pH-dependant cationic polymer.121 Solvent 
exchange can also be used to trigger solidification. Some organic solvents such as 
dimethyl sulfoxide and N-Methyl-2-pyrrolidone have limited a limited toxicity,104,122 
and so are utilised in solvent exchange systems.104 Here, an injection consists of a 
water insoluble polymer, which contains a solvent the polymer is soluble in. When the 
solvent diffuses into the surrounding aqueous environment and vice versa, the polymer 
precipitates to form a depot. However the time taken for these systems to solidify often 
leads to a large burst release of drug.104 Dunn et al. demonstrated   
poly(lactic-co-glycolic acid) could be used to create an ISFI based on solvent 
exchange,123 with the particular polymer also approved by the FDA for therapeutic 
devices, due to its biodegradability and biocompatibility.124 Finally, in situ phase 
separation can be triggered by a change in temperature. Jeong et al. showed that a 
poly(ethylene glycol)-poly(lactic acid-co-glycolic acid)-poly(ethylene glycol) block 
copolymer transitioned from a sol to a gel at physiological temperature due to the 
formation of a hydrophobic core driving micellular arrangement.125  
Kempe and Mäder summarised that an ideal ISFI should be of low viscosity to allow 
injection, allow simple drug loading, contain only biodegradable and biocompatible 
material, good system stability, and low initial burst release and low variability of drug 
release over time.98 However, ISFI’s which have previously been developed generally 
suffer from one or more issues,98 with burst release of drug being a particularly 
prevalent issue across a range of delivery systems.110 
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1.5. Nanogels 
A very recent area of interest for in situ forming implants is the application of nanogels 
to form depots.126 A nanogel is a series of cross-linked polymer chains which form a 
nano-sized particle containing a network of polymers, which has the ability to be 
swollen by a good solvent, (figure 1.4).127  Nanogels form a disperse phase of discrete 
polymeric particles and so exhibit properties of both colloids and gels, and act as an 
intermediate between branched and macroscopically linked systems.128 They are often 
termed microgels in literature,129 as first coined by Baker,130 and synthesised by 
Staudinger and Husemann.131 There does not seem to be a clear consensus in the 
literature with regards to the terms used to refer to different sizes of cross-linked 
swollen nanoparticles, with nanogel and microgel being used interchangeably. 
Generally, the term microgel is favoured for larger particles and vice versa for 
nanogels. Whilst the majority of nanogels in literature fall below 100 nm, there are 
examples of nanogels being defined as particles of less than 200 nm,132 and also 
examples of nanogels above 200 nm,133 300 nm,134 400 nm135 and up to 500 
nm.136 Hence the term nanogel is used in this thesis, as the nanogels under 
investigation were generally in the range of 30 to 1000 nm in diameter, so it was felt 
the prefix ‘nano’ was a better representation for the particles under discussion, as they 
fall below a micrometer in size. 
 
Figure 1.4 Illustration of a nanogel in a bad solvent (collapsed) and good solvent (swollen by 
solvent). 
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1.5.1. Nanogel Applications 
The properties of nanogels allow them to be used in a range of useful applications. 
One example of a nanogel is polystyrene latex, which can be swollen with an organic 
solvent such as tetrahydrofuran (THF). This reversible swelling behaviour can be used 
to allow encapsulation of a hydrophobic compound in the nanogel particles.137 
Although all nanogels are responsive to solvent environment, they can also exhibit 
other properties which can be exploited. Depending on the material they are composed 
of they may also be able to reversibly respond to other environmental stimuli such as 
temperature, pH and ionic strength.127 In terms of drug delivery, nanogels have been 
demonstrated to both encapsulate and release many different bioactive compounds,136 
whilst also achieving targeted delivery by taking advantage of their responsive 
behaviour.138 Used at a high enough concentration, or as two populations of oppositely 
charged particles, they can also achieve the viscosity of a bulk gel when swollen with 
solvent, but with shear thinning behaviour.139 This allows them to act as an injectable 
material.140 One such use is mouldable tissue engineering scaffolds.141,142 Most 
nanogels used in nanomedical applications are hydrogels. Hydrogels consist of a 
water-soluble polymer network containing a large amount of water.143 Cross-linking 
between the polymer chains prevents the network from dissolving. They are 
distinguishable from other bulk gels by the fact that their high water content and 
biocompatibility make them ideal for biological applications such as drug delivery, 
tissue engineering and bionanotechnology.144,145 Increasingly ‘smart’ hydrogels, with 
environmentally sensitive properties are being employed.146 When hydrogels take on 
the particulate form of a nanogel they have a much higher surface-to-volume ratio,126 
and a much faster response to environmental changes than a bulk hydrogel.147 Hence 
hydrogel based nanogels are often more useful smart materials than their bulk 
counterparts. 
1.5.2. Nanogel Based In Situ Forming Implants 
A range of injectable nanogels have recently been demonstrated for use in drug 
delivery systemically, however as the research area is still in its infancy examples of 
injectable nanogels being specifically employed for depot formation as an ISFIs are 
very limited.126 Oppositely charged particles can be synthesised, which are able to 
interact and self-assemble to from a nano-network through electrostatic forces.148 
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Gu et al. demonstrated glucose-mediated insulin delivery was possible using dextran 
based nanogels coated with oppositely charged polymers, allowing the particles to 
self-assemble at the injection site through electrostatic interactions.149 Injection of the 
material is possible because the weak electrostatic interactions can be disrupted by 
shear during injection of the material.141 However with surface charge potentially 
having a cytotoxic effect,150 this could present a barrier to the commercial deployment 
electrostatic of charge interaction-based approaches. Thermo-gelation of chitosan 
particles in situ has also been demonstrated by Hsiao et al. to deliver the hydrophilic 
anti-epilepsy drug ethosuximide,151 as well as in the treatment of diabetes.152 
Chen et al. have also demonstrated the self-assembly of ketal derivative polymers to 
form a micellar nanogel depot for the delivery of the drug paclitaxel.153 Finally 
Nakai et al. demonstrated that salt induced aggregation of hyaluronic acid based 
nanogels could be used to create a solid depot in situ, with high protein loading and 
low denaturation possible using nanogels.154  
1.6. PolyNIPAM Nanogel Based In Situ Forming Implants 
An interesting nanogel which has been demonstrated for use as an ISFI in a small 
number of studies is a nanogel formed of the thermo-responsive polymer 
poly(N-isopropylacrylamide) (polyNIPAM), (figure 1.5).127  
 
Figure 1.5 Chemical structure of a) the monomer N-isopropylacrylamide (NIPAM) and 
b) the corresponding polymer poly(N-isopropylacrylamide) (polyNIPAM). 
 
PolyNIPAM nanogels are able to respond to a rise in temperature above around 
34 °C.155 As this response lies between room temperature and body temperature, and 
these nanogels have also been shown to reduce inflammation response when coating 
other drug depots,96 these nanogels could potentially be used to develop an ISFI which 
is able to meet all the required criteria to reach clinical success. Huang et al. 
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synthesised two species of polyNIPAM nanogels using 10 mol% of allylamine and 
acrylic acid respectively as comonomers. This gave polyNIPAM-co-allylamine and 
polyNIPAM-co-acrylic acid nanogels, which had a hydrodynamic diameter of 372 nm 
and 640 nm respectively at 21 ° C.  Glutaric dialdehyde and adipic acid dihydrazide 
were used to covalently cross-link each of the two nanogel species, allowing the 
formation of a three-dimensional gel network, (figure 1.6, a). Unlike bulk polyNIPAM 
hydrogel, these networks were able to give sustained release of dextran. The rate of 
release was also tuneable using a range of dextran molecular weights, due to the mesh 
size of the cavities formed in between the nanogels covalently linked together to form 
the three-dimensional gel network.156 However, this system would have to be 
implanted rather than injected, and so would lose the less invasive administration 
benefits of an ISFI. Wang et al. showed than thermoresponsive polyNIPAM nanogels 
with an acrylamide comonomer were injectable, and able to gelate under physiological 
conditions.157 These nanogels had a hydrodynamic diameter in the range of 200 to 
300 nm at 25 °C, with nanogels synthesised with less than 5 mol% of cross-linking 
agent showing more abrupt thermoresponsive deswelling in response to an increase in 
temperature. The nanogels were shown to be able to undergo phase transitions between 
a swollen gel, shrunken gel, and liquid, depending on the concentration and 
temperature of the nanogel dispersion, (figure 1.6, b). However, in terms of drug 
delivery significant burst release of anticancer drug Bleomycin was seen from a 
concentrated dispersion of the nanogels (13% w/v), with up to 50% of cumulative drug 
release occurring in the first 5 hours.157 Similar burst release issues were seen in the 
release of 5-Fluorouracil from thermoresponsive polyNIPAM nanogels synthesised 
with the same acrylamide comonomer, to give nanogels with a diameter of 230 nm. 
The release of the biomacromolecule bovine serum albumin was also assessed, and 
reached a plateau of 20% cumulative release, likely due to the large protein remaining 
entrapped between the nanogels. In order to measure drug release from this nanogel, 
an 8.3% (w/v) dispersion loaded with drug was prepared in a flat bottom test tube, 
forming a gel phase at 37 °C. Release medium was then added on top of the gel phase 
and replaced at sampling intervals, (figure 1.6, c).158 Finally Xiong et al. showed 
polyNIPAM nanogels with acrylic acid comonomer were able to gelate in situ in 
response to a change in both temperature and pH. Nanogels with a diameter in the 
range of 100 to 900 nm were created using varying amount of acrylic acid comonomer 
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in the synthesis (0 – 32.9 mol%), with the nanogel diameter also dependant on pH as 
well as temperature. When the nanogels were used as a drug depot, in vivo studies 
showed the nanogels had good biocompatibility and syringability.159 However, with 
no way for the nanogels to degrade, the depot would have to be removed surgically 
after having served its purpose unless a degradable version of the nanogels was 
developed. 
 
Figure 1.6 Illustrations of polyNIPAM based in situ forming implants, a) two dimensional 
representation of  a i) nanogel dispersion and ii) covalent cross-linking of the nanogels, 
allowing release of dextran contained in the mesh of the three dimensional structure.156        
b) concentrated nanogel dispersion as i) a swollen gel, ii) a liquid, and iii) a shrunken gel.157 
c) in vitro drug release i) from the gel phase of a concentrated nanogel dispersion at 37 °C, 
ii) after the introduction of release media to allow drug release from the gel phase.158 
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1.6.1. PolyNIPAM Nanogel Behaviour 
PolyNIPAM nanogels are one of the most highly studied nanogels based on a 
hydrogel.127 PolyNIPAM nanogels were first discovered by a student of Pelton in 
1984.160 The reason for such an interest in this particular nanogel is its temperature 
sensitive properties. Properties such as size, charge density, colloidal stability, light 
scattering and hydrophobicity all gradually change with temperature, however around 
the volume phase transition temperature (VPTT), these properties become very 
sensitive to a small change in temperature. This VPTT is around 34 °C,155 with some 
dependence on factors such as the cross-linker structure and cross-linking 
density,161,162 and is the temperature where the nanogel acquires the largest and 
sharpest hydrodynamic diameter change, (figure 1.7).163 This is close to the lower 
critical solution temperature (LCST) of linear polyNIPAM of 32 °C.164 This gives a 
very defined transition in particle size and other properties as it crosses the VPTT. 
Below the VPTT polyNIPAM exists in a swollen state in which the network is fully 
expanded and swollen by water molecules giving a colloidal hydrogel.129 Favourable 
hydrogen bonding interactions exist between the amide groups of the polyNIPAM 
units and water.165 Upon heating above the VPTT this hydrogen bonding is 
increasingly disrupted, so that the water becomes a poorer solvent and the chains begin 
to collapse expelling most of the water molecules in the process to form a hard 
sphere.129 This causes the switch to inter- and intra- polymer hydrogen bonding and 
polymer-polymer hydrophobic interactions in the nanogel particles.127 Hence the 
dramatic change in particle properties and the ability to switch the hydrogel ‘on and 
off’ with temperature. 
 
Figure 1.7 Swelling behaviour of poly(NIPAM) nanogel dispersed in water, a) swollen 
hydrogel particle below the volume phase transition temperature (VPTT), b) collapsed 
dehydrated particle above the VPTT, water expelled from network upon collapse. 
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This is of importance in biomedical applications, as the VPTT lies close to body 
temperature, and so a dramatic change in material properties can be exploited. One 
such example of this is in a drug delivery application. The drug naltrexone can be 
loaded into swollen polyNIPAM nanogel particles, and then becomes entrapped as the 
polymer network collapses as the particles reach body temperature, which is above 
their LCST. This combined with the switch to a more hydrophobic environment in the 
collapsed nanogel greatly decreases the release rate of the drug.166 The nanogel 
exhibits a “smart” response to its environment. 
1.6.2. PolyNIPAM Nanogel Synthesis 
PolyNIPAM nanogels are usually synthesised by precipitation or dispersion 
polymerisation.167 In a typical precipitation polymerisation the monomer 
N-isopropylacrylamide (NIPAM) along with a cross-linking agent such as 
N,N’-methylenebisacrylamide (BIS) is dissolved in water. This is then heated above 
the LCST of polyNIPAM, followed by the addition of a thermal free radical initiator 
such as potassium persulfate (KPS). As the chain begins to propagate they reach a 
length at which they precipitate through homogeneous nucleation into colloidally 
unstable precursor (primary) particles.168 It has be shown that polyNIPAM only 
requires three oligomer units to phase separate,169 hence the nucleation process to 
precursor particles happens within minutes, ensuring a narrow particle size 
distribution.127 These precursor particles then undergo coagulative association with 
other precursor particles, until they finally reach colloidal stability as larger polymer 
particles.168 It is the charge of the ionic initiator on the chain end of the polymers which 
determines when colloidal stability is reached, and hence the critical particle size. The 
hydrophilic chain ends concentrate at the surface of the particle and so surface charge 
density increase as the particle grows to the point where colloidal stability is 
reached,129 (figure 1.8, a). Dispersion polymerisation is able to take advantage of ionic 
or steric stabilisers. These are able to impart greater colloidal stability to the precursor 
particles, reducing the amount of precursor particles that must coagulate to reach a 
colloidal stability particle.170 Hence the final particle size is smaller and tuneable 
depending on the amount of stabiliser used, (figure 1.8, b). Tuning particle size was 
shown to be possible via electrostatic stabilisation by Pelton et al. by varying the 
amount of ionic sodium dodecyl sulphate (SDS).171 It has also been demonstrated to 
be the case with steric stabilisation, as shown with poly(vinyl alcohol) (PVA).172 
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Figure 1.8 Illustration of a) precipitation and b) dispersion polymerisation to produce 
polyNIPAM nanogels, i) formation of precursor particle and ii) coagulation of precursor 
particles and oligomers to colloidally stable particle. 
1.6.3. PolyNIPAM Nanogel Colloidal Stability  
Although a polyNIPAM nanogel is colloidally stable at the point of synthesis above 
and below its VPTT, further changes to its environment may cause aggregation, such 
as a change in ionic strength. Below the VPTT polyNIPAM nanogel particles usually 
contain between 80 and 99% water in their swollen state.127 Consequently the Van der 
Waals forces of attraction between particles are small, and chain ends extend from the 
particle to act as a steric stabiliser.129 The particles are thus colloidally stable, and 
addition of salt to increase the ionic strength of the solvent has little effect.173 However 
when the particles are heated at high ionic strength they aggregate above the VPTT.160 
This is because the particles contract and expel most of the water contained within 
them. Hence the Hamaker constant of the particle is no longer similar to the medium, 
and Van der Waals forces of attraction now exert a greater influence.155 The chain ends 
are also now collapsed and so no longer provide steric stabilisation.172 The surface 
charge density increases as the particles contract, and this provides electrostatic 
stabilisation to replace the loss of steric stabilisation and counter the increasing van 
der Walls forces in water (figure 1.9, a,i).174 However, the presence of ions in the 
solution may potentially negate this electrostatic stabilisation and hence aggregation 
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of the particles now occurs above the LCST, (figure 1.9, a, ii).175 This is important to 
consider in biomedical applications as a polyNIPAM nanogel will be in its collapsed 
state at body temperature and so the ionic strength of extracellular fluid (0.137 M) will 
cause aggregation if further stabilisation is not provided, such as steric stabilisation. 
Steric stabilisation with polyvinylpyrrolidone (PVP) or poly(vinyl alcohol) (PVA), has 
previously been demonstrated to prevent aggregation of polyNIPAM nanogels.172,176 
Hence these the nanogels can be heated above there VPTT in the presence of higher 
ionic strength, (figure 1.9, b). 
 
Figure 1.9 Illustration of colloidal stability of a) polyNIPAM nanogels and b) polyNIPAM 
nanogels with a steric stabiliser when i) the temperature rises above the VPTT and ii) the ionic 
strength increases whilst a temperature above the VPTT is maintained. 
1.7. Thesis Overview and Research Objectives 
It can be concluded that medication adherence is an issue of great importance, 
especially when taking into consideration the future rise in chronic conditions as the 
size of the global population, and average age, both increases. Whilst a range of 
solutions has been explored, no one particular solution has been shown to give a 
dramatic effect across the multitude of chronic conditions and types of patient which 
exist. Implants have been shown to have some success at removing the burden of 
administering doses by the patient. ISFIs have improved upon this by creating an 
implant which can be implanted with a minimally invasive procedure. However, 
drawback of ISFIs include the fact that they often suffer from a large burst release. A 
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few examples of nanogels ISFIs have been explored which aim to improve upon 
current ISFIs by being easier to formulate and administer, however these systems also 
suffer from a large burst release. 
The main objective of the research presented in this thesis is to develop polyNIPAM 
nanogels for use as an ISFI. These nanogels will be formulated into a dispersion which 
is shear thinning to allow injection into a depot site, and then utilise the smart response 
of the nanogels to undergo triggered solidification under physiological conditions. As 
in section 1.6, only polyNIPAM-co-acrylamide and polyNIPAM-co-acrylic acid 
nanogels have previously been demonstrated to gelate and provide release of a drug 
payload, however the systems suffered from a large burst release and could not be 
degraded into small polymer fragments for excretion from the body. This work seeks 
to develop nanogels which avoid burst release and can be degraded into smaller 
polymer fragments, as well as other advantages such as the ability to control the release 
rate through the chemistry of the nanogel. A novel method of solidification which has 
not previously been investigated will also be explored using aggregation of nanogels 
triggered by physiological temperature and ionic strength. 
The development of a polyNIPAM nanogel based ISFI will first involve the 
exploration of triggering solidification under physiological conditions using three 
different solidification concepts enabled by altering the chemistry of the nanogel. The 
most suitable concept will be taken forward to undergo further development and 
investigation. This will include pursuing further aims to produce an ISFI which is 
potentially commercially and clinically viable, whilst exploring further novelty in the 
system. These objectives include the following (and are shown schematically in figure 
1.10):  
a) Drug release which can be maintained over an extended period of time from 
the ISFI. 
b) A drug release rate which can be tuned via a change in the nanogel chemistry 
by incorporating a comonomer in the synthesis. 
c) A minimal burst release of drug during and shortly after solidification of the 
ISFI to form a drug depot. 
d) Study into how nanogel size effects rheology and drug release rate from an 
ISFI. 
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e) An ISFI with minimal cytotoxicity. 
f) Ability to deliver hydrophobic drugs. 
g) An understanding into the underlying structure of the nanogel depot. 
h) A fully biodegradable depot where the polymer structure of the nanogel is 
transformed into small polymer fragments. 
 
Figure 1.10 Visual representation of the research objectives of a polyNIPAM nanogel based 
ISFI which will be explored in this thesis. Objectives: a-d) illustrated with graph of release 
rate of drug from an ISFI over time, a) sustained release over time  b) altering nanogel 
chemistry to tune release rate, c) achieving low burst release of drug, d) altering nanogel size 
to tune release rate, e) illustration of cell interacting with nanogels; synthesising nanogels with 
low cytotoxicity, f-h) illustration of depot site f) achieving hydrophobic drug delivery, g) depot 
structure investigation and h) biodegradability of nanogel polymer network into short polymer 
fragments. 
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The thesis is structured into the following chapters: 
Chapter 2 
• Exploration of triggering solidification using physiological conditions and 
three different solidification concepts, with the selection of the most promising 
concept for further exploration and development. 
Chapter 3 
• Development of an in situ forming implant in which the aggregation of 
nanogels is triggered by physiological temperature and ionic strength. This 
includes studying the depot structure, in vitro release of drug, cytotoxicity 
studies and tuning drug release based on nanogel composition. 
Chapter 4 
• Exploration into the influence of nanogel size on the in situ forming nanogel 
implant properties. This includes studying the phase and rheological properties 
of the nanogels, and effect on drug release rate. 
Chapter 5 
• Developing a degradable version of the nanogels, whilst maintaining the 
nanogel aggregation response to physiological temperature and ionic strength. 
The degradation process of the nanogels is also explored, and effects such as 
temperature on degradation rate. 
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2.1. Introduction 
Whilst a wide array of in situ forming implant (ISFI) systems are available,1 there are 
very few examples of nanogels being employed as ISFIs, with many of the advances 
in this area being made very recently.2–4 This is despite the potential advantages they 
offer over bulk hydrogel based ISFIs. These include the easier administration of low 
viscosity nanogel dispersions, to reduce invasiveness and discomfort, and fast 
response to stimuli, to reduce burst release of drug from slower depot formation.5 Of 
particular interest are poly(N-isopropylacrylamide) (polyNIPAM) nanogels, which are 
inert, biocompatible, and exhibit physiologically relevant responsive behaviour.6–9 
This can include a response to temperature, pH and ionic strength. Finally, the 
properties of nanogels can also be tuned through the inclusion of comonomers in the 
nanogel synthesis, potentially allowing a tuneable controlled release rate from a 
polyNIPAM nanogel depot. This chapter will investigate three possible concepts in 
which polyNIPAM nanogels can be utilised as an ISFI. These concepts are 1) pH 
enhanced thermally triggered gelation 2) charge-based assembly into a colloidal gel 
network and 3) triggered aggregation through the dual stimuli of temperature and ionic 
strength. The following sections will briefly outline the background to these concepts 
for ISFIs based on polyNIPAM nanogels. 
2.1.1. pH Enhanced Thermally Triggered Gelation Concept 
The incorporation of comonomers such as acrylic acid into the synthesis of 
polyNIPAM nanogels creates nanogels which are able to respond to pH.10 In the case 
of acrylic acid, the monomer has a pKa of 4.25.11 If the pH of a dispersion containing 
polyNIPAM-co-acrylic acid nanogels is raised above the pKa of the carboxylic acid 
functional group of the acrylic acid then the comonomer becomes increasingly 
deprotonated, leading to a greater anionic charge density. These charges cause greater 
intra-particle repulsion, causing the nanogel to expand.12 The pH response can also 
influence the phases present in a polyNIPAM nanogel dispersion at different pH 
values.9,13 Phosphate buffered saline (PBS) is often used in literature to mimic the ionic 
strength and range of salts present in the extracellular environment of the human body, 
and has been used previously in phase studies.14,15 In PBS, a dispersion of concentrated 
polyNIPAM nanogels presents different phases depending on the temperature of the 
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dispersion. At a low temperature the nanogels exist as a self-supporting swollen gel 
(i.e. a gel which is able to remain suspended in a sample vial when inverted), 
(Scheme 2.1, a).16,17 The swollen gel phase arises due the volume blocking mechanism 
of hard sphere theory, in which the nanogel spheres become close packed.18,19 Upon 
heating the particles deswell resulting in a phase transition to a liquid,16 which is 
accompanied by an increase in turbidity. (Scheme 2.1, b).20 This change in turbidity 
arises from the increased difference between the refractive index of the nanogel 
particles and the surrounding liquid as they deswell.21 In PBS, further heating above 
the VPTT of the nanogels causes a phase separated macroscopic aggregate phase to 
form, due to the lack of colloidal stability at the ionic strength of PBS (> 0.1M NaCl) 
(Scheme 2.1, c).22 The addition of acrylic acid into the polymerisation yields a 
dispersion of polyNIPAM-co-acrylic acid nanogels with different phase behaviour. 
Below ~ pH 4, the acrylic acid becomes predominantly protonated, and the nanogels 
are hence less swollen. This also reduces the overlapping of electrical double layers, 
which reduces the viscosity of a concentrated dispersion.23 Hence protonation of the 
acrylic acid comonomer allows a lower viscosity liquid instead of a gel, 
(Scheme 2.1, d).9 This difference allows easier injection. As with the polyNIPAM 
nanogels, the acrylic acid containing nanogels deswell as they are heated, (Scheme 
2.1, e).12 However, the third aggregate phase is replaced with a shrunken gel phase 
under physiological ionic strength, pH and temperature, (Scheme 2.1, f).13,24  This 
shrunken gel is also self-supporting (able to remain suspended in an inverted vial), but 
with high turbidity and a small volume excess of water expelled upon formation. As 
with the aggregate phase, there is an increasing tendency of the nanogels to become 
more hydrophobic with polymer-polymer interactions dominating polymer-water 
interactions as the temperature increases. This behaviour favours aggregation through 
attractive interactions,25,26 however this is opposed by an increased electrostatic 
repulsion from the inclusion of acrylic acid preventing this aggregation occuring.17,27 
Hence polyNIPAM-co-acrylic acid nanogels are injectable at low pH, where they will 
exist as a liquid, and then become more charged at higher pH, to allow formation of a 
shrunken gel depot at the injection site, as demonstrated in previous work.9 These 
nanogels can therefore be used as an ISFI in which gelation is triggered thermally and 
enhanced by a change in pH at physiological temperature and ionic strength. 
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Scheme 2.1 Illustration of phase behaviour under different conditions of polyNIPAM (a,b,c) 
and polyNIPAM-co-acrylic acid (d,e,f) nanogels dispersed as a concentrated dispersion in 
phosphate buffer saline (a,b,c,f), or pH 3 aqueous dispersion (d,e) : a) self-supporting swollen 
gel at 20 °C, b) liquid at 30 °C, c) phase separated aggregate at 37 °C, d) liquid at 20 °C and 
pH 3, e) liquid at 30 °C and pH 3, f) shrunken gel at 37 °C and pH 7.4. 
 
2.1.2. Charge Based Colloidal Gel Network Concept 
Previous work has shown that when two populations of nanoparticles, one with a 
cationic charge, and one with an anionic charge are combined, they can form a 
colloidal gel network through electrostatic attraction between the particles.28–30  These 
charges can be introduced by coating the particle surface with polyelectrolyte,28 or 
achieving an intrinsic charge during the synthesis.29,30 With polyNIPAM nanogels, as 
discussed above, anionic charge can be introduced with the addition of acrylic acid as 
a comonomer in the synthesis. Likewise, cationic charge can be introduced with a 
comonomer such as allylamine in the synthesis in polyNIPAM-co-allylamine 
nanogels.31,32 The conjugate acid of this comonomer has a pKa of 9.49.33 Hence at a 
physiological pH of 7.4, the carboxylic acid groups in polyNIPAM-co-acrylic acid 
nanogels are fully deprotonated, and the amine groups of polyNIPAM-co-allylamine 
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are fully protonated, (scheme 2.2), giving two species of oppositely charged nanogels 
potentially able to interact and form a colloidal gel at a physiologically relevant pH. 
 
Scheme 2.2 Predominate surface charge at different pH values for polyNIPAM nanogels with 
pH responsive comonomer incorporated, a) polyNIPAM-co-acrylic acid and b) polyNIPAM-
co-allylamine. 
 
PolyNIPAM-co-acrylic acid and polyNIPAM-co-allylamine nanogels have previously 
been synthesised and used together in drug delivery.34 However the nanogels were 
covalently cross-linked to each other to form a three-dimensional gel network, rather 
than relying on electrostatic attraction to form a gel after injection, and so could not be 
used as an injectable ISFI.34 When not covalently linked together, polyNIPAM 
nanogels are both nano-sized and shear thinning, giving an injectable dispersion.9,19 
Oppositely charged hydrogel particles were previously demonstrated to be injectable; 
the shear force of the injection syringe destroys the colloidal gel network, which then 
reforms after injection.30 Hence it is reasonable to assume that polyNIPAM-co-acrylic 
acid and polyNIPAM-co-allylamine nanogels can be synthesised and used together as 
an ISFI. Implant formation would take place through the assembly of a colloidal gel 
network through electrostatic interactions, after the shear force of injection through a 
hypodermic needle, (scheme 2.3). The strongest network cohesion is achieved when 
the overall charge of particles is balanced.28   
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Scheme 2.3 Reversible formation of a colloidal gel network after application of shear force 
to nanogels passing through an injection needle. 
 
2.1.3. Triggered Aggregation through the Dual Stimuli of Temperature and Ionic 
Strength Concept 
It is well known in literature that insufficient stabilisation of nanogels will cause them 
to flocculate or aggregate completely above the VPTT. However, Few studies have 
focused on purposefully achieving this, as nanogels are usually required to be 
colloidally stable, particularly for biomedical applications.35 In forming a drug depot 
in situ from aggregated nanogels, a nanogel dispersion at room temperature, 
(Scheme 2.4, a), which is colloidally stable above the VPTT in water, (Scheme 2.4, b), 
but then aggregates only in physiological ionic strength medium, (Scheme 2.4, c) is 
required. This approach avoids potential issues of premature gelation when injected 
into a subcutaneous site; as the nanogel dispersion is injected from a syringe 
(Scheme 2.4, d), if the particles were purely temperature responsive they may 
prematurely aggregate, causing a needle blockage as they heat up travelling along the 
hypodermic needle into the body (Scheme 2.4, e). Additionally, the aggregation 
response of the nanogels once in the tissue and in contact with a higher ionic strength 
is likely to be rapid, so that they aggregate to entrap their payload to avoid a burst 
release of drug into the body, (Scheme 2.4, f). Hence the need for the nanogels to be 
dual responsive, i.e. they aggregate when both above their VPTT, and in the presence 
of physiological ionic strength. There are a few limited examples in which the 
triggered flocculation of polyNIPAM nanogels into larger microscopic flocs has 
previously been used to block both membrane pores,36,37 and release drug,38 however 
there are currently no examples that use triggered aggregation on a macroscopic scale 
to form a drug depot. 
45 
 
 
CHAPTER 2 
 
Scheme 2.4 Illustration of ISFI based on dual triggered aggregation of polyNIPAM nanogels: 
a) swollen nanogels at room temperature in aqueous dispersion form, b) collapsed nanogels 
above VPTT, c) aggregated nanogels above VPTT and in contact with salt, d) aqueous 
dispersion in syringe, e) injection of dispersion through hypodermic needle inserted into 
subcutaneous site f) aggregation of dispersion upon arrival at subcutaneous site. 
 
In designing an ISFI using temperature and ionic strength as dual triggers to induce 
nanogel aggregation there are two main aspects to consider. Firstly, the size of the 
nanogel, and secondly, surfactant or stabiliser used in the synthesis; both of these 
factors could have an effect on depot formation behaviour. This could include the 
porosity of the depot, influencing the drug release rate.38 The uniformity and 
mechanical strength of the depot could also vary, giving potentially unwanted 
fluctuation or variation in drug release rate.39 There may also be flocculation on a 
microscopic scale, rather than complete macroscopic aggregation, and differences in 
the degree of aggregation at different dispersion concentrations. Finally the optimal 
system must undergo fast aggregation to avoid burst release of its payload,40 and only 
display aggregation behaviour selectively at physiological ionic strength and 
temperature, rather than at a temperature above the VPTT of the nanogels alone.  
Control over the size of the nanogels can be achieved by varying the concentration of 
surfactant, as demonstrated previously with sodium dodecyl sulphate (SDS), a 
surfactant which provides electrostatic stabilisation.41 Polymerisation with surfactants 
such as SDS has been shown to allows greater control over the polymerisation; 
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producing particles with lower dispersity. Polyvinylpyrrolidone (PVP) (scheme 2.5), 
a steric stabiliser, may also have an effect on particle size with concentration, as shown 
previously for poly(vinyl alcohol), which is another steric stabiliser.35  
 
Scheme 2.5 Chemical structure of Polyvinylpyrrolidone (PVP). 
2.1.4. Polyvinylpyrrolidone Aided Nanogel Synthesis and Dispersion 
More generally, polyNIPAM nanogel ISFIs for all three solidification concepts could 
also be enhanced with the inclusion of PVP. This is because PVP is a stabiliser which 
complexes with many drugs to increase dissolution rate, as well as acting as a 
dispersing agent for nanoparticles.42 With nanogels usually stored in lyophilised form 
before use, PVP physical absorption would potentially aid in the dispersion process of 
both the nanogels and drug payload, aiding the preparation of the ISFI before injection. 
PVP also exhibits minimal cytotoxicity and immunogenicity in parenteral usage,43 and 
can aid colloidal nanoparticle synthesis and colloidal stability.44 PVP has already been 
incorporated in the synthesis of polyNIPAM nanogels,45 and although it was suggested 
that the PVP is chemically grafted to the surface of nanoparticles in free radical 
polymerisation through the generation of PVP macroradicals,46,47 this is unlikely and 
physical absorption of PVP is instead suggested to take place. This could give greater 
control of particle size and dispersity, as shown to be the case in the synthesis of other 
nanoparticles.44,48 For the charge based colloidal gel network concept, the relative size 
of the two nanogel species likely also has an effect on the cohesion strength of the 
network. Hence PVP could be used to control nanoparticle size through the usage of 
different average molecular weight (Mw) PVP. In the formation of 
poly(glycidyl methacrylate) particles, higher Mw PVP created smaller particles. This 
behaviour was attributed to the higher Mw PVP being able to absorb faster and stabilise 
a larger surface area in the dispersion polymerisation process before the particles have 
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time to agglomerate into larger particles.48 Hence a similar effect should be seen when 
PVP is used in the synthesis of polyNIPAM nanogels to control particle size. 
2.1.5. Chapter Aims 
The aims of this chapter are to determine the feasibility of three different ISFI 
formation concepts which are all based on polyNIPAM nanogels. Generally, the aim 
for each of the three concepts is to alter the chemistry of the nanogels to create 
nanogels that match a set of criteria required to become a good candidate for an in situ 
forming implant. Criteria to be met: a) liquid or injectable gel at room temperature 
b) rapid solidification at 37 °C in PBS* (Phosphate Buffered Saline, 1X strength, 
pH 7.4) c) intended colloidal stability/instability under different conditions. To meet 
this criteria, properties such as surface charge density, size, and colloidal stability will 
be modified through the use of different co-monomers and stabiliser compositions. 
The aims of each concept are as follows: 
1. pH enhanced thermally triggered gelation to form a shrunken gel 
Main objective: 
• Incorporate PVP into a polyNIPAM-co-acrylic acid nanogel, to improve its 
function as an ISFI in terms preventing nanogel aggregation under 
physiological conditions and control over nanogel size and dispersity during 
synthesis.  
Other objectives:  
• Synthesis of PVP and non PVP polyNIPAM-co-acrylic acid nanogels 
(scheme 2.5), to compare the effect of PVP on the synthesis of these nanogels.  
• Study effect of pH and PBS (1X strength, pH 7.4)  on colloidal stability of 
polyNIPAM-co-acrylic acid nanogels across a temperature range. 
• Vary nanogel acrylic acid content and find relationship to nanogel surface 
charge density and pH based swelling. 
• Study effect of nanogel dispersion concentration on phase behaviour. 
                                                          
 
* For the remainder of the thesis ‘PBS’ refers to (Phosphate Buffered Saline, 1X 
strength, pH 7.4) 
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Scheme 2.6 Chemical structure of polyNIPAM-co-acrylic acid nanogels formed from free 
radical precipitation polymerisation. x = polyNIPAM, y = BIS, z = poly(acrylic acid). 
2. Charge based colloidal gel network formation 
Main objective: 
• Demonstrate the formation of a gel via charge interactions between 
polyNIPAM-co-acrylic acid and polyNIPAM-co-allylamine nanogels at 37 °C 
in PBS. 
Other objectives:  
• Synthesis of polyNIPAM-co-allylamine nanogels (scheme 2.6) with different 
sizes and charge densities. 
• Study effect of pH and PBS (1X strength, pH 7.4) on colloidal stability of 
polyNIPAM-co-allylamine nanogels across a temperature range. 
• Compare surface charge density of polyNIPAM-co-allylamine and 
polyNIPAM-co-acrylic acid nanogels across a pH range. 
 
Scheme 2.7 Chemical structure of polyNIPAM-co-acrylic acid and polyNIPAM-co-
allylamine nanogels formed from free radical precipitation polymerisation. x = polyNIPAM, 
y = BIS, z = poly(acrylic acid), a = polyNIPAM, b = BIS, c = allylamine. 
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3. Triggered aggregation through the dual stimuli of temperature and ionic strength 
Main objective: 
• Create a nanogel which as a dispersion can selectively aggregate when both at 
37 °C and in PBS rather than water. 
Other objectives:  
• Determine how SDS and PVP concentration used in the synthesis effects the 
size and dispersity of the polyNIPAM nanogels formed. 
• Investigate the colloidal stability of nanogels synthesised with no surfactant, 
PVP or SDS in water and PBS across a temperature range. 
• Determine how dilute behaviour of nanogels compares with a concentrated 
dispersion in terms of aggregation behaviour. 
 
Scheme 2.8 Chemical structure of polyNIPAM nanogels formed from free radical 
precipitation polymerisation. k = polyNIPAM, l = BIS. 
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2.2. Results and Discussion 
2.2.1. pH Enhanced Thermally Triggered Gelation to give an In Situ Implant 
PolyNIPAM-co-acrylic acid nanogels were synthesised using 5.0 and 15.0 wt% acrylic 
acid as a comonomer via precipitation polymerisation (figure 1.8, a) (AcA-5.0, 
AcA-15.0), (table 2.1). See methods section 2.4.2, for full synthesis details. It was 
previously found that surfactant free polymerisation of NIPAM 
(N-isopropylacrylamide) gave large particles with a broad dispersity above a reactant 
concentration of 0.5% w/v as the charge conferred on the particles from the initiator 
was considered too low.49 This synthesis was improved with the addition of a 
surfactant (dispersion polymerisation), to give much better control over particle size, 
stability, and polydispersity.41,49 The reactant concentration for AcA-5.0 and AcA-15.0 
was 0.7% w/v. It was anticipated that the extra charge provided by the acrylic acid 
comonomer would be great enough to electrostatically stabilise the particles during 
synthesis, however, AcA-5.0 and AcA-15.0 particles were still large compared to the 
usual size of polyNIPAM nanogels (hydrodynamic diameters of 1025 and 1328 nm 
respectively),35 and have a broad dispersity (PdI values of 0.51 and 0.43 respectively). 
However, they showed a swelling in response to pH change, with a significant 
reduction in particle hydrodynamic diameter when the pH was reduced from pH 7 to 
pH 2, (table 2.1). With the introduction of the steric stabilizer PVP 55K (where 55K 
refers to an average molecular weight of 55,000) in the synthesis of samples with 
increasing wt% of acrylic acid comonomer (AcA-0.0-55K, AcA1.5-55K, AcA2.0-55K 
and AcA5.0-55K), the dispersity was narrower than AcA-5.0 and AcA-15.0 (≤0.29 for 
the four samples compared to ≥0.43), owing to the steric stabilisation provided by PVP 
to the precursor particles during synthesis, despite an increase to a reactant 
concentration of 1.9% w/v. The hydrodynamic diameter was also correspondingly 
smaller for the four samples (≤ 688 nm compared to ≥1025 nm); this is an indication 
the  precursor particles were stabilised by PVP in the initial stage of synthesis, allowing 
them to grow at the same rate to maintain a lower dispersity, rather than coalescence 
into larger particles with broader dispersity at a later stage of the synthesis.48,50,51 The 
presence of PVP after synthesis and workup was confirmed with 1H NMR, 
substantiating previous claims that PVP remains physically absorbed to the nanogel 
surface after synthesis, as any non-associated PVP is likely to have been removed in 
the dialysis and centrifugation steps after synthesis (table A.1, figure A.1, 
Appendix).46,47  
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Table 2.1 Properties of polyNIPAM-co-acrylic acid nanogels, with and without PVP. 
Sample Reactant  
concentrationa 
Acrylic acidb PVP Hdc  
(nm) 
PdI 
 (w/v %) (wt%) (Mw) pH 2 pH 7  
AcA-5.0 0.7 5.0 - 637 1025 0.51 
AcA-15.0 0.7 15.0 - 846 1328 0.43 
AcA-0.0-55K 1.9 0.0 55K 442 474 0.21 
AcA-1.5-55K 1.9 1.5 55K 418 424 0.29 
AcA-2.0-55K 1.9 2.0 55K 419 391 0.20 
AcA-5.0-55K 1.9 5.0 55K 426 688 0.28 
a percentage mass of NIPAM, BIS and acrylic acid in reaction solvent volume. 
b wt% of acrylic acid used in the synthesis of the nanogel (wt% of NIPAM and acrylic 
acid mass). 
c Hydrodynamic diameter (Hd) measurements performed at 1mg ml-1, 25 °C using DLS 
with the mean value of triplicate measurements used. 
 
Lower wt% acrylic acid additions were used in the PVP nanogels (0.0, 1.5, 2.0, 
5.0 wt% in PVP nanogels vs 5.0 and 15.0 in non PVP nanogels), and from this it can 
be seen that a minimum of 5.0 wt% of acrylic acid is required to give a great enough 
charge density for a pH swelling response to be seen in nanogels on increasing from 
pH 2 to pH 7 with or without PVP (there is no significant change in particle 
hydrodynamic diameter at pH 2 and pH 7 with <5 wt% acrylic acid nanogels, table 
2.1). 
Firstly, the colloidal stability of the non PVP nanogels was investigated. This was done 
by probing the AcA-15.0 nanogels at different pH values. This was of interest as in 
previous work, polyNIPAM-co-acrylic acid nanogels used in ISFIs were only 
stabilised electrostatically rather than sterically (e.g. with PVP) above the VPTT.9 As 
mentioned previously, at a pH < 4.25, the carboxylic acid functionality of the acrylic 
acid comonomer is predominantly protonated, due to its pKa value of 4.25, greatly 
reducing electrostatic stabilisation. Hence if polyNIPAM-co-acrylic acid nanogels are 
heated above their VPTT at low pH, there is the potential for the nanogels to flocculate 
or aggregate as electrostatic stabilisation is minimised. In use as an ISFI, the nanogels 
are injected at lower pH to give a less viscous, more easily injectable liquid. However, 
if the nanogels experience a temperature rise during the injection before the pH of their 
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dispersion increases, they could potentially aggregate prematurely and become 
difficult to inject into the body. The stability of polyNIPAM-co-acrylic acid nanogels 
above the VPTT at low pH was tested with AcA-15.0. This sample was heated at pH 4, 
pH 3 and pH 2 and analysed by dynamic light scattering (DLS) to observe the colloidal 
stability of the nanogels above the VPTT with decreased electrostatic stabilisation of 
lower pH values, (figure 2.1). Using the pKa value of 4.25 for acrylic acid, the 
percentage of carboxylic acid groups in carboxylate anion form at pH 4, 3 and 2 can 
be estimated as 36.0, 5.3 and 0.5% respectively, by using a form of the 
Henderson-Hasselbalch equation previously used to determine the degree of ionisation 
of comonomers at a given pH in polyNIPAM nanogels.10,52 When heated at pH 4 the 
hydrodynamic diameter of the AcA-15.0 nanogels decreased with increasing 
temperature as the particles deswelled from 1330 nm at 25 °C to 630 nm at 35 °C. 
Hence it can be concluded that they remained colloidally stable above the VPTT, 
owing to the electrostatic stabilisation provided by the acrylic acid, with an estimated 
36% in ionised form, (figure 2.1, a). At pH 3 a decreasing fraction of the acrylic acid 
is ionised (c.a. 5.3%), reducing electrostatic stabilisation. Again, the particles began to 
reduce in diameter as they deswelled with increasing temperature, however, above the 
VPTT the particles now began to flocculate, indicated by a rise in hydrodynamic 
diameter to ~2750 nm, which likely represents the average hydrodynamic diameter of 
multiple particles contained in flocs (figure 2.1, b). At pH 2 the electrostatic 
stabilisation is very low, essentially provided only by potassium persulfate initiator 
(c.a. 0.5% of acrylic acid in ionised form), and consequently the particles completely 
aggregated above the VPTT, with a rapid increase in hydrodynamic diameter to 
> 4000 nm as macroscopic aggregates form (figure 2.1, c). If these particles are 
injected at < pH 4 there is the potential for them to flocculate or macroscopically 
aggregate and cause difficulties in injection, or complete needle blockage.  
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Figure 2.1 Colloidal stability of AcA-15.0 when heated from 20 °C to 40 °C at different pH 
values as a 1 mg ml-1 dispersion. Top left inset: Graphical representation of charge density at 
different pH values, KPS = potassium persulphate initiator fragment, COOH = carboxylic acid 
functional group of acrylic acid comonomer. Samples measured using DLS with the mean 
value of triplicate measurements used. 
Interestingly, this temperature triggered aggregation behaviour above the VPTT, 
specifically in deionised water, is most likely only possible when acrylic acid or other 
pH responsive comonomers are incorporated into the nanogel and the pH is then 
lowered. This is because a lower charge density is required to give lower electrostatic 
stabilisation, allowing aggregation above the VPTT in water. Particles cannot simply 
be synthesised with lower charge density to allow their aggregation above the VPTT, 
as the synthesis is also conducted above the VPTT. Hence particles would keep 
growing in size until a higher charge density is reached, or synthesis fails with the 
creation of bulk aggregated material. To summarise, some of the charge density in the 
particle synthesis must be provided by a pH responsive comonomer, so charge density 
can be reduced post synthesis, via a change in pH, to allow temperature triggered 
aggregation in deionised water. As aggregation occurs when the temperature is > 31 °C 
and pH is <4, this provides us with nanogels which are able to undergo triggered 
aggregation at low pH and physiological temperature, which may find future usage. 
Examples would be in the potential application to release drug or adhere to tissue in 
an acidic environment,53,54 or to protect drug as it transits through the stomach for 
delivery to the intestine.55 
It is well known that polyNIPAM nanogels and particles with a polyNIPAM shell used 
for biomedical applications often become colloidal unstable in physiological ionic 
strength medium (e.g. PBS) if sufficient colloidal stabilisation is not provided. This is 
because electrostatic stabilisation is reduced by the screening of surface charge in the 
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high ionic strength media.56 Previous examples show the result of this is that 
aggregation can occur at physiological temperature and ionic strength.57,58 When PVP 
is physically absorbed to the nanogels, it provides steric stabilisation of the nanogels 
above the VPTT to prevent aggregation.35,45 A sample containing 55K PVP, and no 
acrylic acid comonomer, AcA-0.0-55K, was heated in water and PBS to assess the 
colloidal stability of these nanogels above the VPTT in ionic strength medium.   The 
sample without acrylic acid was selected, as this then determines colloidal stability 
provided only by the steric stabilisation of PVP, avoiding any extra contribution to 
colloidal stability from the electrostatic stabilisation provided by acrylic acid. It can 
be seen that with PVP physically absorbed to the nanogel, the particle deswelled to a 
smaller particle diameter in both water and PBS with increasing temperature, 
suggesting the sample remained colloidally stable when heated both in water and PBS, 
(figure 2.2). This can be compared to electrostatically stabilised polyNIPAM nanogels, 
which are often not colloidally stable when heated above the VPTT in physiological 
ionic strength medium.59 PBS can also be seen to shift the VPTT of AcA-0.0-55K to 
lower temperature compared to water. The electrolyte concentration of PBS is 0.15 M, 
and similar VPTT shifts were seen for polyNIPAM nanogels when the electrolyte 
concentration reached > 0.1 M,6,60 as well as the LCST of linear polyNIPAM.61  
  
Figure 2.2 Colloidal stability of AcA-0.0-55K when heated from 15 °C to 45 °C in water and 
PBS as a 1 mg ml-1 dispersion. Samples measured using DLS with the mean value of triplicate 
measurements used. 
The hydrodynamic diameter and zeta potential of the 55K PVP nanogels which were 
synthesised with acrylic acid comonomer were then measured at different pH values 
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to ascertain the pH at which swelling of the nanogels occurs, (figure 2.3). As the pH 
increased, the zeta potential of each nanogel sample decreased from an initial value of 
-2 mV, except for AcA-0.0-PVP, which does not contain any pH responsive acrylic 
acid comonomer. The zeta potential reached a maximum value of -4.5, -8.4 
and -22.8 mV for 1.5, 2.0 and 5.0 wt% of acrylic acid used in the particle synthesis 
respectively when a pH of 7 was reached. The onset of increasing negative zeta 
potential occurred at pH 3.5 for all the nanogel samples containing acrylic acid. The 
hydrodynamic diameter of the particles however remained constant with increasing 
pH, at ~420 nm. Only the sample with 5 wt% of acrylic acid (AcA-5.0-55K) showed 
a change in hydrodynamic diameter with pH. These particles started to swell at pH 5, 
by which point they had reached a corresponding negative zeta potential value 
of -13 mV. Therefore it seems likely that swelling of the particles only occurs once a 
sufficient negative zeta potential value is reached, where there is a great enough 
density of ionised acrylic acid groups to cause internal repulsion and hence particle 
swelling. The other acrylic acid nanogels (AcA-1.5-55K, AcA-2.0-55K) did not show 
swelling as pH increased, as the maximum value of zeta potential they reach is below 
the zeta potential value at which the onset of swelling in AcA-5.0-55K (-13 mV) 
occurred. 
 
Figure 2.3 pH responsive change in hydrodynamic diameter (■) and zeta potential () of 55K 
PVP polyNIPAM nanogels containing varying amounts of acrylic acid comonomer in the pH 
range 2-7 of nanogels dispersed as a 1 mg ml-1 dispersion with 10 mM NaCl at 25 °C. Samples 
measured using DLS and laser doppler electrophoresis (LDE) with the mean value of triplicate 
measurements used. 
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The increase in zeta potential magnitude with pH can be related to the increasing 
proportion of deprotonated carboxylic acid groups providing greater surface charge, 
as zeta potential reflects the electrostatic potential at the outer boundary of a nanogel, 
which is effected by a change in charge density.29,62 The α-value, as derived 
previously,10 gives the fraction of deprotonated carboxylic acid groups for a given pKa 
value, can be determined with a derivative of the Henderson-Hasselbalch equation:10,52 
 
The pKa of poly(acrylic acid) is 4.5.63 This is higher than the respective monomer pKa 
of 4.25,11 due to the polyelectrolyte effect. This effect is caused by a high density of 
deprotonated carboxylic acid groups in the polymer chain opposing the formation of 
more deprotonated groups, due to the increased electrostatic repulsion this would 
cause, increasing the pKa value.10 We can assume the density of carboxylic acid 
groups in polyNIPAM-co-acrylic acid particles is similar to poly(acrylic acid), as the 
hydrophilicity of the comonomer will concentrate it towards the surface of the particle. 
Hence the negative value of α (when pKa = 4.5), representing the fraction of 
deprotonated carboxylic acid groups, mirrors the increase in zeta potential of the 
AcA-5.0-55K particles with pH, due to the change in charge density of the particles 
(figure 2.4). The increase in zeta potential of the particles occurred at an even higher 
pKa value than is accounted for with the polyelectrolyte effect, (figure 2.4), which was 
previously attributed to factors such as the hydrophobic microenvironment of the 
nanogels hindering formation of deprotonated carboxylic acid groups.10,64 
 
Figure 2.4 Comparison of fraction of deprotonated carboxylic acid groups (α) based on a 
pKa value of 4.5 with zeta potential () of AcA-5.0-55K at different pH values. Samples 
measured using LDE with the mean value of triplicate measurements used. 
57 
 
 
CHAPTER 2 
AcA-5.0-55K particles showed pH responsive swelling, and colloidal stability at 
physiological ionic strength and temperature. These properties are desirable in a 
system which undergoes pH triggered gelation to form an implant. Hence this sample 
was selected to conduct a phase study. Concentrated dispersions were formed in PBS 
(1X strength, pH 7.4) at 37 °C to ascertain whether a shrunken gel phase could be 
formed, (table 2.2). In previous work, a shrunken gel was found to form in a 4 wt% 
and 3.5 wt% dispersion of polyNIPAM nanogels at 37 °C.16,17 The viscosity of the 
liquid dispersion formed by AcA-5.0-55K increased with increasing concentration, but 
only became a gel at a concentration of 350 mg ml-1 (25.9% w/w). There was also no 
expulsion of any solvent from the gel as occurs upon shrunken gel formation. These 
results suggest that PVP physically absorbed to the surface of the nanogels disrupts 
the particles from forming a shrunken gel. Instead a swollen gel was formed due to a 
volume blocking mechanism of hard sphere theory in which the nanogel spheres 
become close packed at high enough concentration.18,19  
 
Table 2.2 AcA-5.0-55K phase behaviour with concentration. 
Concentration Phasea 
(mg ml-1)  
100 Liquid 
200 Liquid 
300 Liquid 
350 Gel 
a Phase behaviour in PBS (1X strength, pH 7.4) dispersion at 37 °C 
 
Upon cooling the 350 mg ml-1 dispersion a gel remained with a reduction in turbidity, 
(table 2.3). Further heating of the sample resulted in aggregation at 60 °C, see images 
in table A.2, Appendix. This further suggests the formation of a swollen gel of close 
packed particle, as a shrunken gel would be expected to change phases into a liquid as 
it cooled,16,17 whereas a swollen gel would remain in the gel phase. This finding means 
PVP nanogel samples are not suitable for an ISFI, as a very high concentration of the 
sample is required to form a depot and injectability of this gel would potentially present 
issues. Hence other alternative methods of forming an ISFI were explored. 
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Table 2.3 AcA-5.0-55K phase behaviour with temperature. 
Temperature Phasea 
(°C)  
5 Gel 
18 Gel 
25 Gel 
37 Gel 
45 Gel 
60 Aggregate 
a Phase behaviour in PBS dispersion at 350 mg ml-1 
 
To conclude, it was found that pH 4.5 was the optimal pH to inject 
polyNIPAM-co-acrylic acid nanogels without steric stabilisation, which are intended 
for use in an ISFI. This is because pH 4.5 lies above the pH 4 limit of colloidal stability, 
but below the onset of particle swelling at pH 5. However, injection at this pH may 
causes discomfort for a patient.65 These nanogels could also potentially be used for 
triggered aggregation at low pH and physiological temperature. When PVP is 
physically absorbed to the surface of the nanogels, they remain colloidally stable under 
physiological conditions, and at least 5.0 wt% of acrylic acid is required to give a 
swelling response, however the PVP appears to disrupt the ability of the nanogels to 
form a shrunken gel. 
2.2.2. Charge Based Assembly to form a Colloidal Gel Network Implant 
PolyNIPAM-co-allylamine nanogels with increasing PVP Mw were synthesised, with 
moles of PVP and allylamine used kept constant in samples AlA-2.6-10K, 
AlA-2.6-25K, AlA-2.6-40K and AlA-2.6-55K, (table 2.4), whilst average molecular 
weight (Mw) of PVP increased.  
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Table 2.4 Properties of polyNIPAM-co-allylamine nanogels. 
Sample Allylaminea 
(wt%) 
PVP 
(Mw) 
Hd  
(nm)b 
PdI Zeta Potential (ζ) 
(mV)c 
     pH 5 pH 10 
AlA-2.6-10K 2.6 10K 1600 0.45 - 
* 
* 
* 
- 
AlA-2.6-25K 2.6 25K 487 0.18 - - 
AlA-2.6-40K 2.6 40K 385 0.18 - - 
AlA-2.6-55K 2.6 55K 218 0.13 0.5* -4.6* 
AlA-5.0-10K 5.0 10K 475 0.06 10.3 
 
-6.4* 
AlA-10.0-10K 10.0 10K 390 0.22 14.1 
 
-5.0* 
AlA-15.0-10K 15.0 10K 392 0.07 15.4 -5.4* 
a wt% of allylamine used in the synthesis of the nanogel (wt% of NIPAM and allylamine 
mass). 
b Hydrodynamic diameter (Hd) measurements performed at pH 7, 1 mg mL-1 in water at 25 °C 
using the mean of three DLS measurements. 
c Zeta Potential measured at pH 5 and pH 10, 1mg ml-1, 25 °C, in 10 mM NaCl, samples 
measured using LDE with the mean value of triplicate measurements used. 
*Zeta potential value negligible (< ±10mV)  
 
Figure 2.5 Hydrodynamic diameter (Hd) and Polydispersity index (PdI) of 
polyNIPAM-co-allylamine nanogels with 2.6 wt% allylamine comonomer and varying Mw 
PVP. Samples measured using DLS with the mean value of triplicate measurements used. 
 
It can be seen that larger Mw PVP leads to smaller particles, (figure 2.5). There was a 
big decrease in particle hydrodynamic diameter (from 1600 to 487 nm) and PdI (from 
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0.45 to 0.18) on increasing PVP Mw from 10K to 25K respectively. This was followed 
by a much more gradual decrease on increasing PVP Mw from 25K, to 40K and then 
55K (487, 385, 218 nm and 0.18, 0.18, 0.13 for 25K, 40K, 55K stabilisation 
respectively). The zeta potential of the AlA-2.6-55K particles was measured, but was 
found to be negligible (< ±10mV), suggesting the positive charge from the allylamine 
comonomer at 2.6 wt% counters the negative charge of the persulfate initiator chain 
end fragment, leaving an overall neutral surface charge, (table 2.4). This suggests that 
with the loss of electrostatic stabilisation, the particle synthesis relied on steric 
stabilisation. 10K PVP did not appear to be adequate to provide full stabilisation during 
the dispersion polymerisation, leading to large particles with broad dispersity. From 
25K to 55K PVP, the particles become gradually smaller, and can be attributed to the 
greater surface area of a precursor particle which can be stabilised by a longer PVP 
chain, and greater rate of PVP absorption to the particle surface.48 To determine 
whether electrostatic stabilisation was able to produce particles of small size and low 
dispersity, 10K PVP was used in conjunction with higher allylamine wt%, where 
increasing allylamine should provide greater electrostatic stabilisation, without the 
influence of steric stabilisation from PVP with a Mw higher than 10K. In the synthesis 
of AlA-5.0-10K, AlA-10.0-10K and AlA-15.0-10K, 5.0, 10.0 and 15.0 wt% of 
allylamine respectively were used. This lead to a measurable positive zeta potential at 
pH 5, as the charge contributed by allylamine comonomer outweighed that of the 
persulfate initiator, (table 2.4). At pH 10 the zeta potential is negligible as the amine 
groups become predominantly deprotonated (allylamine has a pKa of 9.49). When we 
compare these samples to AlA-2.6-10K, smaller particles of low dispersity are 
achievable, (figure 2.6). This time, despite the 10K PVP not being able to provide 
significant enough steric stabilisation, the greater allylamine content allows 
electrostatic stabilisation of the precursor particles in the polymerisation process. It 
can be concluded that stabilisation during synthesis was provided sterically by PVP 
with a Mw of 25K or greater, or by a sufficient charge density for electrostatic 
stabilisation. In the case of allylamine nanogels, a greater than expected comonomer 
addition was required to achieve electrostatic stabilisation, as some of the charge is 
effectively neutralised by using a negatively charged persulfate initiator. 
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Figure 2.6 Hydrodynamic diameter (Hd) and Polydispersity index (PdI) of 
polyNIPAM-co-allylamine nanogels with 10K PVP and varying wt% of allylamine 
comonomer. Samples measured using DLS with the mean value of triplicate measurements 
used. 
 
With an understanding of the effect of precursor particle stability with increasing PVP 
Mw and allylamine wt%, the stability provided by these steric or electrostatic 
contributions on the nanogel above its VPTT and in the presence of PBS was 
determined. AlA-10.0-10K was heated in water at different pH values and in PBS. In 
water, at pH 7.4 we can see that the electrostatic stabilisation provided by the 
allylamine prevents the nanogels from flocculating or aggregating, (figure 2.7, a). 
When conducted at pH 10, the particles aggregated as electrostatic stabilisation was 
removed with the deprotonation of the amine groups, and 10K PVP again, was unable 
to provide the steric stabilisation required, (figure 2.7, b). In pH 7.4 PBS, the 
electrostatic stabilisation was also screened to a great enough extent that the particles 
aggregate above the VPTT, (figure 2.7, c). The particle deswelling and aggregation 
takes place at a lower temperature in PBS than at pH 10. As mentioned previously, the 
higher electrolyte content of PBS (1X strength, pH 7.4) shifts the VPTT to lower 
temperature.6,60 This effect is especially prominent with Cl- ions, (which along with 
Na+) are the highest concentration ions in PBS. In a range of ions, these were found to 
have the largest effect on the disruption of water molecules in the hydration shell 
around polyNIPAM.66 
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Figure 2.7 Hydrodynamic diameter (Hd) as a fraction of hydrodynamic diameter at 15 °C 
(Hd15 °C) of polyNIPAM-co-allylamine nanogels with 10K PVP and 10 wt% of allylamine 
comonomer (AlA-10.0-10K) in water at a) pH 7 and b) pH 10 and c) PBS at pH 7.4. Samples 
measured using DLS with the mean value of triplicate measurements used. 
 
The zeta potential of AlA-10.0-10K with changing pH was measured and compared 
with AcA-5.0-55K to observe the pH value at which both polyNIPAM-co-allylamine 
and polyNIPAM-co-acrylic acid nanogels reside at maximum zeta potential. This 
value was found to be pH 6.5, (figure 2.8), however extracellular pH lies at pH 7.4. At 
this pH the polyNIPAM-co-allylamine nanogel would be at 70% of its maximum zeta 
potential. The two nanogels were dispersed separately in water at pH 7, where they 
behaved as a flowable liquid at 25 °C. The two species have a significant magnitude 
of zeta potential at pH 7, (table 2.5). When these two liquid dispersions were combined 
in an equal mass ratio to form a 7 wt% aqueous dispersion, a self-supporting gel was 
formed in water when at room temperature (25 °C), (figure 2.9). However upon 
heating, this turned into a liquid. Upon heating the nanogels deswell as the PNIPAM 
reduces contact with water. It is likely that the PVP physically absorbed to the surface 
of the nanogel, remains extended into solution. This would create a greater separation 
of the charges which are contained in the receded PNIPAM chains, so that they can no 
longer interact strongly enough to form a colloidal gel network. As in section 2.2, the 
PVP appears to disrupt the phase behaviour of the nanogels. In this case it prevents the 
formation of a colloidal gel network to form an in-situ drug delivery depot. 
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Figure 2.8 Zeta potential of AlA-10.0-10K and AcA-5.0-55K with change in pH, 
a) pH 6.5, b) pH 7.4. Samples measured at 25 °C using LDE with the mean value of 
triplicate measurements used. 
 
Table 2.5 Properties of nanogels used to form a colloidal gel network. Samples 
measured using LDE and DLS in triplicate and mean value used. 
Sample Zeta Potential (ζ)a 
(mV) 
Hdb 
(nm) 
PVP 
(Mw) 
AlA-10.0-10K  +14 390 10K 
AcA-5.0-55K -22 688 55K 
a Zeta Potential measured at pH 7, 1mg ml-1, 25 °C, in 10 mM NaCl.  
b Hydrodynamic diameter (Hd) measurements performed at pH 7, 1mg ml-1, 25 °C. 
Samples measured using DLS with the mean value of triplicate measurements used. 
 
 
Figure 2.9 Photograph (digital image) of self-supporting gel formed from AlA-10.0-10K and 
AcA-5.0-55K in an equal mass ratio as a 7 wt% dispersion. The respective starting nanogels 
were liquid dispersions which formed a self-supporting gel when combined. 
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2.2.3. In Situ Implant Formation Triggered by Temperature and Ionic Strength 
PolyNIPAM nanogels were synthesised in the presence of SDS, PVP, or without 
surfactant and the hydrodynamic diameter and PdI of the particles were measured 
(table 2.6). The samples AcA-5.0 and AcA-15.0 in section 2.2.1 and nanogels 
previously synthesised without surfactant or stabiliser showed that often large 
nanogels with high dispersity are produced without surfactant present,41,49 however 
particles with lower dispersity have also previously been produced, with the 
concentration of monomer, initiator and cross-linking agent amongst factors which 
affect the quality of the nanogels produced.67,68 Nanogels without added surfactant or 
stabiliser were considered a good candidate for a depot which forms through 
aggregation, as the relatively small amount of electrostatic stabilisation from the 
persulfate initiator may allow rapid aggregation of the nanogels in PBS at 37 °C to 
entrap a payload without a burst release. Hence nanogels with a NIPAM monomer 
concentration of 6 mg ml-1 and BIS cross-linking agent concentration of 0.6 mg ml-1 
where synthesised in a series of five repeats, PNA-00, PNA-00-2, PNA-00-3, PNA-00-
4, PNA-00-5. These concentrations lie well below the maximum concentration at 
which Pelton and Chibante found ‘good’ nanogels were no longer formed.67 It can be 
seen that whilst a reasonably low dispersity is achieved in all samples, there is some 
variation in the size of the nanogels formed, (figure 2.10), likely because a surfactant 
is required in the synthesis for complete control over particle size.41,49  
Table 2.6 Properties of polyNIPAM nanogels.  
Sample 10K PVP SDS Z-Avea PdI 
 (mg ml
-1) (mg ml-1) (nm)  
PNA-00 - - 581 0.10 
PNA-00-2 - - 879 0.13 
PNA-00-3 - - 776 0.07 
PNA-00-4 - - 605 0.10 
PNA-00-5 - - 884 0.11 
PVP-0.3 0.3 - 604 0.06 
PVP-0.9 0.9 - 629 0.15 
SDS-0.015 - 0.015 573 0.01 
SDS-0.030 - 0.030 496 0.03 
SDS-0.060 - 0.060 370 0.01 
a Hydrodynamic diameter (Hd) measurements performed at 1mg ml-1, 
25 °C. Samples measured using DLS with the mean value of triplicate 
measurements used. 
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Figure 2.10 Hydrodynamic diameter (Hd) and Polydispersity index (PdI) of 
surfactant/stabiliser free polyNIPAM nanogels with an identical repeat synthesis. Samples 
measured using DLS with the mean value of triplicate measurements used. 
Samples were also synthesised with different concentrations of 10K PVP, (PVP-0.3 
and PVP-0.9), which contained 0.3 and 0.9 mg ml-1 PVP respectively. These samples 
are similar in size and dispersity to the non-PVP samples, as the 10K PVP was 
previously demonstrated to not provide steric stabilisation in the nanogel synthesis, 
and hence any significant effect on the resulting nanogel size and dispersity. Finally 
an increasing concentration of SDS was used in the synthesis of SDS-0.015, 
SDS-0.030 and SDS-0.060 of 0.015, 0.030 and 0.060 mg ml-1 respectively. Increasing 
amounts of SDS reduce the particle size, (figure 2.11), as shown previously.41 The 
dispersity of these samples was also very low (≤0.03). 
 
Figure 2.11 Decrease in hydrodynamic diameter (Hd) with increasing SDS concentration 
used in particle synthesis. Samples measured using DLS with the mean value of triplicate 
measurements used. 
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To assess the aggregation behaviour of the nanogels they were heated as a dilute 
dispersions (1 mg ml-1) to monitor changes in the dispersion properties using DLS, and 
as a concentrated dispersion (175 mg ml-1) to visually observe aggregation in water 
and PBS. Ideally the samples should remain colloidally stable as an aqueous dispersion 
as both a dilute and concentrated dispersion at elevated temperatures, where a 
concentrated dispersion should exist as a liquid phase rather than aggregating. In PBS 
the samples should aggregate, and a concentrated dispersion should phase separate 
when heated to act as a suitable ISFI. This aggregation should be into a single uniform 
depot material, as opposed to irregular fragments of fractured or varying sized 
aggregates. Sample PNA-00 (no surfactant or stabiliser) remained stable as a dilute 
dispersion (1 mg ml-1) when heated in water, and aggregated completely in a narrow 
temperature range (32.5 °C ±0.5) in PBS, as indicated by monitoring the 
hydrodynamic diameter of the dispersion over a temperature range (figure 2.12, a). As 
a concentrated dispersion the same behaviour was reflected in the visual phase 
behaviour; a swollen gel at 25 °C transitions to a liquid when the nanogels are 
dispersed in water, (figure 2.12, b). In PBS this swollen gel phase separates when 
heated, rapidly forming a single piece of aggregate which expels excess solvent and 
retains the uniform shape of the cylindrical vial. 
 
 
Figure 2.12 Dilute and concentrated nanogel dispersion behaviour of sample PNA-00, a) 
dilute dispersion colloidal stability in water and PBS measured using DLS, samples 
measured using DLS with the mean value of triplicate measurements used, b) Photographs 
(digital images) of concentrated dispersion phase behaviour in water (left) and PBS (right), 
arrows show transition from 25 °C to 37 °C. 
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With the PVP nanogels, the same dilute dispersion behaviour as PNA-00 can be seen 
for PVP-0.3, with aggregation at (32.5 °C ±0.5), however with greater PVP content, 
PVP-0.9 only flocculates to a diameter of 930 nm above 40 °C, resisting complete 
aggregation in PBS (figure 2.13, a). This was most likely due to the greater steric 
stabilisation provided by a large amount of PVP  physically absorbed to the nanogel.44 
Unlike PNA-00, the PVP based nanogels show varying degrees of aggregation in water 
as a concentrated dispersion. PVP-0.3 partially aggregates at 37 °C, and PVP-0.9 
completely aggregates. This suggests that whilst PVP provides colloidal stability in a 
dilute dispersion, it induces aggregation in a concentrated dispersion, (figure 2.13, b). 
This behaviour may be due to an attractive depletion force existing between the 
nanogels at higher concentration, where the separation distance of the particles is much 
smaller.69 At higher colloidal particle concentration, PVP has been shown to first 
bridge particles, followed by depletion phase separation as the concentration is further 
increased.70 The flocculation rate through bridging was also found not to be effected 
by the existence of double layer repulsion in negatively charge colloids,71 hence the 
negatively charged polyNIPAM nanogels created with persulfate initiator are unable 
to resist the PVP flocculation at higher concentration. PVP flocculation at high 
concentration also explains why PVP-0.9 is more completely aggregated than 
PVP-0.3, as it contains a higher proportion of PVP to enable the aggregation to occur. 
The PVP-0.9 sample also forms a less uniform aggregate, with the aggregate having a 
visibly rough surface, and imperfections in the cylindrical shape formed, especially in 
PBS.  
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Figure 2.13 Dilute and concentrated nanogel dispersion behaviour of PVP-0.3 and PVP-0.9, 
a) dilute dispersion colloidal stability in water and PBS, measured using DLS, samples 
measured using DLS with the mean value of triplicate measurements used, b) Photographs 
(digital images) of concentrated dispersion phase behaviour in water (left) and PBS (right), 
PVP-0.3 (top), and PVP-0.9 (bottom), arrows show transition from 25 °C to 37 °C. 
 
Finally, with nanogels synthesised in the presence of SDS, the colloidal stability and 
phase behaviour were almost identical to the PNA-00 nanogel, (figure 2.14). As a 
dilute dispersion the aggregation temperature is 1 °C lower than PNA-00 at 31.5 °C 
±0.5. This aggregation temperature was the same for the three samples, despite 
different concentrations of SDS being used to create particles of different sizes. In a 
concentrated dispersion highly uniform aggregates were formed in PBS. 
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Figure 2.14 Dilute and concentrated nanogel dispersion behaviour of SDS-0.015, SDS-0.030 
and SDS-0.060, a) dilute dispersion colloidal stability in water and PBS, samples measured 
using DLS with the mean value of triplicate measurements used, b) Photographs (digital 
images) of concentrated dispersion phase behaviour in water (left) and PBS (right), SDS-0.015 
(top), SDS-0.030 (middle), and SDS-0.060 (bottom), arrows show transition from 25 °C to 
37 °C. 
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In summary, PNA-00 and SDS based nanogels remain a liquid when heated in water, 
and aggregate below 37 °C in PBS, over a wide concentration range of 1-175 mg ml-1. 
This makes them suitable candidates for an ISFI. PVP based nanogels unfortunately 
aggregate at a higher concentration in water, and form less uniform aggregates in PBS, 
suggesting they are not as suitable, as the injection needle could become blocked, and 
the variation in the shape of the aggregate could lead to a variation in the release rate 
of drug.1  
2.3. Conclusions 
For an ISFI to function, a solidification must occur in situ. Three different approaches 
were investigated in order to find ways to trigger this solidification in response to 
physiological pH, ionic strength and temperature. PVP was physically absorbed to the 
nanogels for the two concepts which used pH to trigger the formation of a shrunken 
gel, and the formation of a self-assembled gel through charge interactions. This aided 
the synthesis process, producing nanogels with a lower dispersity and controlled size, 
as well as providing the nanogels with colloidal stability under physiological 
conditions to prevent aggregation. However, in both cases the PVP appeared to disrupt 
the formation of a gel under physiological conditions, and solidification under 
physiological conditions is a vital aspect required of an ISFI. This led to the 
elimination of these systems from further development. This was because the 
preliminary study into nanogels which selectively aggregate under physiological 
conditions was more promising as an ISFI, due to the rapid and complete aggregation 
under physiological conditions. Using PVP, SDS, and no stabiliser or surfactant, 
nanogels could be synthesised which were a liquid at room temperature and 37 °C in 
water, and aggregated when heated to 37 °C in PBS. However as a concentrated 
dispersion PVP based nanogels aggregated when heated in water, and so were 
eliminated as a potential candidate. The nanogels created with SDS, and without 
surfactant both remains liquid in water, and formed a macroscopic aggregate in PBS 
when heated as a concentrated dispersion, as desired. However, SDS gave the added 
advantage that nanogel size could also be tuned, with no impact of their phase 
behaviour, and the formation of the most uniform aggregates. SDS and surfactant free 
nanogels are therefore likely able to be injected and then solidify in situ when used as 
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a dispersion for an ISFI. These nanogels were taken forward for further development 
and testing. Although the nanogels form an aggregate rapidly, the ability of the 
nanogels to entrap a payload, and avoid a large burst release needs to be assessed, as 
well as the ability of the aggregate matrix which forms to allow sustained release over 
time.  
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2.4. Materials and Methods 
2.4.1. Materials 
N-Isopropylacrylamide (NIPAM, ≥99%), allylamine (AlA, ≥99%), acrylic acid (AcA, 
99%), N,N-methylenebis(acrylamide) (BIS, 99%), potassium persulfate (KPS, ≥99%), 
sodium chloride (NaCl, ≥99.5%), anhydrous sodium hydroxide pellets (NaOH, 
analysis grade), sodium dodecyl sulphate (SDS, ≥99%), polyvinylpyrrolidone, average 
mol wt 10,000 (PVP 10K), polyvinylpyrrolidone, average mol wt 25,000 (PVP 25K), 
polyvinylpyrrolidone, average mol wt 40,000 (PVP 40K), polyvinylpyrrolidone, 
average mol wt 55,000 (PVP 55K), were purchased from Sigma-Aldrich Company 
Ltd, Gillingham (Dorset) UK, a subsidiary of Merck KGaA, Darmstadt, Germany. 
Phosphate buffered saline tablets (Bioreagent), hydrochloric acid 37% (HCl, analytical 
grade), were purchased from Fischer Scientific UK, Loughborough, UK, a part of 
Thermo Fisher Scientific. Type I distilled water obtained from a water purification 
system with a resistivity of >18 MΩ cm−1 (PURELAB option R, Veolia). Spectra/Por 
2 Dialysis Tubing (MWCO = 12-14 kDa) was purchased from Spectrum Europe B.V., 
Breda, The Netherlands. All materials were used as received. 
2.4.2. PolyNIPAM Nanogel Synthesis 
The polyNIPAM nanogels were synthesised by precipitation polymerisation, or 
dispersion polymerisation where SDS or PVP was included in the synthesis. A 
summary of the formulation which was used for each nanogel species can be found in 
Table M.2.1. In a typical synthesis, the NIPAM monomer and 
N,N′-methylenebis(acrylamide) (BIS) cross-linking agent were dissolved in distilled 
water in a 250 ml two-neck round bottom flask equipped with a reflux condenser, 
along with any additional comonomers (acrylic acid or allylamine), surfactants (SDS) 
or stabilisers (PVP). This was then sealed, and nitrogen was bubbled through the 
aqueous solution for 1 hour whilst stirring (400 rpm) to remove dissolved oxygen. The 
solution was then heated to 60 °C. Separately potassium persulfate (KPS) initiator was 
dissolved in distilled water (25 mg ml-1) and degassed with N2 for 1 hour before being 
transferred to the flask containing the monomers. The reaction was maintained under 
a N2 atmosphere for 4 hours at 60 °C before being cooled down to room temperature. 
To remove unreacted impurities, the nanogel suspension was dialysed for 5 days using 
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12-14 kDa MWCO dialysis tubing, replacing the distilled water every 12 hours. 
Nanogels containing PVP were also further purified by centrifugation (Thermo 
Scientific Heraeus Megafuge 8R centrifuge) at a relative centrifugal force (RCF) of 
10,900 in 50 mL centrifuge tubes for 1 hour, and washed with distilled water 
(ca. 50 mL), this process was repeated four times. The purified suspension was then 
lyophilised (Virtis Benchtop K with ultra-low temperature condenser) and sealed for 
storage. 
Table M.2.1 The composition of reactants used in nanogel synthesis 
Sample NIPAM AcA AlA BIS SDS PVPa PVP KPS Waterb 
 mg mg mg mg mg Mw mg mg ml 
AcA-5.0 712.5 37.5 - 75.0 - - - 75.0 130 
AcA-15.0 637.5 112.5 - 75.0 - - - 75.0 130 
AcA-0.0-55K 750.0 - - 75.0 - 55 750.0 75.0 85 
AcA-1.5-55K 738.6 11.4 - 75.0 - 55 750.0 75.0 85 
AcA-2.0-55K 734.8 15.2 - 75.0 - 55 750.0 75.0 85 
AcA-5.0-55K 712.0 38.0 - 75.0 - 55 750.0 75.0 85 
AlA-2.6-10K 2000.0 - 53.0 80.0 - 10 363.6 60.0 85 
AlA-2.6-25K 2000.0 - 53.0 80.0 - 25 909.0 60.0 85 
AlA-2.6-40K 2000.0 - 53.0 80.0 - 40 1454.5 60.0 85 
AlA-2.6-55K 2000.0 - 53.0 80.0 - 55 2000.0 60.0 85 
AlA-5.0-10K 2000.0 - 105.3 80.0 - 10 363.6 60.0 85 
AlA-10.0-10K 2000.0 - 222.2 80.0 - 10 363.6 60.0 85 
AlA-15.0-10K 2000.0 - 352.9 80.0 - 10 363.6 60.0 85 
PNA-00 750 - - 75.0 - - - 75.0 130 
PNA-00-2 750 - - 75.0 - - - 75.0 130 
PNA-00-3 750 - - 75.0 - - - 75.0 130 
PNA-00-4 750 - - 75.0 - - - 75.0 130 
PNA-00-5 750 - - 75.0 - - - 75.0 130 
PVP-0.3 750 - - 75.0 - 10 50 75.0 130 
PVP-0.9 750 - - 75.0 - 20 150 75.0 130 
SDS-0.015 750 - - 75.0 2.5 - - 75.0 130 
SDS-0.030 750 - - 75.0 5.1 - - 75.0 130 
SDS-0.060 750 - - 75.0 10.0 - - 75.0 130 
a Mw of PVP used, e.g. average molecular weight of 10,000 = 10 (K) 
bTotal volume of water, including addition of KPS dissolved in water. 
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2.4.3. Characterisation 
Dynamic light scattering (DLS) measurements were performed at 25 °C with a 
1 mg mL-1 nanogel dispersion using an equilibration time of 600 seconds, unless 
otherwise stated, with a Malvern Zetasizer Nano ZS (running Malvern Zetasizer 
software V7.12) (Malvern Instruments, Malvern, UK) with 633 nm He–Ne laser and 
the detector positioned at 173°. 1 cm path length disposable polystyrene cuvettes were 
used for measurements. Measurements were repeated in triplicate to give a mean 
Z-average diameter and polydispersity index (PdI) value. Adjustments of dispersion 
pH were made with NaOH and HCl solutions, and dispersion pH measurements were 
made with a HI-11310 pH Edge Electrode (HANNA Instruments, Bedfordshire, UK). 
Zeta potential measurements were performed using DTS1070 folded capillary cells 
(Malvern, UK). The pH of the sample was measured before performing zeta potential 
measurements. Capillary cells were flushed with ethanol and water prior to usage. The 
zeta potential measurement was made with a minimum of 10 and maximum of 40 runs, 
and the voltage applied was automatically selected by the software. The Smoluchowski 
approximation f(Ka) = 1.5 was used, and dispersions contained 10 mM NaCl and were 
measured at 25 °C. Hydrodynamic diameter and zeta potential measurements across a 
pH range were measured using an MPT-2 multipurpose autotitrator (Malvern 
Instruments, Malvern, UK) equipped with HCl and NaOH solutions, and connected to 
a Malvern Zetasizer Nano ZS, with measurements made using a DTS1070 folded 
capillary cell. 1H nuclear magnetic resonance (NMR) spectra were recorded in D2O 
using a Bruker Avance spectrometer operating at 400 MHz. Chemical shifts (δ) are 
reported in parts per million (ppm) and TMS (Tetramethylsilane) was used as an 
internal standard. Lyophilised microgel sample was dissolved in D2O at 30 mg mL
−1. 
2.4.4. Phase Studies 
To form nanogels at different wt% in water and PBS the lyophilised nanogels were 
first packed at the bottom of glass sample vials. Water or PBS (1X strength, pH 7.4)  
was then added to the sample vials and the samples were held at 20 °C for 30 minutes 
to allow the solvent to soak into the lyophilized nanogel material. The samples were 
then held at 27 °C for 24 hours to allow the nanogels to completely disperse. The 
samples were then added to a sonication bath (S 100/H, Elmasonic) for 30 minutes to 
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remove any trapped air bubbles formed in the high concentration dispersions. This was 
repeated up to three times and the temperature of the bath was kept below 25 °C. For 
phase studies the sample was allowed to equilibrate for 5 minutes at each temperature. 
The phase of each sample was then observed by visual inspection and the vial inversion 
method:72 A liquid flowed down to the bottom of the vial; a swollen gel remained self-
supporting and did not flow over 10 seconds; a shrunken gel remained self-supporting 
and adhered to the sides of the vial over 10 seconds with a small excess of water phase 
separating; an aggregate formed a pellet which was not self-supporting and with a large 
excess of water phase separated. 
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Figure A.1 Assignment of NMR chemical shifts of polyNIPAM-co-acrylic acid nanogels stabilised with 55K PVP. AcA-1.5-55K dispersed at 30 mg ml-1 in 
D20 containing TSP (Trimethylsilylpropanoic acid) as an internal reference. 
2.5. Appendix 
Table A.1 NMR Chemical shifts in polyNIPAM, poly(acrylic acid) and PVP. 
Assignment in NMR 
Spectra 
H1 H2 H3 H4 H5 a b c d e f g D2O TSP 
Chemical shift (ppm) 3.67 3.33 2.33 2.04 1.75 * * 3.90 7.78 1.15 * * 4.84 0.00 
* NMR peak masked by polyvinylpyrrolidone peaks 
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Table A.2 Photographs (digital images) of AcA-5.0-55K dispersed at 350 mg ml-1 in 
phosphate buffered saline at different temperatures. 
Temperature 
25 °C 35 °C 60 °C 
Phase 
Gel Gel Aggregate 
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3.1. Introduction 
Chapter 2 demonstrated that polyNIPAM nanogels in the form of a concentrated 
dispersion displayed dual-stimuli responsive behaviour. These dispersions formed 
shape persistent bulk aggregates in the presence of both salt (at physiological ionic 
strength) and at body temperature (above the lower critical solution temperature of the 
polymer); such materials could potentially act as a controlled drug delivery depot. This 
responsive property of the nanogels represented an attractive opportunity for use as an 
ISFI. 
3.1.1. In Vitro Release Experiments  
In order to assess the drug release behaviour of a depot, in terms of whether burst 
release occurs, and sustained release is achieved, the amount of drug released from the 
depot over time must be quantified to obtain a drug release profile. Drug release is 
usually studied in vitro before progressing to in vivo studies. ‘In vitro’ refers to drug 
release testing of a parental formulation into a release medium.1 There are currently 
no regulatory guidelines for measuring drug release from parenteral controlled drug 
delivery systems,2 with different experimental techniques suiting different materials 
and formulations of ISFI’s. In terms of in vitro release, this can include pumps, 
agitation and stirring, release through a dialysis membrane, complete or partial 
replacement of the release media, and release into agarose gel.3–6 In vitro drug release 
experiments can be broadly categorised into sample and separate, continuous flow, and 
dialysis based methods.7 For implant based drug delivery systems, implants are usually 
placed in glass vials, and the surrounding release media is sampled,8 falling into the 
sample and separate methodology category. One downside of this in vitro method is 
the lack of accountability for tissue inflammation response at the implant site on the 
drug release rate,9 and so variation can exist between in vitro and in vivo drug release 
rate. Olanoff and Anderson showed that an implant can be surrounded by a fibrous 
capsule of collagen fibrils,10 and so an in vivo release rate study was required to 
develop a pharmacokinetic model to describe plasma concentration of drug.11 As 
polyNIPAM nanogels have previously been shown to be susceptible to protein 
absorption on their surface, this could be a factor which influences the drug release 
in-vitro-in-vivo correlation.12 However, generally, if an in vitro experiment is designed 
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suitably there should be an in-vitro-in-vivo correlation.8 Using a typical example of a 
release experiment, by Hyun et al., depot material was incubated at 37 °C for 1 hr to 
form solid depot material, and then release media was sampled from the vial over 
time.13 This sampling technique is appropriate to the behaviour of the polyNIPAM 
nanogels in Chapter 2, which formed a single shape persistent aggregate in a glass vial 
when incubated at 37 °C. In this variation of the sample and separate methodology, 
release media could easily be sampled from around a cylindrical shape persistent 
polyNIPAM aggregate depot, and the technique is hence the most suitable for in vitro 
drug release quantification from this material.  
 
3.1.2. Quantification of Drug Release Using High Performance Liquid 
Chromatography 
To quantify the amount of drug release from a parenteral formulation into release 
media in an in vitro release experiment high performance liquid chromatography 
(HPLC) is widely used.4,14,15 This technique can separate the analyte of interest (the 
drug payload) from any other material released by the depot, to quantify the drug 
release.16 It is also able to accurately quantify low concentrations of drug.17 This gives 
HPLC important advantages over another quantification technique, UV-Vis 
spectrophotometry, despite being more time consuming and less economical to 
perform.18  
HPLC analysis also has other benefits. In some depots, the drug may not be fully 
stable. This could simply be due to the drug degrading when held in an aqueous 
environment at 37 °C for an extended period of time,19 or due to the modification of 
the drug by the depot materials.2 For example, in certain implantable gels, degradation 
of the gel in the drug release time frame causes a drop in pH which can degrade the 
drug payload.20 This degradation can be monitored using HPLC. Where a drug starts 
to degrade, the degradation product will often appear as a new chromatogram peak at 
different retention times specific to the drug under analysis and HPLC methodology 
employed.21  
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3.1.3. Drug Release Profile 
Through sampling release media at appropriate intervals, and quantifying release with 
HPLC, a drug release profile can be created. The drug release profile provides insight 
into drug release from a depot. First of all it can be used to assess the performance of 
the ISFI, for example by indicating if a burst release occurs.22 The ‘burst release’ from 
an implant is when a significant percentage of total drug is released over a short time 
period at the start of the release period (c.a. 24 hrs), and is often seen in drug implants, 
preventing them from being safe to use.23,24 The drug release profile also reveals 
whether sustained release of drug over a long period is achieved, and allow the 
determination of the rate of this release.25 Also if a depot fails structurally, for example 
breaking into smaller fragments of larger surface area, fluctuations in the release 
profile are seen.26  Mathematical release models have been fitted to release profiles to 
determine the kinetics of release, and the mechanism by which release occurs, to gain 
a deeper understanding of the way drug release occurs from the depot.27,28  
3.1.4. Mathematically Modelling Drug Release 
In order to understand the drug release profile from polyNIPAM nanogels, the models 
of drug release from other drug depots must be considered. When a drug delivery depot 
consists of a drug which is dispersed through a polymer network, this network is 
referred to as a matrix. The main mechanism for drug release from a matrix is via 
diffusion of the drug through this polymer network, assuming this rather than 
partitioning into the surrounding aqueous environment it the limiting factor.27 Drug 
diffusion occurs as there is random movement of drug from high concentration in the 
depot to low concentration at the surface of the depot where drug partitioning into the 
surrounding medium occurs.29 Many physical and chemical phenomena can affect the 
drug release kinetics, and provide alternative mechanisms to diffusion for release 
through a matrix type system, giving a complex model for drug release.26 In the case 
of aggregated polyNIPAM nanogels, a non-biodegradable and non swellable matrix is 
formed. Hence the physical properties and dimensions of the matrix are likely to 
remain constant over time, and so the release rate can be simplified to a diffusion 
controlled model, based on Fick’s second law of diffusion, as erosion, degradation and 
swelling based release will not occur.28 The Higuchi mathematical model was 
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developed to describe this drug release, based on Fick’s second law of diffusion, where 
drug is dispersed through a matrix.30,31  This describes the amount of drug released in 
time (t) per unit area (Q) in relation to unit area (A), the diffusivity of the drug 
molecules in the matrix (D), initial drug concentration (C), drug solubility in the matrix 
media (Cs) in equation (1). 
𝑸 = 𝑨√𝑫(𝟐𝑪 − 𝟐𝑪𝒔)𝑪𝒔. 𝒕           (𝟏) 
A very simple equation (2) was later derived from the Ritger-Peppas mathematical 
model.32  
𝑭𝒕 = 𝒌𝒕
𝒏      (𝟐) 
The fraction of total drug released (Ft), is given by the diffusional exponent (n) and the 
constant (k), at time (t). The constant (k) is dependent on the characteristics of the 
matrix and drug. When n = 0.5, the release is Fickian, giving a simplified equation to 
represent the mathematics of Higuchi release. The equation accurately models release 
from non-swellable matrix devices, including cylinders, for the first 60% of the release 
curve, and even when near-perfect sink conditions are not obtained.33 Equation (1) was 
previously applied to drug release from a depot formed through thermo gelation of 
chitosan nanoparticles, demonstrating Fickian diffusion based release to occur.34 
Fickian diffusion was also shown to control the release from a swollen gel consisting 
of polyNIPAM nanogels.35 As such, this equation should be well suited to modelling 
the drug release behaviour of the cylindrical polyNIPAM nanogel aggregates, and give 
insight into how drug is released from polyNIPAM nanogel aggregates. 
3.1.5. Drug Payload 
With over 60% of new drug candidates estimated to be poorly water soluble,36 there is 
a need for an ISFI that can deliver poorly soluble drugs over an extended period of 
time at a greater rate of dissolution than is permitted by the very low solubility of 
hydrophobic drugs, which are often crystalline in nature.12,37 One way to increase the 
rate of dissolution of poorly water soluble drugs is to nanoformulate the drug into solid 
drug nanoparticles (SDNs).38–42 SDN’s have an increased surface area,43 and 
amorphous nature,44 aiding the rate of dissolution.  They are also able to form a 
nanosuspension, where drug can exist at a much higher concentration in a liquid than 
in the free drug from.45  
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Poorly water soluble drugs have also been shown to have a slower release rate from a 
hydrophobic matrix than more water soluble drug.46 Poorly water soluble drugs also 
favour the hydrophobic environment of polyNIPAM nanogels at physiological 
temperature.47 Hence, by varying the hydrophobicity of a drug release matrix the rate 
of release of a drug is likely tuneable. PolyNIPAM becomes less hydrated and more 
hydrophobic in character above its LCST, expelling water from its polymer network 
in nanogel form, which has been shown to encourage the absorption (and hence 
retention) of hydrophobic species.12,48 A comonomer which remains hydrophilic at 
37 °C such as allylamine,49 would give a polyNIPAM nanogel with a less hydrophobic 
character above it’s LCST,50 therefore a greater release rate of hydrophobic drug 
would be expected.  
3.1.6. Cytotoxicity 
PolyNIPAM has been widely used as a potential biomaterial for drug delivery and has 
been shown not to display cytotoxic properties in numerous studies including 
polyNIPAM in nanogel form.51–53 Additionally,  Kjøniksen et al have revealed that 
even at a high concentration polyNIPAM nanogels are not cytotoxic,54 which is 
important when they are used in aggregated form. One important consideration for 
polyNIPAM nanogels is the incorporation of charged comonomers and their potential 
cytotoxicity. Surface charge can have a cytotoxic effect, depending on charge type and 
density,55 and so cytotoxicity of nanogels should be studied where charged 
comonomers are included, by assessing if charge has an effect on cell plasma-
membrane integrity or causes mitochondrial damage.56 
3.1.7. Chapter Aims 
In order to progress the polyNIPAM nanogel ISFI concept further, research can be 
grouped into three key areas; (i) understanding the aggregation process and formation 
of an implant, (ii) characterising the structure of the aggregate and (iii) investigating 
the relationship between the structure of the aggregate and drug release behaviour. It 
is also important to acknowledge that during development, ISFIs developed previously 
in other studies have suffered from a number of issues. For example a large burst 
release of drug is very prevalent in ISFI’s.57 There are also others issues which have 
been encountered which should also be accounted for and investigated; these include 
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the long-term stability of drug within the implant,20 mechanical stability of the 
implant,58 injectability issues,59,60 variation in the shape of the implant formed, which 
leads to a variation in the amount of drug released,2 as well as potential cytotoxicity of 
the depot.9,61 All of these potential issues can be tested as part of the development of 
the polyNIPAM nanogel responsive aggregation ISFI concept.  
The main aim of this chapter is to demonstrate the suitability of polyNIPAM nanogels 
to act as a dual stimuli responsive ISFI for the delivery of poorly water soluble drug 
loaded in the from solid drug nanoparticles (SDNs), (scheme 3.1).  
In doing so the following five objectives will be achieved: 
• Synthesise and characterise two species of nanogels to act as ISFI depot 
biomaterials, one of which will include allylamine comonomer.  
• Test the aggregation behaviour, injectability, and depot formation and 
structure. 
• Demonstrate the tuneable release rate of drug when different ratios of the two 
nanogel species are used to tune the hydrophilicity of the depot. 
• Investigate and explain release rates and burst release from depots containing 
free drug in powdered crystalline form and its solid drug nanoparticle form. 
This will include the application of a drug release model to the drug release 
data to explain the mechanism of release, and probing burst release with 
polystyrene particles. 
• Perform initial cytotoxicity study on the nanogels, to indicate any cytotoxicity 
issues which may need further investigation. 
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Scheme 3.1 Nanogel/solid drug nanoparticle composite ISFI system (a) Nanogel/SDN 
solution loaded into syringe (b) De-swelling of nanogel particles in hypodermic needle above 
VPTT (c) Aggregation of nanogel particles entrapping SDNs at depot site, due to contact with 
salt. 
3.2. Results and Discussion 
3.2.1. Nanogel Synthesis and Characterisation 
Two species of polyNIPAM nanogels were synthesised using precipitation 
polymerisation (surfactant/stabiliser free). In chapter 2 nanogels synthesised with and 
without SDS both proved adequate for triggered aggregation. Therefore SDS was not 
used in the synthesis of these nanogels as unbound SDS is potentially cytotoxic, and 
so functional nanogels synthesised without SDS have less potential to be cytotoxic. 
These consisted of a polyNIPAM (PNA-00), and polyNIPAM-co-allylamine 
(PNA-25) samples, in which 25 mol% allylamine comonomer as a mol% of all 
reactants was used in the synthesis, (table M.3.1, methods section). These nanogels 
were then characterised using dynamic light scattering (DLS), scanning electron 
microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), 1H NMR and 
potentiometric titration. As in section 2.4, chapter 2, PNA-00 nanogels were 
synthesised using a concentration at the limit which allows the production of surfactant 
free polyNIPAM nanogels with a narrow dispersity to be produced (~0.5% w/v);62 in 
this case 5.8 mg ml-1. Reasonably narrow polydispersity particles, (mean 
hydrodynamic diameter = 567 nm, PdI = 0.24 at 25 C) were produced, (figure 3.1 a)). 
When the charged comonomer allylamine was introduced at 25 mol% the 
concentration of NIPAM in the synthesis could be increased to 25.0 mg ml-1 whilst 
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still obtaining monodisperse particles of a similar size, as in PNA-25 (mean 
hydrodynamic diameter = 547 nm, PdI = 0.11 at 25 C)  (figure 3.1, b). This was 
attributed to the amount of allylamine comonomer used in the synthesis being able to 
provide electrostatic stabilisation of the precursor particles, preventing aggregation 
when the concentration of particles during synthesis is increased, as explored in 
Chapter 2, section 2.3, (25 mol% PNA-25 equals 15 wt% of allylamine for 
comparison). SEM images show that discrete monodisperse particles were formed for 
both nanogel samples PNA-00 and PNA-25, with a diameter corresponding to the 
hydrodynamic diameter of the particles above the VPTT measured via DLS 
(approximately 250 nm). 
 
Figure 3.1 Characterisation of (a) PNA-00 and (b) PNA-25 nanogels by SEM, and DLS. (left 
column) DLS size distribution by intensity at 25 C and 50 C, samples measured using DLS 
with the mean value of triplicate measurements used and (middle and right column) SEM 
images of the dried nanogel particles with a beam intensity of 3.0 kV. All SEM images created 
using back scattered electrons with the exception of PNA-25 image with 250 nm scale bar, 
created with low angle back scattered electrons. Nanogels prepared as a 0.01 mg mL-1 aqueous 
dispersion for SEM imaging. 
1H NMR and FTIR spectra was consistent with previous nanogel characterisations, 
with all proton signals of polyNIPAM accounted for in PNA-00 and PNA-25, 
(figure 3.2), with a weak signal detected at 2.81 ppm for the CH2 in the side group of 
the poly(allylamine) repeat unit in PNA-25.63–65 NMR analysis also demonstrated that 
all unreacted monomers were removed during workup of the nanogels as no vinyl 
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peaks can be seen in the range 5.5-6.5 ppm. The FTIR spectra for the nanogels were 
found to match that of previously studied polyNIPAM nanogels, however there was 
no noticeable difference between the IR spectra for PNA-00 and PNA-25. This was 
likely because the mol% of comonomer allylamine incorporation was low, or due to 
overlap between the signals for the primary amines of the poly(allylamine) repeat unit 
with the signal from the amides contained in poly(N-isopropylacrylamide), 
(figure A.1, Appendix).66 Due to the lack of clear signals to prove allylamine inclusion, 
potentiometric titration was used to quantify the number of ionisable amines present 
in the sample, as used in previous studies. Two equivalence points can be seen 
(figure 3.3, a).67–69 The difference in volume of 0.1M NaOH between the equivalence 
points for HCl (140 µL) and allylamine (280 µL) was used to calculate the moles of 
allylamine contained in PNA-25, (figure 3.3, b). This suggests only 3.1 mol% 
allylamine was incorporated into the nanogel, concluding with FTIR and NMR results 
that only a low percentage of allylamine used in the synthesis is incorporated into 
PNA-25. 
Figure 3.2 1H NMR Spectra of  PNA-00 (black) and PNA-25 (red). Identification of 
polyNIPAM peaks in 1H NMR spectra of PNA-00. Peak at 2.81 ppm indicates presence of 
allylamine comonomer due to NH2 protons.  
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Figure 3.3 a) Potentiometric titration curve of PNA-25. Sample solution prepared by 
dispersing 50 mg of lyophilized nanogel into 50 mL of distilled water, followed by lowering 
sample pH to <pH4 with HCl. Sample titrated with 0.1M NaOH at 25 °C +/- 0.5 °C under a 
nitrogen atmosphere. b)  Differential of titration curve, difference between two equivalence 
points used to calculate allylamine content in nanogel. 
 
In order to investigate the dual-stimuli responsive properties of the nanogel samples, 
the hydrodynamic diameter of the nanogels were measured at intervals over the 
temperature range 15 to 55 C for both PNA-00 and PNA-25. As PNA-00 was heated 
in water the particles de-swelled but remain colloidally stable, resulting in the dramatic 
decrease in hydrodynamic diameter at the VPTT, (figure 3.4, a), as first shown by 
Pelton et al.70 In the presence of salts at physiological concentrations (PBS, 
1X strength, pH 7.4) the particles flocculated as they reached the VPTT, indicated by 
the dramatic increase in hydrodynamic diameter beyond 32 C.71 The sample 
containing 25 mol% allylamine, (PNA-25), showed the same colloidal stability in 
water and triggered flocculation in PBS, (figure 3.4, b). The salt-responsive 
flocculation of the nanogels was also investigated with a range of NaCl concentrations. 
Previous work by Rasmusson et al has shown that polyNIPAM nanogels synthesised 
with BIS and a sulphate initiator flocculate in NaCl above a concentration of 0.025M 
when raising the temperature.72 At a low NaCl concentration the interparticle 
electrostatic repulsion was great enough to prevent flocculation. At a higher 
concentration this electrostatic repulsion was weakened enough to allow flocculation. 
They also found that with increasing NaCl concentration the temperature of 
flocculation decreases as the higher ionic strength creates a poorer solvent 
environment for the polyNIPAM. PNA-00 and PNA-25 displayed a similar response 
in both respects, (table 3.1). The higher aggregation temperature of PNA-25 compared 
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to PNA-00 in 0.1 M NaCl suggests the extra electrostatic stabilisation from allylamine 
is able to resists aggregation to a greater extent. Analysis of the zeta potential of 
PNA-00 with increasing temperature in water displayed an initial negative 
zeta_potential of -12 mV up to 25 C (figure 3.4, a), attributed to the KPS initiator 
providing a negative surface charge on the nanogels through its incorporation at the 
polymer chain ends. As the temperature increases above the VPTT the zeta potential 
shows a corresponding decrease to > -40 mV as the surface charge density increases 
with the decrease in particle surface area, and the chains ends collapse onto the surface. 
For sample PNA-25 the zeta potential was positive (figure 3.4, b), indicating 
successful incorporation of allylamine comonomer to give a cationic charge that 
counters the anionic charge of the chain ends. When the particles were heated above 
their VPTT the zeta potential increased as the reduction in size resulted in an increase 
in charge density. 
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Figure 3.4 Temperature responsive behaviour of (a) PNA-00 and (b) PNA-25 nanogels by 
DLS and laser Doppler electrophoresis. DLS measurements performed on nanogels as 
1 mg ml-1 nanogels dispersions in water and PBS. Zeta potential measurements performed on 
aqueous dispersion only at pH 7. Samples measured using DLS and LDE with the mean value 
of triplicate measurements used. 
Table 3.1 Nanogel flocculation in NaCl 
[NaCl] 
(M) 
Aggregation Temperature (°C)a 
PNA-00 PNA-25 
0.001 - - 
0.010 - - 
0.100 34 42 
1.000 24 24 
aSamples heated in 1°C intervals from 15 to 55 °C. 
Flocculation temperature indicated by large increase in 
hydrodynamic diameter, as shown in Figure 3.3. 
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The two nanogels show temperature and salt responsive behaviour, with flocculation 
only occurring when both the temperature is above the VPTT and the ionic strength 
was equivalent to 0.1 M NaCl or greater. This is ideal for triggered aggregation in 
response to physiological conditions in an ISFI system. 
 
3.2.2. PolyNIPAM Nanogel Aggregate Studies 
Given the propensity for the nanogels to flocculate in a dilute dispersion, the 
concentration of the dispersion was increased to confirm that bulk aggregation on a 
macroscopic scale was possible, as demonstrated in chapter 2, section 2.4. The 
concentration (% (w/w)) of PNA-00 and PNA-25 in PBS at 25 C was increased and 
studied via the tube inversion method until a gel was formed. The concentration 
required for a self-supporting gel was 6.24% (w/w) for PNA-25 and 14.90% (w/w) for 
PNA-00. These values were used to form swollen gels at 25 C for aggregation studies. 
The lower % (w/w) of material required to form a gel with PNA-25 is postulated to be 
due to the polyampholytic nature of PNA-25. These nanogels contain both positive 
charge from allylamine, and negative charge from persulfate initiator, and so 
inter-particle electrostatic attraction could occur, in a similar manner to the 
electrostatic interactions which allow the formation of a colloidal gel network.73,74 
Hence a lower (% w/w) of PNA-25 was required to form a self-supporting gel in PBS 
than PNA-00. Upon heating to 37 C both gels aggregate and expel solvent in the 
process. The nanogels formed a phase separated disc shape of aggregated material, due 
to the cylindrical shape of the vial used, (figure 3.5). The aggregated form of the 
nanogels was observed as the surface charge of the nanogel was not great enough to 
form a shrunken gel.75 
The formation of aggregate over time was also studied, with samples contained in a 
glass vial slowly heated by being placed in an incubator at 37 C, (figure 3.6), with 
both samples forming dense aggregates in approximately 90 minutes. This process was 
reversible, after being held at 37 C for 1 hour and cooling, the aggregate returned to 
a self-supporting gel that re-adsorbed the expelled solvent within 1 hour.  
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Figure 3.5 Images of dual-responsive transition of the nanogels in PBS (1X strength, pH 7.4); 
from swollen self-supporting gels to bulk aggregates. Nanogel samples as swollen gel (left) 
and bulk aggregate (right). PNA-00, 14.90% (w/w) (top) and PNA-25,  6.24% (w/w) (bottom). 
 
Figure 3.6 Images of nanogel aggregate formation from swollen gel over time. The swollen 
gel was formed in PBS using 14.90% (w/w) PNA-00 and 6.24% (w/w) PNA-25, and placed 
in an incubator at 37 °C. This meant the time taken to aggregate is in relation to the rate of 
heat transfer from the incubator, and so aggregation is more rapid when in direct contact with 
a heated fluid environment such as in figure 3.8. 
 
The aggregate formed by PNA-25 has visibly larger dimensions than PNA-00, despite 
being formed from a swollen gel consisting of a lower mass of nanogel, (figure 3.6). 
This suggested the aggregate was less dense, as the PNA-25 sample contains 
hydrophilic allylamine comonomer which will resists complete expulsion of water 
above the VPTT as the aggregate forms. Hence the water content of PNA-00 and 
PNA-25 were measured both above and below the VPTT to confirm this, (table 3.2). 
Below the VPTT the water content of the samples were 85.1% and 93.8% for PNA-00 
and PNA-25 respectively. The hydrophilic nature of allylamine is independent of 
temperature,49 hence the sample containing allylamine, PNA-25, remained much more 
hydrophilic above the VPTT (at 37 °C) containing 76.8% w/w water while PNA-00 
contained only 34.3% water. This difference in the water content of the aggregates was 
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reflected in the reduction in volume when the swollen gel forms an aggregate. As 
swollen gels at 25 °C PNA-00 and PNA-25 had the same initial starting volume, 
however, the volume of PNA-00 on forming an aggregate was smaller than PNA-25.  
This is reflected in a larger percentage reduction in volume than PNA-25 upon forming 
an aggregate. It’s important to remember that PNA-00 also contains a higher % (w/w) 
of nanogel despite shrinking in volume by a greater percentage. This suggests the 
aggregate of PNA-25 contains a much greater volume of free space between 
aggregated nanogel particles. 
 
 
To give more insight into the difference in structure and porosity between the 
aggregates of PNA-00 and PNA-25 the aggregates were dried and imaged by SEM 
and are shown in (figure 3.7, A-B) respectively. SEM has previously been used to 
study the porosity of biomaterials,74 and hence describe the greater burst release of a 
payload with increasing porosity.23,76 The PNA-00 aggregate displayed a dense 
structure with a tendency to film-form while the PNA-25 aggregate presented a looser, 
fibrous structure in which individual particles could easily be distinguished. AFM 
analysis was then utilised to assess the topography of the samples, (figure 3.7, C and 
D for PNA-00 and PNA-25 respectively) these images revealed that PNA-25 presented 
a fibrous structure compared to the irregular structure of PNA-00. The differences in 
the topography of the samples are clearly shown in the 3D representation of the AFM 
characterisation, (figure 3.7, E) for PNA-00 and (figure 3.7, F) for PNA-25. The 
surface of the PNA-25 aggregate was much rougher than PNA-00 and revealed 
potential pores between the fibres. This fibrous structure of the PNA-25 aggregates 
was not expected and is an aspect for further investigation in the future.  
Table 3.2 Water content of the nanogels at 25 C and 37 C and change in volume. 
 % (w/w) of water contained 
 within the sample 
% reduction in volume upon 
forming aggregatea 
Sample 25 C 37 C 
PNA-00 85.1 34.5 76 
PNA-25 93.8 76.8 66 
aThe height and diameter of the cylindrical swollen gel and corresponding aggregate 
were used to calculate the change in volume (see figure 3.5 for images of the samples). 
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Figure 3.7 Characterisation of nanogel aggregates. (A,B) SEM images, (C,D) AFM images 
and (E,F) 3D representations of (C,D) respectively. PNA-00 shown in (A,C,E) and PNA-25 in 
(B,D,F). Aggregates formed at 14.90% (w/w) PNA-00 and 6.24% (w/w) PNA-25 in 1x 
strength PBS for imaging.‡
 
                                                          
 
‡ AFM imaging of samples (figure 3.6, E-F) was performed by Dr. Riaz Akhtar (Department 
of Mechanical, Materials and Aerospace Engineering, School of Engineering University of 
Liverpool, George Holt Building, Brownlow Hill, Liverpool, L69 3GH, UK). 
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The differences between the two aggregates explains the higher water content of 
PNA-25 due to its greater porosity and may alter the rate of drug release from the 
aggregates. The propensity for the nanogels to flocculate in response to both 
temperature and salt could be utilised to give a macroscopic aggregate at high nanogel 
concentrations. Potentially the porosity and relative hydrophilicity of an aggregate can 
also be tuned by mixing PNA-00 and PNA-25 due to their different water content and 
apparent structural differences in aggregated form. 
We must also consider the fact that upon injection as an ISFI the swollen gel will be 
in contact with interstitial fluid, which contains the metal ions magnesium and calcium 
as part of a complex mixture of inorganic salts.77 This inorganic salt composition can 
be simulated by Hank’s balanced salt solution (HBSS). On moving from PBS to HBSS 
there is a slight decrease in ions with a more chaotropic nature (weakly hydrated) 
(i.e.  K+, Na+), and the introduction of more kosmotropic ions (strongly hydrated) 
(i.e.  Mg2+, Ca2+). Chaotropic ions accumulate at the polyNIPAM/water interface to 
increase the zeta potential of the nanogel,78 and above the VPTT colloidal stability is 
dictated by electrostatic stabilisation in PNA-00 and PNA-25. Hence aggregation 
behaviour may change in different ion compositions. Therefore the aggregation of the 
nanogels was assessed in HBSS instead of PBS. Aggregation was found to occur in 
HBSS (figure  A.2, Appendix) in a similar manner to the PBS studies and hence the 
different metal ions present in HBSS were not found to greatly affect the aggregation 
process.  
3.2.3. Injection Studies 
With the demonstration of the formation of an aggregate from a concentrated nanogel 
dispersion upon exposing it to physiological conditions, the suitability of injection into 
tissue was assessed. For this purpose agarose gel was utilised as a matrix which acts 
as a subcutaneous tissue mimic at 37 C. Agarose gel has previously been utilised in 
UV imaging of drug diffusion as its transparency allows visual observations of drug 
diffusion through the agarose matrix.79 Hence the depot shape and formation can be 
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easily observed. Agarose gel also resembles the macromolecular properties, 
rheological behaviour and water content of extracellular matrix.80–83 Hence, it was 
employed in the injection studies of nanogel dispersions. The concentrated nanogel 
dispersion at ambient temperature was injected through a hypodermic needle into 
agarose gel formed using PBS at 37 C. PolyNIPAM nanogels show shear thinning 
behaviour,84 and so even at the concentration at which PNA-00 and PNA-25 form a 
swollen gel they could be injected through a 18G needle (0.84 mm internal diameter). 
This was 14.90% (w/w) for PNA-00 and 6.24% (w/w) for PNA-25. This was then 
followed by rapid aggregation of the particles into an aggregate depot. Additionally, 
depot formation was also possible with lower nanogel concentrations; PNA-00 was 
injected at 9.1% (w/w) and PNA-25 was injected as a liquid at 2.0% (w/w) and 
displayed the same aggregation behaviour as higher nanogel concentrations, 
(figure 3.8, a,b). The ability to obtain depot formation at lower concentrations is 
beneficial as a liquid is more desirable for ease of formulation with drug and loading 
into a syringe for as an ISFI.61 The nanogel aggregate formed a planar depot that is 
most likely due to the fracturing of the agarose gel by the hypodermic needle, and the 
subsequent filling of the void by the nanogel outwards along the fault line.  
The injection of the nanogel dispersion was further studied ex vivo into tissue to 
determine how this would affect depot shape. Intravitreal injection of drug is often 
used to treat the growing prevalence of conditions such as diabetic retinopathy85 and 
age-related macular degeneration,86 which effects 30% of individuals with diabetes,87 
and 25% of people over 75 respectively.88 These intravital injections are performed by 
injecting drug in to the vitreous humour of the eye, which is a gel network of collagen 
fibres and glycoprotein. With the potential for this ISFI system to reduce injection 
frequency into the eye by providing long term release, porcine vitreous humour was 
used to demonstrate nanogel injection ex vivo. Vitreous also has the benefit of being 
optically transparent, to allows visual observation of the aggregation formation and 
shape. A 9.1% (w/w) dispersion of PNA-00 combined with Ponceau Red dye was 
injected into porcine vitreous at 37 C, which led to the formation of a globular 
aggregate depot (figure 3.8, c). It is acknowledged that further exploration of injections 
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ex vivo in subcutaneous tissue is required to understand what shape an aggregate would 
form in at this type of injection site, and how much variation in this shape would exist. 
 
 
Figure 3.8 Digital images showing injection of PNA-25 and PNA-00 through 18G 
hypodermic needle: (a) PNA-00 at 9.1% (w/w) injection into 37 C agarose gel. (b) PNA-25 
at 2.0% (w/w) injection into 37 C agarose gel, timepoints: (i) 0 (ii) 5 (iii) 12 and 
(iv) 19 seconds. (c) PNA-00 at 9.1% (w/w) combined with ponceau red dye injection into 37 
C porcine vitreous humour.‡  
 
3.2.4. Model Payload Entrapment Study 
An ISFI will ideally display no initial burst release, in our system as the nanogels come 
into contact with physiological strength medium and aggregate they should be able to 
rapidly entrap a payload of drug containing nanoparticles with high entrapment 
efficiency.2 To probe this ability, Oil Red O dye-containing polystyrene (PS) 
nanoparticles were synthesised as a model payload which mimics the entrapment of 
solid drug nanoparticles. Like solid drug nanoparticles, Oil Red O dye-containing PS 
nanoparticles can form a suspension in water, and are a similar size, however the Oil 
                                                          
 
‡ Porcine vitreous experimental work, (figure 3.7, c), was performed by Dr. Dinos Caserides 
(Eye and Vision Science, Institute of Ageing and Chronic Disease, William Henry Duncan 
Building, 6 West Derby Street, Liverpool, L7 8TX, UK). 
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Red O which is contained within the PS particles allows quantification of the amount 
of particles released using UV-Vis spectroscopy. Firstly, the PS particles were 
synthesised using adaptations from a previously published dispersion polymerisation 
method.47 The PS nanoparticles were then dyed with the hydrophobic dye Oil Red O 
(OR), using adaptations from a previously published PS particle dying method which 
uses the solvent tetrahydrofuran to swell the particles and load dye.48 Release could 
then be quantified at a wavelength of 580 nm, where there is negligible absorbance by 
any potential polyNIPAM fragments lost from the aggregate. These dye containing 
particles will be denoted as PS-OR. The PS colloids were characterised using DLS 
after synthesis and when dispersed into PBS as PS-OR after dying and lyophilisation 
(table 3.3). The slightly larger hydrodynamic diameter after dying can be accounted 
for by entrapment of dye. SEM images revealed that monodisperse particles with 
spherical morphology were synthesised, along with a second population of much 
smaller particles (Figure A.3, Appendix). The absorbance spectra of PS-OR particles 
was deconvoluted to form a calibration curve based on the Oil Red dye peak of the 
PS-OR particles, (Figure A.4, Appendix).89  Nanocomposites containing PS-OR 
nanoparticles and PNA-25 nanogel were then prepared. With PNA-25 showing a less 
dense more porous structure in aggregate studies, this nanogel was considered more 
likely to fail to entrap a payload and show burst release, hence this nanogel was 
selected to form nanocomposites. PNA-25 was dispersed at 6.24% (w/w) in PBS to 
give a swollen gel and then PS-OR nanoparticles were mixed into the gel at 10, 20 and 
40% (w/w) of the total mass of PS-OR nanoparticles and lyophilised mass of PNA-25. 
These samples remained as swollen self-supporting gels even with 40% (w/w) PS-OR 
nanoparticles loaded, (figure 3.9, a (i)). Upon heating to 37 C to induce aggregation, 
the expelled solvent was visibly colourless, suggesting that PS-OR particles remained 
entrapped as a nanocomposite with the nanogel (figure 3.9, a (ii)). This burst release 
behaviour was quantified by UV-Vis to determine the concentration of PS-OR 
particles in the expelled liquid. This analysis showed low burst release (<13%) for all 
samples, but that increasing the concentration of PS-OR nanoparticles led to greater 
burst release, particularly from 20 to 40 % w/w loading, (figure 3.9, b). These data 
indicate the nanogels are able to retain the majority of a nanoscale payload distributed 
through the nanocomposite as it aggregates from a swollen gel. This is despite a 
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substantial volume of PBS being expelled from the polymer network of the contracting 
nanogel particles. 
 
Table 3.3 Polystyrene nanoparticle properties 
PS after synthesis  PS-OR dispersed in PBS 
Hd 
(nm) 
PdI  Hd 
(nm) 
PdI 
802 ± 14 0.05 ± 0.03  821 ± 25 0.05 ± 0.04 
 
 
Figure 3.9 (a) (i) Swollen gel composite of 40% (w/w) PS-OR nanoparticle loaded into 
PNA-25  at 25 C and (ii) Aggregation of composite at 37 C with entrapment of PS-OR 
nanoparticles. (b) Percentage of total PS particles released 1 hour after aggregation of 
composite. 
 
3.2.5. In Vitro Release Study 
To test the release rate of a drug from the nanogel aggregates in vitro, formulations 
were created from the mixing of poorly water-soluble antiretroviral drug lopinavir 
(LPV) in its powder form, or solid drug nanoparticle (SDN) form, into swollen gels, 
(table 3.4).  
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Table 3.4 Formulations of nanogel-drug for ISFI’s 
Formulation LPV 
(mg) 
LPV SDNa 
(mg) 
PNA-00 
(mg) 
PNA-25 
(mg) 
% (w/w) 
waterb 
Free SDN - 44.4 - - - 
PNA-25-SDN - 44.4 - 66.6 76.8 
PNA-00/25-SDN - 44.4 87.5 33.3 56.4c 
PNA-00-SDN - 44.4 175.0 - 34.5 
PNA-25-LPV 22.2 - - 66.6 76.8 
a LPV SDNs consist of 50% (w/w) LPV the remainder is 40% PVA and 10% Kolliphor 
TPGS.  
b % (w/w) of water in aggregate at 37 °C.  
c Calculated from: total amount of water contained in mass of each nanogel, and total 
mass of nanogel in formulation. 
 
LPV is a potent HIV-specific protease inhibitor which is administered in combination 
with ritonavir as a booster and requires daily oral dosing for life.90,91 We selected LPV 
as the model hydrophobic drug in our study given its very low aqueous solubility 
(predicted to be 0.00192 mg mL−1) and on-going evaluation of LPV SDNs in clinical 
trial (clinicaltrials.gov reference NCT02631473) identifying it as a potentially 
commercially relevant payload. LPV also shows no degradation in an aqueous 
environment at 80 °C over extended periods, making it suitable for quantification via 
HPLC in our drug release study.92 The LPV SDNs used had a hydrodynamic diameter 
of 330 nm and PdI of 0.18 (figure A.5, Appendix). The SDNs were composed of 50% 
(w/w) LPV, 40% PVA and 10% Kolliphor TPGS.§  
An LPV drug calibration curve was created from the LPV HPLC chromatograms, 
which contained a single elution peak at a retention time of 7.1 minutes, allowing 
quantification of drug release within a linear working range of 0.24-15 µg ml-1 
(figure A.6, Appendix). It was anticipated in the release study that LPV drug could be 
released into the release media in dissolved form, or still in the form of an SDN, 
                                                          
 
§ LPV SDNs were synthesised in conjunction with Dr. Marco Giardiello, Department of 
Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD,UK. 
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especially in the case of burst release. Hence a known concentration of 50% (w/w) 
LPV SDN was analysed alongside a known concentration of LPV drug to verify LPV 
SDNs fully dissolved in the HPLC mobile phase (30% v/v aqueous acetonitrile) to 
ensure accurate quantification of the drug still in its SDN form was possible. No 
variation in the HPLC chromatograms of the two samples can be seen, and single LPV 
peak can be seen for both LPV and LPV SDN samples, (figure A.7, Appendix). As the 
concentration of LPV was made to the same value in LPV and LPV SDN samples, the 
ratio of the area under the SDN LPV HPLC elution peak (ISDN) to LPV drug standard 
(ILPV) should equate to 1 assuming LPV SDN completely dissolved in the mobile phase 
of the HPLC. The value determined from HPLC samples was 1.002 (i.e. 0.2% 
difference) confirming the SDNs fully dissolve in the mobile phase, 
(table A.1, Appendix). No degradation products were seen for LPV or LPV SDN in 
the HPLC chromatograms. This is expected as degradation peaks existed at lower 
retention time in previous studies which used a C18 column only when LPV underwent 
a forced degradation under strongly acidic and alkali conditions.92,93  
In the ISFI formulations, nanogels were used at a concentration at which they formed 
a swollen gel, so that aggregated disk shaped samples formed upon heating, to simplify 
sampling release media in the release experiment, and eliminate the variation of 
aggregate shape having an effect on drug release rate (figure A.8., Appendix). Utilising 
the large difference in the water content and porosity of the PNA-00 and PNA-25 
aggregated nanogel materials at 37 °C, (table 3.2), allows the two nanogel samples to 
be mixed in different ratios to tune the water content of the aggregate. We expected 
the water content and structure of the different aggregates to control the rate of release 
of drug. PNA-00 and PNA-25 were used together with a mass of each that gave a 
self-supporting gel at room temperature in 1 mL of PBS, and 56.4% (w/w) water in 
the aggregated form (denoted as PNA-00/25-SDN), giving an intermediate water 
content between that of the two nanogels when used separately. The release of drug 
into the PBS surrounding the nanogel/SDN nanocomposites was then measured over 
time, using HPLC. Due to the low saturation concentration of the drug, the release 
media was completely removed and replaced during the release experiment at each 
sample interval.9 The nanocomposites showed excellent mechanical stability, 
remaining in their original shape over the complete release period. Comparing the 
release of LPV from the formulations PNA-25-SDN, PNA-00/25-SDN and 
PNA-00-SDN it can be seen that if the depot has a higher % (w/w) water content the 
release rate is enhanced, with PNA-25-SDN having the highest % (w/w) water content, 
and hence the greatest release rate and largest total cumulative release after 120 days, 
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(figure 3.10, a-b). The release rate and total cumulative release is reduced for 
PNA-00/25-SDN, and lowest for PNA-00-SDN, which has the lowest water content. 
This effectively allows us to tune the release rate from the depot. Based on the 
characterisation of the aggregate with SEM and AFM it is speculated that this could 
be due to the formation of a more porous structure containing more water, which has 
been linked with faster drug release.54 We applied the Ritger-Peppas equation 
(equation (1), section 3.1.4) assuming Fickan release, (figure 3.10, c).94 This suggests 
that for PNA-25-SDN and PNA-00/ 25-SDN there are two phases of release (I and II). 
In phase I the porosity introduced by PNA-25 could allow SDNs to be released from 
the aggregate, giving a much larger dissolution constant than the other formulations, 
(table 3.5). This early release was followed by phase II where it appears that the 
remainder of the SDNs are unable to diffuse out of the aggregate and instead are 
released as drug molecules which then diffuse with a dissolution constant similar to 
the other formulations. PNA-00-SDN and PNA-25-LPV only displayed one release 
phase. PNA-00-SDN only contains PNA-00 nanogel which forms a much less porous 
structure, suggesting there was only release of drug molecules rather than SDNs.  
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Figure 3.10 Release of LPV drug from aggregated nanogel discs over 120 days; quantified by 
HPLC analysis, measurements made in duplicate with mean value used. An SDN control 
without nanogel, ‘Free SDN’, was performed. After 120 days the depot was dissolved in 
acetonitrile for HPLC analysis to check remaining drug + amount released = 100% (a) 
cumulative release (b) release rate, lines are guides for the eye (c) application of the 
Ritger-Peppas equation to the LPV release over 120 days giving two phases of release (I, II) 
in PNA-25-SDN and PNA-00/25-SDN. 
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Table 3.5 Correlation coefficient (Rc) and dissolution constant (k). 
Formulation 
Phase I  Phase II 
Rc k Rc k 
PNA-25 0.994 5.25  0.993 1.16 
PNA-00/25-SDN 0.999 6.33  0.966 2.34 
PNA-00-SDN 0.999 3.05  - - 
PNA-25-LPV 0.992 1.43  - - 
 
In PNA-25-LPV the lopinavir drug was in the form of a micrometer sized powder 
(figure A.9, Appendix), not as SDNs. Hence no two stage release is seen, as the large 
powder particles are not able to diffuse through the aggregate and instead only 
dissolved drug molecules are released. This rate of release is slower due to the reduced 
surface area and crystallinity of these larger particles of drug compared to amorphous 
SDNs.  
The burst release from the initial aggregation of the nanocomposites was only 4.3% 
and 3.4% for PNA-00/25-SDN and PNA-00-SDN respectively. The PNA-25-SDN 
nanocomposite was the only sample to show appreciable burst release of 33.1%. As 
seen in the SEM/AFM analysis, (figure 3.7), the PNA-25 nanogel aggregate was the 
most porous, therefore it is possible that the SDNs near the surface of the aggregate 
were squeezed out rapidly through the pores during the initial aggregation, leading to 
a burst release. This theory is also supported by the concentration of LPV obtained 
during the burst release, much higher than the solubility of the hydrophobic drug 
lopinavir which would only be possible if the drug was released in SDN form. 
However, the water content of PNA-00/25-SDN nanocomposite was also reasonably 
high at 56.4% (w/w) and may have presented porosity and yet very little burst release 
was found. This difference could also be attributed to different particle packing; the 
opposite surface charges in PNA-00/25-SDN may lead to attractive interactions 
between nanogel particles reducing the porosity of the material. Also of note, a 
maximum of 13% burst release was seen with PS-OR particles in a PNA-25 depot 
(compared to 33.1% for the SDNs), however these particles had a hydrodynamic 
diameter of 821 nm compared to 330 nm for the SDNs, implying larger particles are 
more effectively entrapped by the more porous PNA-25 nanogel aggregate. 
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The formulation PNA-25-LPV, which contains the drug in powdered form, rather than 
as an SDN, displayed the slowest release rate with total release lower than all the SDN 
formulations, despite being loaded into the most porous depot formed from PNA-25. 
Hence, loading of the drug in SDN form allows the release rate from the depot to be 
enhanced, likely due to the much greater surface area of the SDNs assisting 
dissolution;43 or their amorphous nature,44 which aids in dissolution rate of drugs 
compared to the crystalline drug form.37 This behaviour potentially offers an additional 
mechanism of controlling the rate of drug release from the nanocomposite. In 
powdered drug form the burst release was also minimal at 0.5%, despite the SDNs 
having a 33.1% burst release from the same PNA-25 nanogel. This reinforces the idea 
of porosity being linked to water content of the aggregates, with smaller nanoparticles 
releasing at a greater rate than the powdered form of the drug.  
The minimum effective concentration for LPV has been shown to be 3000 ng ml-1.95 
Based on the assumption of 5 litres of blood in the human body, then 16 g of the 
PNA-00/25 LPV SDN nanocomposite (which displayed sustained release of over 
1000 μg day-1 over 20 days), would potentially provide LPV concentrations exceeding 
the minimum effective concentration. However, this does not take into account the 
clearance rate of the drug. Furthermore, dosing 16 g of the nanocomposite by 
subcutaneous/intramuscular injection would not be feasible. Although the release rate 
was not clinically relevant for LPV, we have used the drug as a model to demonstrate 
sustained release and the potential for the rate of release to be tuneable for the drug 
and it’s SDN form. Hence, this system should be applicable to other more potent 
poorly water-soluble drugs. These release studies showed that the rate of release of 
dissolved drug molecules can be tuned by blending nanogels with different polymer 
composition, and by varying the form of the drug. 
 
3.2.6. Cytotoxicity Study 
With primary amine groups showing moderate cytotoxicity effects in some studies,96 
cytotoxicity studies were conducted on the nanogels, particularly to determine whether 
the nanogels containing poly(allylamine) exhibited any cytotoxicity. ATP, 
(figure 3.11), and MTT (figure A.10, Appendix) assays97 were conducted on PNA-00 
and PNA-25 nanogels. These assays detect the viability of cells when exposed to the 
nanogels compared to a negative control of cells without exposure, and a positive 
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control of cells exposed to rotenone which greatly reduces cell viability. These assays 
showed that when Madin-Darby canine kidney (MDCK-II) cells were incubated with 
PNA-00 and PNA-25 for 72 hours, at concentrations ranging from 0.04 mg ml−1 to 
10 mg ml−1, no sign of cell toxicity could be detected. It can be concluded that the 
MTT assay appears to show no reduction of cell mitochondrial activity in the presence 
of PNA-00 and PNA-25. The ATP assay could measure the cell viability by measuring 
the luminescent signal given out when beetle luciferin is oxidised to oxyluciferin in 
the presence of ATP obtained from the cells after lysis, and again showed no reduction 
in the presence of nanogel. The positive control rotenone was characterised by reduced 
cell viability compared to the control at all tested concentrations (from 0.19 µM to 
100 µM), (figure  A.11, Appendix). Considering the nature of the MTT and ATP assay, 
other cytotoxic effects cannot be dismissed; consequently, future investigations to 
support the development of PNA-00 and PNA-25 clinical applications should include 
a comprehensive evaluation of cellular, immunological and tissue toxicities. 
 
 
Figure 3.11 Cytotoxicity of nanogels towards cells in ATP assay, samples measured in 
quadruplet. Rotanone control = 0.19 µM, full range of rotanone control concentrations found 
in figure A.11.**  
 
                                                          
 
** All cytotoxicity assay experimental work was conducted by Rohan Gurjar, Department of 
Molecular and Clinical Pharmacology, University of Liverpool, Block H, 70 Pembroke Place, 
Liverpool, L69 3GF, UK. 
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3.3. Conclusions 
After the initial investigation of an ISFI based on the aggregation of nanogels in 
Chapter 2, further investigation in this chapter has proved more thoroughly that these 
nanogels have very promising potential for use in an ISFI system. The polyNIPAM 
(PNA-00) and polyNIPAM-co-allylamine (PNA-25) nanogels were found to provide 
a long term sustained release of the hydrophobic drug LPV and its SDN form. 
PolyNIPAM nanogels could be formulated to contain a nanoparticulate payload to 
form an injectable nanocomposite material which rapidly aggregated in response to a 
dual stimulus of temperature and salt. The system also overcomes some of the common 
problems associated with ISFIs that have previously been developed. For example, the 
formulation with drug was simple to perform, it was easily injectable through a 
minimally invasive hypodermic needle, showed minimal burst release, and mechanical 
stability throughout the release. Sustained release of drug from the material was also 
maintained for a period of at least 120 days. The potential to easily tune the release 
rate from the system by adjusting the ratio of the two nanogel species PNA-00 and 
PNA-25, or enhance the release rate of the drug by using the form of SDNs was also 
demonstrated, and explained by investigating the structure of the aggregate depots. It 
was also shown through mathematical modelling that drug release occurred through 
Fickian diffusion of drug through the matrix. This drug delivery system should be 
applicable to other hydrophobic drugs and nanoparticulate payloads, and cytotoxicity 
was not an issue. This makes the system a suitable candidate as an ISFI for 
hydrophobic drugs and SDNs, where injections could possibly be given as infrequently 
as twice a year to improve adherence rates in the treatment of long term and 
particularly chronic conditions. The inflammation response at the depot site still 
requires investigation. There is also the potential to release multiple drugs as a 
combination therapy. There are also further opportunities to develop and understand 
the ISFI system, for example in terms of nanogel size and how this affects rheological 
and release rate behaviour, Chapter 4. Also a major drawback of this system is its lack 
of degradability, with the possibility to incorporate degradability explored in 
Chapter 5. 
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3.4. Materials and Methods 
3.4.1. Materials 
N-Isopropylacrylamide (NIPAM, ≥99%), allylamine (≥99%), 
N,N-methylenebis(acrylamide) (BIS, 99%), potassium persulfate (KPS, ≥99%), Oil 
Red O (OR), agarose (BioReagent, for molecular biology), sodium chloride (NaCl, 
≥99.5%), styrene (≥99%), 50% (w/v) aqueous poly(acrylic acid) (P(AcA), 
Mn = 2000), dichloromethane (DCM, analytical grade), polyvinyl alcohol (PVA grade 
4–88, MW 57–77 000), sodium phosphate dibasic dihydrate (Na2HPO4, ≥99%) 
potassium phosphate monobasic (KH2PO4, ≥99%), sodium phosphate dibasic 
dihydrate (Na2HPO4 · 2H2O, ≥99%), (orthophosphoric acid solution 50% (H3PO4, 
HPLC Grade), anhydrous sodium hydroxide pellets (NaOH, analysis grade), 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 98%), 
dulbecco’s modified eagle’s medium (DMEM, suitable for cell culture), rotenone 
(>95%), Hank’s balanced salt solution (HBSS), MDCK-II cell lines, 
N,N-dimethylformamide (DMF, 99.8%), sodium dodecyl sulphate (SDS, ≥99%) were 
purchased from Sigma-Aldrich Company Ltd, Gillingham (Dorset) UK, a subsidiary 
of Merck KGaA, Darmstadt, Germany. Lopinavir (ABT-378) (LPV) was purchased 
from WuXi PharmaTech, Shanghai, China. Kolliphor TPGS was purchased from 
BASF, Ludwigshafen, Germany. CellTiter-Glo® substrate and CellTiter-Glo® buffer 
were purchased from Promega UK, Southhampton UK. Phosphate buffered saline 
tablets (Bioreagent), tetrahydrofuran (THF, HPLC grade), ethanol (EtOH, analytical 
grade), Acetonitrile (MeCN, HPLC grade), hydrochloric acid 37% (HCl, analytical 
grade), were purchased from Fischer Scientific UK, Loughborough, UK, a part of 
Thermo Fisher Scientific. Type I distilled water obtained from a water purification 
system with a resistivity of >18 MΩ cm−1 (PURELAB option R, Veolia). 
Spectra/Por 2 (MWCO = 12-14 kDa) dialysis tubing was purchased from Spectrum 
Europe B.V., Breda, The Netherlands. Chromafil Xtra PET 0.45 µm syringe filters 
were purchased from Hicrom Ltd. Theale, UK. All materials were used as received.  
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3.4.2. Synthesis of PolyNIPAM Nanogels 
The polyNIPAM nanogels were synthesised by precipitation polymerisation. A 
summary of the formulation which was used for each nanogel species can be found in 
Table M.3.1. In a typical synthesis, the NIPAM monomer, allylamine comonomer and 
BIS cross-linking agent were dissolved in distilled water (130 mL for PNA-00 and 
160 mL for PNA-25) in a 250 ml two-neck round bottom flask equipped with a reflux 
condenser. This was then sealed and nitrogen was bubbled through the aqueous 
solution for 1 hour whilst stirring (400 rpm) to remove dissolved oxygen. The solution 
was then heated to 60 °C. Separately KPS initiator was dissolved in distilled water 
(3.75 mL for PNA-00 and 10.5 mL for PNA-25) and degassed with N2 for 1 hour 
before being transferred to the flask containing the monomers. The reaction was 
maintained under a N2 atmosphere for 4 hours at 60 °C before being cooled down to 
room temperature. To remove unreacted impurities, the nanogel suspension was 
dialysed for 5 days using 12–14 kDa MWCO dialysis tubing, replacing the distilled 
water every 12 hours. The purified suspension was then lyophilised (Virtis Benchtop 
K with ultra-low temperature condenser) and sealed for storage. 
Table M.3.1 The composition used in nanogel synthesis. 
Sample NIPAM 
(mol%) 
allylamine 
(mol%) 
BIS 
(mol%) 
KPSa 
(mol%) 
[NIPAM] 
(mg ml-1) 
PNA-00 94.3 - 3.6 2.1 5.8 
PNA-25 70.9 24.8 2.7 1.6 25.0 
a KPS dissolved at 20 mg ml-1 in distilled water. 
 
3.4.3. Characterisation of PolyNIPAM Nanogels and Aggregate Material 
Characterisation of the nanogel dispersions and aggregates was carried out using 
dynamic light scattering (DLS), laser Doppler electrophoresis (LDE), scanning 
electron microscopy (SEM), 1H nuclear magnetic resonance (NMR), potentiometric 
titration, atomic force microscopy (AFM) and Fourier transform infrared spectroscopy 
(FTIR). DLS and LDE was performed using a Malvern Zetasizer Nano ZS (running 
Malvern Zetasizer software V7.11) (Malvern Instruments, Malvern, UK) with 633 nm 
He–Ne laser and the detector positioned at 173°. Dialysed samples were diluted to 
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1 mg mL−1. The hydrodynamic diameter was recorded in the range (20–50 °C) using 
a thermal equilibration time of 600 seconds in 1 cm path length disposable cuvettes. 
Measurements were repeated in triplicate to give a mean hydrodynamic diameter and 
polydispersity index (PdI). Zeta potential measurements were performed using 
DTS1070 folded capillary cells (Malvern, UK). The pH of the sample was measured 
before performing zeta potential measurements, and for both samples fell in the range 
pH 7 ± 0.5. DTS1070 folded capillary cells were flushed with ethanol and water prior 
to usage. The zeta potential measurement was made with a minimum of 10 and 
maximum of 40 runs, and the voltage applied was automatically selected by the 
software. The Smoluchowski approximation where f(Ka) = 1.5 was used, and 
dispersions contained 10 mM NaCl and were measured at 25 °C. To prepare the 
nanogel dispersions for SEM imaging, the samples were diluted to 0.01 mg mL−1 in 
distilled water. 50 μL of solution was pipetted onto a circular cover glass (10 mm 
diameter) attached to a carbon adhesive disc on an aluminium SEM specimen stub 
(12.5 mm diameter). For SEM images of the aggregated material, swollen gel (14.90% 
(w/w) PNA-00 and 6.24% (w/w) PNA-25) was formed in PBS (1X strength, pH 7.4) and 
then adhered to a coverslip on an SEM stub. This was heated to 37 °C to induce 
aggregation. The samples were left to air-dry for 24 hours, followed by sputter coating 
with gold (EMITECH K550X) with a deposition current of 25 mA for 100 seconds 
before imaging. SEM images of the nanogel morphology were then obtained using a 
Hitachi S-4800 FE-SEM at 3 kV. To record 1H NMR spectra lyophilised nanogel 
sample was dissolved in D2O at 20 mg mL
−1 and analysed on a Bruker 400 MHz 
spectrometer (Bruker, MA, USA). The potentiometric titration of PNA-25 was 
conducted with a 50 mL aqueous dispersion of PNA-25 at 1 mg mL−1. The sample pH 
was then lowered below pH 4 using 0.1 M HCl. The sample was then titrated with 0.1 
M NaOH at 25 °C ± 0.5 °C under a nitrogen atmosphere. A Hanna Instruments 
HI-11310 pH electrode (Hanna Instruments, Bedfordshire, UK) was used to record the 
change in pH. To record FTIR spectra a blank background scan was performed, 
followed by a recording of the spectra of lyophilised nanogel ca. 5 mg, which was 
clamped onto the ATR crystal of a Bruker alpha platinum ATR (Bruker, Santa 
Barbara, CA, USA). Atomic force microscopy (AFM) was carried out using a Bruker 
Multimode 8 system (Bruker, Santa Barbara, CA, USA) operated with ScanAsyst 
Mode in ambient conditions. All testing was conducted using a Bruker RTESPA-150 
probe with a nominal radius of 8 nm and a spring constant of 5 N m−1. Each scan was 
conducted with a resolution of 256 pixels per line and with a scan rate of 0.799 Hz. 
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The samples were prepared by placing a thin layer of swollen gel formed in PBS 
(1X strength, pH 7.4) (14.90% (w/w) PNA-00 and 6.24% (w/w) PNA-25) onto glass 
coverslips, which were then incubated at 37 °C in a water saturated atmosphere for 
72 hours. The coverslips were then adhered to 15 mm diameter metal stubs for 
mounting in the AFM. The AFM images were analysed off-line using Bruker 
Nanoscope Analysis 1.7 software 
3.4.4. PolyNIPAM Nanogel Gelation and Aggregation Studies 
The concentration at which the nanogel samples formed a self-supporting gel was 
found by first adding 10 mg of material to 1 mL of phosphate buffered saline 
(1X strength, pH 7.4) in a glass vial with an internal diameter of 20 mm. Using the 
tube inversion method, the mass of nanogel was increased in increments until the 
nanogel no longer flowed upon inversion of the vial for 30 seconds. The percentage 
(w/w) of water contained in the nanogel at 25 °C was calculated from the mass of 
freeze dried nanogel and water in the swollen nanogel formed from the tube inversion 
method. After heating to 37 °C the aggregate was separated from the eluted solvent to 
determine its mass. The mass of nanogel remains constant, so the difference in mass 
is due to any solvent remaining in the aggregate, allowing the % (w/w) of water at 
37 °C to be calculated. 
3.4.5. Tissue Injection Simulation 
Agarose powder (0.5% (w/w)) was slowly added to a beaker of PBS (1X strength, pH 
7.4) whilst stirring, and then weighed, before covering the beaker with plastic wrap 
with a hole for ventilation, and heating to 95 °C for 10 minutes. Hot water was then 
added to bring the contents to the original weight. This was then cooled to 55 °C and 
cast into pre-warmed vials with an internal diameter of 20 mm. These were then left 
for 12 hours at 37 °C before use. PNA-25 at 6.2% and 2.0% (w/w) and PNA-00 at 
14.9% and 5.7% (w/w) in distilled water were injected through a 18G hypodermic 
needle into 0.5% (w/w) agarose gel at 37 °C. For injection into tissue ex vivo, a 9.1% 
(w/w) dispersion of PNA-00 combined with ponceau red dye (1 mg ml-1) was injected 
into porcine vitreous at 37 C. 
3.4.6. Polystyrene Nanoparticle Synthesis and Oil Red Dye (OR) Encapsulation 
Polystyrene (PS) nanoparticles were prepared using modifications of a dispersion 
polymerisation method in which colloidal stability was provided by poly(acrylic 
acid).98 Briefly, styrene monomer (15.35 mL) was dissolved in ethanol (26.23 mL) and 
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distilled water (101.05 mL) in a 250 mL two-neck round bottom flask equipped with 
a reflux condenser. 50% (w/v) aqueous poly(acrylic acid) (2.92 mL) was then added 
along with KPS (234 mg) in distilled water (3.32 mL). This was then sealed and 
nitrogen was bubbled through the aqueous solution for 1 hour whilst stirring (400 rpm), 
to remove dissolved oxygen. The solution was then heated to 70 °C. The reaction was 
maintained under a N2 atmosphere for 24 hours before being cooled to room 
temperature. The PS nanoparticle suspension was purified by centrifugation (Thermo 
Scientific Heraeus Megafuge 8R centrifuge) at a relative centrifugal force (RCF) of 
10,900 in 50 mL centrifuge tubes for 1 hour, and washed with distilled water 
(ca. 50 mL), this process was repeated twice. Oil Red O (OR) was encapsulated into 
the particles by modifying a previous swelling-diffusion technique.99 Firstly, the 
aqueous PS suspension (32 mg mL−1, 25 mL) and aqueous Pluronic F127 (72 mg mL−1, 
8.3 mL) were added to a 50 ml centrifuge tube. This was vortexed at 3000 rpm for 
60 seconds and then left for 24 hours on a tube roller (33 rpm). Tetrahydrofuran (THF) 
(16.66 mL, 33% (v/v)) containing OR (14.7 mg) was added to the suspension, and then 
vortexed at 3000 rpm for 600 seconds, followed by 0.5 hours on a tube roller (33 rpm). 
The colloid was then washed five times with distilled water using a centrifuge 
(RCF = 10 900, 1 hour) between washes and then lyophilised (Virtis Benchtop K with 
ultra-low temperature condenser). A sample of the PS nanoparticles with encapsulated 
OR was prepared at a concentration of 0.1 mg mL−1 and was analysed with DLS after 
synthesis and after lyophilisation. 
3.4.7. Polystyrene Nanoparticle Entrapment Study  
In a glass vial with internal diameter 20 mm, 66.6 mg of PNA-25 was mixed with 
lyophilised PS nanoparticles of 10, 20 and 40% (w/w) relative to the nanogel. After 
adding 1 mL of PBS (1X strength, pH 7.4) the dispersion was left for 10 min to allow 
the lyophilised nanogel to swell. The samples were then vortexed at 300 rpm to mix 
the PS nanoparticles through the swollen nanogel dispersion. These samples were then 
heated (in a water bath) to 37 °C for 1 hour to form shrunken discs of aggregated 
nanogel, with excess PBS (1X strength, pH 7.4) expelled from the discs in the heating 
process. A negative control of nanogel alone and positive control of PS particles alone 
were conducted alongside the samples. 0.2 mL of solution was removed for UV-visible 
spectrophotometric analysis (Thermo Scientific NanoDrop 2000c) with a 1 cm path 
length quartz cuvette at a wavelength of 565 nm (λmax for OR). To determine the 
concentration of PS nanoparticles a stock solution of 1 mg mL−1 dispersed in PBS 
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(1X strength, pH 7.4) was serially diluted to form a linear calibration curve of 
absorbance at 565 nm against concentration in the range 1–100 μg mL−1. 
3.4.8. Lopinavir (LPV) Solid Drug Nanoparticle (SDN) Synthesis 
The LPV SDNs were prepared by emulsion-spray-drying as described by Giardiello et 
al.44 Briefly, a stock solution of LPV (200 mg mL−1 in dichloromethane (DCM)), 
polyvinyl alcohol (PVA grade 4–88, MW 57–77 000) (50 mg mL−1 in water), 
Kolliphor TPGS (50 mg mL−1 in water) were prepared. Three stock solutions were 
mixed in the LPV: PVA : Kolliphor TPGS ratio of 60 : 192 : 48 (mL) in a 1 : 4 DCM 
to water mixture. Emulsification was conducted using a Hielscher UP400S ultrasonic 
processor equipped with a H14 Probe at 100% output (140 W) for 180 seconds, with 
immediate spray-drying using a benchtop spray-dryer (BUCHI Mini-290) with an air-
atomizing nozzle and compressed air as the drying gas. Spray-drying process 
conditions: 7 mL min−1 solution flow rate; 65 °C outlet temperature; 110 °C inlet 
temperature. Resultant powders were further dried under vacuum for 48 hours to 
remove residual DCM. SDN dispersions result from subsequent powder dispersion in 
water; for DLS characterisation, powders were dispersed in distilled water at 
2 mg mL−1 (1 mg mL−1 cf. LPV). 
3.4.9. Drug Release in Phosphate Buffered Saline (PBS) 
The in vitro drug release was performed using adaptations of the sample and separate 
method,8 as performed in previous work.13 The required amount of each lyophilised 
nanogel, 6.24% (w/w) for PNA-25, and 14.90% (w/w) for PNA-00, was dispersed to 
form a swollen self-supporting gel in 1 mL of PBS (pH 7.4, 0.137 M NaCl and 
0.0027 M KCl) in a glass vial of internal diameter 20 mm. To this 22.2 mg of LPV or 
44.4 mg of LPV SDNs (50% (w/w) loading of LPV) were vortexed to give 22.2 mg of 
LPV per formulation. These were then heated to 37 °C for 1 hour to form shrunken 
discs with excess PBS expelled from the discs in the heating process, this was removed 
and used as the first release time point. These discs were transferred to larger 250 mL 
glass sample jars with 100 mL of fresh PBS. Subsequent release samples were taken 
at pre-determined intervals by removing 100 mL from the vessel and replacing with 
100 mL of fresh PBS at 37 °C to prevent a saturation limit with a large excess of 
solvent. Release vessels were kept at 37 °C ± 0.5 °C in a water bath. The amount of 
LPV released was quantified by HPLC analysis.  
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3.4.10. HPLC Procedure 
The HPLC method is adapted from the method published by Giovanni Di Perri et al.100 
Briefly, HPLC grade acetonitrile (MeCN) (1.8 mL) was added to each release sample 
(4.2 mL) to create 30% (v/v) MeCN samples, followed by filtering through a 0.45 μm 
PTFE syringe filter. 40 μL of the solution was injected into a HPLC-PDA system 
(PerkinElmer Series 200). The mobile phase was composed of solvent A (KH2PO4 
50 mM dissolved in HPLC grade water then pH adjusted with H3PO4 to reach pH 
3.23) and solvent B (MeCN) with the gradient reported in Table M.2. 
Chromatographic separation was performed with an Agilent ZORBAX Eclipse Plus 
3.5 μm C18 column (100 × 4.6 mm ID, Santa Clara, CA) maintained at 25 °C in a 
column oven with a solvent flow rate of 0.5 mL min−1 giving a retention time of LPV 
of 9.6 ± 0.2 min. The PDA detector was set to 210 nm with a bandwidth of 2 nm. The 
concentration of LPV in the samples was calculated against known standards using the 
area under the chromatogram peaks. Three standards covering the concentration range 
of the HPLC method were used to verify the results, and samples were analysed in 
duplicate. 
Table M.2 The solvent gradient used in the HPLC method 
Time 
(min) 
Solvent A  
% (v/v) 
Solvent B  
% (v/v) 
Flow  
(mL min-1) 
0.0 70 30 0.5 
1.0 70 30 0.5 
3.0 30 70 0.5 
11.5 30 70 0.5 
12.0 70 30 0.5 
12.5 70 30 0.5 
  
3.4.11. In Vitro Nanogel Cytotoxicity Study 
Cytotoxicity experiments were carried out on MDCK-II cell lines by MTT and ATP 
assay (Promega CellTiter-Glo® Luminescent Cell Viability Assay, Madison, WI). In 
both assays cells were seeded on 96-well plates at a density 2 × 104 cells per well in 
100 μL of Dulbecco’s Modified Eagle Medium (DMEM) and incubated for 24 hours. 
Ten different concentrations of the nanogels were prepared by ten-fold serial dilution 
with the media, starting at 10 mg mL−1. A ten-fold serial dilution of rotenone from 
100 µM acted as a positive control, and cells alone in media as a negative control. 
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Cells were incubated for 72 hours at 37 °C. In the ATP assay the wells were then 
equilibrated at room temperature for 30 minutes. 100 μL of Beetle Luciferin 
(CellTiter-Glo® Reagent) was added and mixed on an orbital shaker for 2 minutes to 
induce cell lysis. After incubation for 10 minutes at room temperature the luminescent 
signal was measured using a GENios microplate reader (TECAN). Samples were 
repeated in quadruplicate. The background luminescence of DMEM was subtracted 
from the sample luminescence. In the MTT assay after the 72 hour incubation period, 
5 mg of MTT was dissolved in 1 mL of hank’s balanced salt solution (HBSS). 20 μL 
was added to each well and incubated for 2 hours, followed by 100 μL of lysis buffer 
(50% DMF in water containing 20% SDS) for 12 hours. The absorbance of each well 
was measured at a wavelength of 560 nm using a GENios microplate reader (TECAN). 
Samples were repeated in quadruplicate. The absorbance of DMEM, and the 
absorbance of nanogel interaction with MTT without cells present, was subtracted 
from the sample absorption. 
3.5. Appendix 
Table A.1 Comparison of area under LPV HPLC elution peak to validate quantification of 
LPV in LPV SDNs. 
[LPV] 
µg ml-1 
[SDN]a 
µg ml-1 
Area under LPV elution peak  
ISDN ILPV ISDN/ILPV 
14.0 28.0 2,067,615 2,071,892 1.002 
 
 
Figure A.1 FTIR Spectra of nanogels. PNA-00 (black) and PNA-25 (red). 910–665 cm-1 (s, 
b) N-H wag 1˚, 2˚ amines, 3400–3250 cm-1 (m) N–H stretch 1˚, 2˚ amines, amides, 1650–
1580 cm-1 (m) N–H bend 1˚ amines, 1250–1020 cm-1 (m) C–N stretch aliphatic amine. 
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Figure A.2 Images of dual-responsive transition of the nanogels in HBSS; from swollen 
self-supporting gels to bulk aggregates. Nanogel samples as swollen gel (left) and bulk 
aggregate (right). PNA-00, 14.90% (w/w), (top) and PNA-25, 6.24% (w/w), (bottom). 
 
 
 
Figure A.3 SEM image of polystyrene particles. Sample diluted to 0.01 mg mL-1 in distilled 
water. Sputter coated with gold (EMITECH K550X) with a deposition current of 25 mA for 
100 seconds before imaging. SEM images were then obtained using a Hitachi S-4800 FE-SEM 
at 3 kV. 
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Figure A.4 (a) UV-vis absorbance spectrum of oil red dyed polystyrene nanoparticles, 
deconvoluted into two component peaks using Gaussian amplitude peak fitting with a 
Gaussian response width of 2 standard deviations using peakFIT®v4.11 software. (b) UV-Vis 
calibration data using absorbance of deconvoluted oil red dye peak, linear relationship between 
absorbance and concentration from 5-100 μg mL-1. 
 
 
Figure A.5 DLS analysis of lopinavir solid drug nanoparticles. Size distribution by intensity 
at 25 °C. Z-average diameter = 330 nm, PdI = 0.18. 
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Figure A.6 Linear working range of LPV calibration curve (inset LPV HPLC chromatogram). 
 
 
Figure A.7 HPLC Chromatograms of LPV elution peak at retention time of 9.7 minutes for 
(a) LPV drug, 14 µg ml-1 and (b) LPV SDNs, 28 µg ml-1. 
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Figure A.8 LPV release experiment a) example of formulation of nanogel and LPV SDNs at 
room temperature b) formulation in shrunken disk form after heating to 37 °C and transferring 
to 100 mL of release medium (PBS). 
 
 
Figure A.9 (left) LPV drug particulates and (right) LPV SDN’s. Both dispersed in water at 
1mg ml-1. 
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Figure A.10 Cytotoxicity of nanogels towards cells in MTT Assay. 
 
 
Figure A.11 ATP assay cell viability results of positive control (rotenone) at concentrations 
of 0.19 µM to 100 µM.
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4.1. Introduction 
An in situ forming implant (ISFI) based on the aggregation of dual responsive 
behaviour of polyNIPAM nanogels was discovered in Chapter 2 and developed in 
Chapter 3. It was anticipated that the size of the nanogel used in this ISFI would have 
an impact on the ISFI behaviour, in terms of phase behaviour, rheological properties, 
drug payload entrapment and drug release rate. Hence a range of four different sized 
polyNIPAM nanogels were synthesised and studied to demonstrate how size modifies 
this set of properties. Alongside nanogel size, the effect of temperature, dispersion 
concentration and ionic strength on the phase transition and rheological behaviour of 
the nanogel dispersions was also studied. 
4.1.1. Nanogel Size Effect on Internal Structure 
Less than a decade after the discovery of polyNIPAM nanogels in 1986 by Pelton and 
Chibante,1 studies began to probe the internal structure of nanogels. It was found that 
heterogeneous cross-linking density existed within the nanogel particles under 
investigation,2 with Pelton speculating that a zone of relatively high cross-linking 
density existed within the particles, due to the commonly employed 
N,N′-methylenebis(acrylamide) (BIS) cross-linking agent reacting faster than the 
NIPAM monomer.3 Other studies concluded that a higher cross-link density core and 
lower cross-link density shell exists within polyNIPAM nanogels,4 known as a 
core-shell structure.5 Some variation in the nature of this structure was found 
depending on the synthesis conditions of the nanogels studied, with examples 
including the proposal of a uniform cross-link density core, and shell with graduated 
decrease in cross-link density,6 and the existence of a thin shell (20 nm) which is 
polyelectrolyte rich.7 It was also found that the core-shell structure could be influenced 
by different factors, such as the amount of cross-linking agent used.6 A homogeneous 
cross-link density can also be achieved if the feed of monomer and cross-linking agent 
into the polymerisation reaction are regulated. This produces optically clear particles, 
as a highly cross-linked core is avoided.8 Sodium dodecyl sulphate (SDS) is commonly 
employed to synthesise nanogels of different sizes.9 Importantly, whilst controlling the 
size of the nanogel, SDS concentration also appears to have an effect on nanogel 
internal structure. The ratio of radius of gyration to hydrodynamic radius (Rg/Rh) 
describes the distribution of mass within a sphere, sometimes referred to as the shape 
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factor, ρ. Homogeneous radial density spheres have a ρ value of 0.775, and a swollen 
nanogel with a denser core typically has a ρ value of ~0.6.10 Arleth et al. used a high 
concentration of SDS to create nanogels below 100 nm in size. These nanogels had a 
homogeneous cross-link density instead of a core-shell structure with a ρ value close 
to that of a sphere of homogeneous radial density (0.775).11 It was suggested that high 
SDS concentration prevents the formation of permanent solid particles by creating a 
better solvent environment in the polymerisation to give more homogeneous 
particles.12 As the SDS concentration was lowered to create larger particles, an 
increasing degree of core-shell internal structure was presented, with a 
correspondingly lower ρ value of 0.73 at 25 °C measured for nanogels of 116 nm in 
diameter.13 Similar results are seen in other work.10,14 To summarise, if nanogels are 
synthesised at low SDS concentration, large nanogels with a core-shell structure will 
form (figure 4.1, a), and a high SDS concentration will give small nanogels with a 
uniform radial density (figure 4.1, b). In between high and low SDS concentration, an 
intermediate structure exists, which contains some core-shell character. It is likely that 
not only nanogel size, but the variation in internal nanogel structure that accompanies 
different sized nanogels will alter the nanogel phase behaviour,  rheological properties, 
and drug payload entrapment and release rate. 
 
Figure 4.1 Illustration of polyNIPAM nanogel structure in terms of cross-linking density when 
synthesised using SDS a) low SDS concentration; large nanogel (>100 nm) with highly 
cross-linked core, and shell of decreasing cross-link density, b) high SDS concentration; small 
nanogel (<100 nm) with uniform cross-linking density. 
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4.1.2. Phase Studies 
In using polyNIPAM nanogels as an ISFI, it would be of great benefit to understand 
the phase behaviour and rheological properties of the nanogels under the various 
conditions experienced by the nanogels when used as an ISFI. Although the 
macroscopic phase changes from ambient to body temperature was shown visually in 
Chapter 3 (figure 3.4), it would be useful to study the phase behaviour in more detail. 
An understanding of how the phase behaviour occurs over a range of concentrations, 
nanogel sizes and associated internal structure, and temperatures, would be very useful 
when designing the optimal conditions for an ISFI based on nanogels.  
The aggregation of polyNIPAM nanogels above the VPTT temperature and at 
sufficient ionic strength, which was demonstrated in chapter 2 and 3, is a phase 
separation, which is just one of many possible rich phase change behaviour that can 
occur in a polyNIPAM dispersion.15 Interestingly, unlike other nanogel dispersions, 
polyNIPAM nanogels are able to undergo thermoreversible gelation, transitioning 
from a liquid to a shrunken gel as the temperature increases.16 Other phase changes 
such as a swollen gel transition at low temperature and high concentration, and 
colloidal crystal fluids have also been observed in polyNIPAM based nanogels.16–19 
Xiong et al. found the existence of at least four phases for polyNIPAM-co-acrylic acid 
nanogels.18 For  inter-penetrating polymer networks of polyNIPAM and poly(acrylic 
acid) nanogels, six phases were observed.17 These phases are possible because of the 
many different combinations of colloidal interactions between the nanogels under 
specific conditions.5 Below the VPTT colloidal interactions between nanogels include 
the steric stabilisation by polymer chain ends extending out from the particle into 
solution.20 This steric stabilisation is lost above the VPTT, however, as the nanogels 
deswell, the charges introduced from the initiator on the polymer chain ends are 
concentrated more closely together giving an enhanced electrostatic repulsion between 
the nanogels. Above the VPTT the attractive dispersion interaction is also much 
greater.21 PolyNIPAM nanogel dispersion phases have been studied previously using 
techniques such as visual observations, rheology16,19,22–25, microscopy,23 static and 
dynamic light scattering26–28, SANS26, DSC and turbidimetry.29 Rheology is a useful 
and widely used technique for studying the phase behaviour of nanogel dispersions, as 
the shear storage (G’) and shear loss (G’’) modulus’ of oscillatory rheometry often 
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change dramatically between different phases,16,22,24,30,31 allowing the supplementation 
of visual observations of phase transitions more accurately with rheological 
measurements.  
There are a number of reasons why it is important to study and understand how these 
phases occur with different nanogel size, concentration, temperature and ionic 
strength. First of all, phase changes may occur very close to ambient or body 
temperature. This could be an issue, for example, if a solidification phase change 
occurs just above 25 °C. If the ambient temperature of an environment is not well 
regulated, then an increase in temperature could cause nanogels to solidify in storage, 
or in the syringe before being injected. This problematic solidification would also be 
enhanced if heat was transferred to the syringe as it was handled during injection 
preparation. Alternatively, if macroscopic aggregation at physiological salt strength 
only occurs just below mean body temperature, then solidification could be very slow 
or unsuccessful, as body temperature fluctuations occur at different sites in the body 
and across different patients.32,33 Therefore, any solidification phase change behaviour 
should ideally lie well above the upper limit of recommended temperature for storage 
of essential medicines (25 °C),34 and aggregation should lie well below core body 
temperature (37 °C).35 Phase changes and rheological properties of a nanogel 
dispersion are also likely to be dependent on their concentration. A dispersion which 
is too concentrated may be too viscous to inject. A lower concentration would give a 
liquid a room temperature, which is easier to formulate and inject, however, if the 
concentration is too low then the dispersion may not macroscopically aggregate until 
a higher temperature is reached. Hence a concentration range of a nanogel dispersions 
at different temperatures could be studied to build a two-dimensional understanding of 
phase behaviour. A further factor for consideration is how the size and internal 
structure of a nanogel used will also likely influence the temperature dependence of 
phase behaviour and the rheological properties of the different phases. Nanogels of a 
certain size may provide optimum performance in regards to their use as an ISFI. To 
summarise, under certain combination of nanogel size, concentration and temperature, 
unexpected phases and rheological properties may exist which hinder the performance 
of the nanogels as an ISFI, these variables need to be identified.  
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4.1.3. Drug Release 
The size and internal structure of nanogels used is also likely to affect the maximum 
drug loading and release rate from a polyNIPAM nanogel and SDN loaded ISFI. The 
maximum payload of solid drug nanoparticles that can be successfully loaded into a 
polyNIPAM nanogel ISFI is also not yet known. This is an important factor to 
understand, as the larger the payload, the less depot material is required to be injected 
to obtain the same therapeutic effect. It is anticipated that as wt% of payload is 
increased there will eventually become a point at which burst release occurs, as there 
is no longer enough aggregate material to form a mechanically stable depot which can 
contain the payload. Many matrix controlled drug delivery systems contain a large 
burst release (~30 to 80%) regardless of the size of the payload,36,37 and so if high 
loading can be achieved without burst release occurring, this gives the nanogel system 
a very useful advantage.  
Nanogel size and internal structure may also have an effect on drug release rate. Drug 
release rate from a matrix is dependent on many factors such as drug characteristics, 
formulations aspects, and polymer variables, which all influence the release constant.38 
However, by keeping all aspects fixed except for nanogel size, the variation in release 
rate is limited to potential changes to the structure of the matrix due to the usage of 
different sized nanogels. When drug release occurs in a hydrophobic polymer matrix, 
particularly for drug loaded at a concentration above its solubility limit, release of the 
drug occurs via diffusion through interconnected water-filled pores.38–40 It is 
anticipated that nanogels of different size will create aggregates of different pore size 
and pore interconnectivity, and hence change the diffusion rate of drug through the 
matrix. In terms of pore size, the pores created between the packing of larger nanogels 
(and openings between these pores) are naturally likely to be larger and so allow 
greater permeability than those between smaller nanogel particles.41 In terms of pore 
interconnectivity, polyNIPAM nanogels act as soft spheres,42 which as a concentrated 
dispersion undergo compression, deformation, and possibly interpenetrate.31,43,44 
Hence it is important to understand the role of nanogel size and structure on release.  
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4.1.4. Aims 
The main aim of this chapter is to investigate how different sized nanogels determine 
the phase behaviour, rheological properties and drug entrapment and release from a 
nanogel depot. 
In doing so the following objectives will be achieved: 
• The synthesis and characterisation of polyNIPAM nanogels across a range of 
four different nanogel sizes and internal structures. 
• Determine how phase changes across different nanogel sizes, concentrations 
and temperatures in water occur. This will lead to the selection of a nanogel 
dispersion concentration with most interesting phase behaviour to study in PBS 
(1X strength, pH 7.4) to compare phase behaviour with water. 
• Study of rheological changes in water and PBS (1X strength, pH 7.4) based 
dispersions of nanogels with a comparison to visual phase changes. 
• Examination of how a) drug release rate and b) burst release is affected by 
aggregates formed from different sizes of nanogel, and with different wt% of 
payloads. This includes finding the maximum wt% of payload that can be 
successfully employed before a large burst release and mechanical failure of 
the depot occur, as well as an in vitro release study to determine drug release 
rates. 
4.2. Results and Discussion 
4.2.1. Nanogel Synthesis and Dilute (1 mg mL-1) Dispersion Characterisation 
Nanogels of four different sizes were synthesised by using different amounts of the 
surfactant sodium dodecyl sulphate (SDS) (table M.4.1, methods), following the 
relationship previously reported by Pelton et al.9 The relationship between nanogel 
size and SDS concentration used can be seen in figure A.1, Appendix. These samples 
are denoted PNA65, PNA160, PNA310 and PNA450, corresponding to their 
hydrodynamic diameter in water at 25 °C, and should not be confused with allylamine 
content, as allylamine was not used in the synthesis of these nanogels as in the previous 
chapter. The mean hydrodynamic diameter and polydispersity index (PdI) of each 
nanogel as determined by three DLS measurments was: PNA65, 65 nm, 0.13; 
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PNA160, 160 nm, 0.02; PNA310, 310 nm, 0.01; PNA450, 450 nm, 0.03. The size 
distribution of the samples as determined by DLS can be seen in figure 4.2. a), and the 
clear relationship between particle size and scattering intensity can be seen in 
figure 4.2 b). Tyndall scattering was observed for PNA310, (figure A.2, Appendix), 
while samples with a larger diameter were completely turbid.  
 
 
Figure 4.2. Nanogels synthesised in a range of sizes a) DLS size distribution by intensity at 
25 °C for each nanogel as a 1 mg ml-1 aqueous dispersion, samples measured in triplicate and 
mean value used. b) Nanogel dispersion turbidity as a 15 mg ml-1 aqueous dispersion at 25 °C.  
 
The change in hydrodynamic diameter of these nanogels in response to a rise in 
temperature when dispersed in water can be seen in figure 4.3. At the lowest 
temperature measured (15 °C), the nanogels were at their most swollen state, and hence 
at their maximum hydrodynamic diameter at this temperature. All samples then 
showed the characteristic thermoresponsive behaviour of polyNIPAM nanogels, with 
a dramatic decrease in hydrodynamic diameter at the VPTT of 34 °C, at which 
de-swelling occurs at a much greater rate with rise in temperature. As discussed in 
previous chapters, this occurs as the polymer-solvent hydrogen bonding becomes less 
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favourable and the polymer-polymer interactions dominate. The samples also all 
displayed similar swelling/deswelling behaviour, as was quantified by the swelling 
ratio (the ratio of the nanogel diameter at a given temperature to the diameter at 55 °C), 
(figure A.3, Appendix). All samples displayed values of 1.75-1.93 at 25°C. It can be 
noted that smaller nanogels PNA65 and PNA160 underwent greater deswelling upon 
heating with swelling ratios (at 25 °C) of 1.83 and 1.93 compared to the larger nanogels 
which had swelling ratios of 1.77 and 1.75 for PNA310 and PNA450 respectively, 
(table 4.1).  
Table 4.1 Swelling ratio of nanogels diameter upon cooling from 55 to 25°C. 
Sample PNA65 PNA160 PNA310 PNA450 
Swelling Ratioa 1.83 1.93 1.77 1.75 
aSwelling ratio calculated from DLS measurement of hydrodynamic diameter (Hd) 
using 1 mg ml-1 aqueous dispersion, swelling ratio = Hd (25°C) / Hd (55°C) 
 
This was likely due to differences in the internal structures of the nanogels, as 
discussed in section 4.1.1, it has previously been shown that using a higher 
concentration of SDS (c.a. 1.9 mg mL-1) during the dispersion polymerisation route 
used for nanogels creates smaller more homogeneous partices.12 While, using a lower 
concentration of SDS (c.a. 0.15 mg mL-1) generates larger particles with a more 
heterogeneous structure which contains a dense gel particle core.11 Therefore, it is 
likely that the larger particles contained a denser core which can be considered to have 
restricted swelling, surrounded by a less densely cross-linked polymer shell. 
PolyNIPAM nanogels have previously been shown to undergo less swelling when the 
particle is restrained by a highly cross-linked core, compared to greater swelling when 
cross-linking is homogeneous.8 This core-shell type structure is likely to have caused 
restraint in the amount of swelling able to take place in the larger nanogels (PNA310 
and PNA450), and hence the swelling ratio decreases with increasing nanogel particle 
size.  
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Figure 4.3. Hydrodynamic diameter of nanogels in Type I distilled water with a resistivity of 
>18 MΩ cm−1 water (circles) and PBS (1X strength, pH 7.4) (squares), samples measured 
using DLS with the mean value of triplicate measurements used. 
 
The existence of a core-shell structure in the larger nanogels can also be seen in zeta 
potential and turbidity properties of the nanogel samples. The zeta potential was 
measured below (25 °C) and above (40 °C) the VPTT as shown in (figure 4.4). The 
zeta potential at 25 °C was similar for all the samples with the values ranging between 
-11.7 and -18.1 mV. When the nanogels were heated to a temperature of 40 °C all the 
samples become more charged with zeta potential values between -19.6 and -36.9, with 
a clear trend for samples with larger mean diameters having greater surface charge. 
The larger nanogels also have a much higher turbidity (figure 4.2, b). Andersson and 
Maunu showed that a similar substantial zeta potential increase and higher turbidity 
was seen for polyNIPAM nanogels with a hydrodynamic diameter of 194 and 400 nm, 
but not for smaller nanogels synthesised with a higher SDS concentration. Only the 
larger nanogels formed a highly cross-linked core, which gave rise to a higher turbidity 
and a polyelectrolyte rich shell.12 Another study into core-shell nanogels also found 
that they contained a polyelectrolyte rich shell.7 Based on swelling ratio, zeta potential 
and turbidity, it is reasonable to speculate that PNA450 and PNA310 have a core-shell 
like nature, whilst PNA65 effectively has a homogeneous internal structure, and 
PNA160 lies between the two structures.  
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Figure 4.4. Zeta Potential measurements of nanogels at 25 °C and 40 °C, measured using 
Laser Doppler Electrophoresis with 1 mg ml-1 aqueous dispersions with 10 mM NaCl at pH 7 
and taking the mean value of triplicate measurements. 
When the nanogels were dispersed in PBS below their VPTT, (figure 4.3), generally 
each nanogel sample had approximately the same diameter in PBS as in water at the 
same temperature, however, the PNA450 nanogel had a significantly smaller diameter 
when dispersed in PBS compared to water, with a 24% reduction in diameter at 25 °C, 
giving it a diameter similar to PNA310 when dispersed in PBS. In water the sulphate 
groups from the initiator fragment located at the end of the polymer chains may 
provide some swelling due to the electrostatic repulsion within the particles, in the 
presence of PBS these charges will be screened by the increased concentration of ions 
and result in less swelling. Vincent and Rasmusson have shown that even a low NaCl 
concentration led to a reduction in the diameter of larger (700 nm) particles due to 
electrolyte screening of sulphate initiator fragments on the surface of the nanogel.21 In 
the synthesis of nanogels, growth continues until a large enough charge density to 
achieve colloidal stability is achieved.2,20 Hence, PNA450 is expected to contain the 
greatest amount of sulphate groups in each particle and the screening of these charged 
groups hence causes a pronounced shrinkage in diameter, as the swelling caused by a 
high amount of sulphate groups is reduced in PBS. Heating the nanogels in PBS 
resulted in the aggregation of the particles. It was seen that aggregation occurs at 33 
°C for all samples, being completely independent of the particle size in a dilute 
dispersion. This aggregation was due to the loss of all colloidal stabilisation of the 
particles. Below the VPTT the nanogels were sterically stabilised by the solvated 
polymer chains on the surface of the particles,20 and electrostatically stabilised by the 
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surface charge provided by the sulphate groups at the chain ends that were derived 
from the persulfate initiator.9 Upon heating above the VPTT the steric stabilisation 
was likely lost as the solvated surface chains collapse and any colloidal stability was 
from the electrostatic repulsion between the particles.45 However, in the presence of 
PBS the electrostatic repulsion was screened and the particles aggregated.46 Increasing 
the ionic strength of the solvent has the effect of it becoming a poorer solvent for the 
nanogels. Hence, the aggregation occurs at lower temperature with increasing NaCl 
concentration, (table A.1, Appendix), as the polymer-polymer hydrogen bonding 
becomes more favourable than the polymer-solvent hydrogen bonding.44 This result is 
similar to previous work by Vincent et al.21 
4.2.2. Phase Behaviour 
The samples were then prepared at a range of higher concentrations in order to draw a 
comparison between the data generated on the dilute dispersions and phase behaviour 
of the concentrated nanogels. In order to use nanogels at a higher concentration the 
nanogels were first lyophilised and then dispersed. To ensure complete dispersion of 
the nanogels the hydrodynamic diameter and PdI of the samples were measured before 
and after dispersal. It was found PNA65, PNA160 and PNA310 fully dispersed upon 
mechanical mixing, but PNA450 required a short period of sonication to fully disperse 
the sample (table  A.2, Appendix). 
In order to allow direct comparison between the different nanogel samples the phase 
behaviour of the samples dispersed in water was investigated in detail. The maximum 
concentration was limited by the amount of nanogel which could be dispersed to give 
a homogeneous dispersion, and so the nanogels were studied in increments of 2 wt% 
from 2 wt% up to a maximum value for each nanogel of: PNA65, 24 wt%; PNA160, 
16 wt%; PNA310, 22 wt%; PNA450, 16 wt%. The samples were heated from 20 °C 
to 45 °C in 1 °C increments. The temperature responsive swelling of the nanogels 
resulted in a rich phase behaviour with swollen gel, liquid, shrunken gel and aggregate 
(phase separation) phases all observed under specific combinations of nanogel size, 
concentration and temperature, as seen in previous work.47,48 Each of the four phases 
are shown using example combinations of nanogel size, concentration and temperature 
in figure 4.5.  
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Figure 4.5 –  Nanogel phases, a) swollen gel (PNA160, 10 wt%, 25 °C), b) liquid (PNA160, 
10 wt%, 40 °C), c) shrunken gel (PNA65, 20 wt%, 40 °C), d) aggregate (phase separation) 
(PNA160, 16wt%, 40 °C). 
The phase diagrams in figure 4.6, a) reveals the phase changes with temperature and 
concentration for each size of nanogel. At low temperature the three larger nanogel 
samples PNA160, PNA310 and PNA450 all showed a liquid to swollen gel transition 
above a certain concentration. At 20 °C swollen gels were observed at all 
concentrations above 7 wt% for PNA160 and 10 wt% for both PNA310 and PNA450. 
The swollen gels all had a low turbidity and were self-supporting. At higher 
temperatures an increased concentration of nanogel was required before a swollen gel 
was obtained, likely due to the smaller diameter of the particles as the temperature 
increases towards the VPTT. At temperatures below 30 °C nanoparticle interaction 
potential can be considered as purely repulsive,23 with no significant change in the 
attractive part of the interaction potential. The swollen gel phase arises due to a volume 
blocking mechanism of hard sphere theory in which the nanogel spheres become close 
packed without significant deformation.31,49 As the particles deswell upon heating this 
swollen gel transitioned into a turbid liquid, as seen in other polyNIPAM nanogels 
dispersions.50 The deswollen particles were no longer large enough to form a gel 
through volume blocking, and hence a higher concentration is required to obtain a 
swollen gel at this temperature. Turbidity also increased with temperature due to the 
increased difference between the refractive index of the nanogel particles and the 
surrounding liquid.
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Figure 4.6 – Comparison of nanogel phase behaviour and rheological properties in water and PBS at temperatures between 20 °C and 45 °C with a heating rate 
of 1 °C min-1 for the different nanogel samples with mean diameters from smallest (left) to largest (right), 65 nm, 160 nm, 310 nm and 450 nm respectively. a) 
The phase diagrams of different nanogel samples dispersed in water at concentrations ranging from 2 wt% up to a maximum of 24 wt%. b) The phase diagrams 
of nanogel samples dispersed in PBS at 12 wt%. c) Rheological measurements of 12 wt% nanogels dispersions. Lines are a guide for the eye between the phase 
changes seen in the phase diagrams in water (dashed line) and PBS (dotted line) and the rheological data.
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The temperature at which the swollen gel to liquid transition occurred can be explained 
when considering the effective volume fraction (φeff) of the different nanogels. The 
effective volume fraction gives a measure of the packing of the nanogels, and is both 
temperature and concentration dependent. An effective volume fraction of ~0.74 is the 
close packing limiting value for monodisperse hard spheres,51 when the effective 
volume fraction is greater than this value the particles are restricted to volumes smaller 
than their dilute solution equilibrium swelling volumes.23 Hence if the spheres are able 
to compress and deform a value greater than this can be achieved.19 This is because 
the effective volume fraction does not take into account any effect of deformation, 
deswelling or interpenetration of particles on the volume fraction.52 The effective 
volume fraction can be estimated using the viscosity of a dilute dispersion and the 
Batchelor equation (Figure 4.7, Equation (1).53,54 Along with equation (2) and (3), this 
has been used to calculate the effective volume fraction of polyNIPAM nanogel 
dispersions in many previous studies.19,23,24,28 If equation (2) is substituted into 
equation (1), the conversion constant (k) at a given temperature can be determined by 
fitting the Batchelor equation to measurements of viscosity at different dilute 
concentrations as a fixed temperature. The value of k can then be used in conjunction 
with the ratio of hydrodynamic diameters of a nanogel at different temperatures, 
equation (3), to obtain effective volume fraction at different temperatures for a given 
dispersion concentration. 
 
Figure 4.7 Equations used to calculate ϕeff. (1) Batchelor equation, ƞrel =  relative viscosity, c 
= concentration in w/w %, k = constant, ϕeff = effective volume fraction. (2) k = conversion 
constant. (3) Dh = hydrodynamic diameter, T= temperature (°C). 
The relative viscosity (ƞrel) of a range of dilute dispersions at different concentrations 
at 20 °C was measured, (figure 4.8, a), which gave a conversion constant (k) for each 
nanogel at this temperature (table A.3, Appendix). The value of k for each nanogel at 
20 °C was then used to calculate the effective volume fraction at different 
temperatures, illustrated in figure 4.8, b) for a 12 wt% dispersion of each nanogel.  
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In the case of the nanogels, it was found that the smaller the nanogel the larger the 
effective volume fraction, and an increase in temperature causes the effective volume 
fraction for each nanogel to decrease. At the temperature of visual transition from 
swollen gel to liquid for a 12 wt% dispersion, the effective volume fraction for 
PNA160, PNA310 and PNA450 is 1.1, 1.1 and 1.0 respectively, see (*) and dashed 
line in figure 4.8 b). This suggests that the three larger nanogels are able to deform, 
deswell or interpenetrate slightly, as observed previously,55 with the nanogels 
behaving as soft spheres below 30 °C.56 This is most likely possible due to the 
existence of a lower cross-linking density shell. 
 
Figure 4.8 Determination of effective volume fraction (φeff) using the Batchelor equation and 
viscometry data. a) Relative viscosity data for nanogels measured at 20 °C fitted with 
Batchelor equation (ƞrel=5.9(kc)2+2.5(kc)+1, φeff=kc). b) φeff of 12 (w/w) % nanogel aqueous 
dispersion across a temperature range. PNA450, (squares) PNA310 (circles), PNA160 
(triangles) and PNA65 (diamonds). Swollen gel to liquid visual phase transition occurs at 
dashed line (*). 
The fact that the transition from swollen gel to liquid occurs at the same effective 
volume fraction for all three of the larger nanogels suggest they have a similar core 
shell structure, allowing the same degree of deformation, deswelling or 
interpenetration. Therefore any temperature induced deswelling of the particles (as 
shown in figure 4.3) that lowers the effective volume fraction below ~1 will lead to a 
swollen gel to liquid transition. Using this value the temperature this transition occurs 
at for other dispersion concentrations can be predicted with a good correlation with the 
actual temperature the phase transition was observed at for PNA160, PNA310 and 
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PNA450. This is demonstrated in table 4.2, where different nanogels and dispersion 
concentrations give a predicted transition temperature close to the transition 
temperature observed in figure 4.6. 
 
Table 4.2 Comparison of predicted and visual swollen gel to liquid temperature 
transition for aqueous dispersions of different sized nanogels. 
Nanogel Dispersion wt% Predicted transition 
temperaturea 
Visual transition 
temperatureb 
PNA450 16 30 30.5 
PNA310 16 31 30 
PNA310 22 33.5 34 
PNA160 16 33 32.5 
aBased on temperature at which φeff=1.1 for a given wt% dispersion concentration. 
bAs observed in visual phase transition (figure 4.6). 
 
Interestingly, the smallest nanogel PNA65 did not display a swollen gel phase under 
the conditions tested, even at concentrations exceeding 12 wt% at 20°C, and despite 
this sample having an effective volume fraction well over 1. The viscosity of PNA65 
was found to be considerably higher than the other three nanogel samples. Tan et al 
and Wolfe have previously shown that the viscosity of nanogels increases with 
decreasing cross-linking density,57,58 and Senff and Richtering determined 
polyNIPAM nanogels of lower cross-linking density to act as softer particles.42 
Therefore, it is likely that PNA65 was composed of a lower cross-linking density 
without a dense gel core, and so the particles contained more lightly cross-linked 
chains with linear polymer character, and hence were able to have more hydrodynamic 
corona overlap,24 reducing the mobility of the particles and giving a larger calculated 
effective volume fraction.22,29 Despite an apparently high volume fraction the PNA65 
nanogel cross-linking density was not of sufficient density to be able to form a swollen 
gel phase even at a high wt%. Instead, we propose that the nanogels are soft spheres 
which able to undergo large deformations to remain fluid as they behave more like 
lightly cross-linked polymers with linear polymer characteristics than hard spheres.19 
This is likely due to their perceived lack of core-shell structure, in which heterogenous 
cross-linking leads to a more highly cross-linked core which resists deformation. Bae 
and Han previously showed that no swollen gel phase was observable for linear 
polymers as a high concentration dispersion.59  
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The PNA65 sample did however form a shrunken gel at concentrations above 11 wt% 
and above 35 °C.  The shrunken gel was also self-supporting but with high turbidity 
and a small excess of water expelled upon formation. Shrunken gel formation was 
observed for the PNA160 sample at the same temperature and concentration. The 
PNA310 sample only formed a shrunken gel above 21 wt% and 36 °C. While the 
largest nanogel sample PNA450 displayed no shrunken gel phase. It is clear that as the 
nanogel samples increased in diameter then a greater concentration was required for 
shrunken gel to be observed, it is most likely that this was not observed for PNA450 
due to it occurring at a higher wt% than could be successfully dispersed and studied. 
This shrunken gel was formed due to the increasing tendency of the nanogels to 
become more hydrophobic and favour polymer-polymer instead of polymer-water 
hydrogen bonds as the temperature increases, favouring aggregation,44,60 as well as an 
increasing electrostatic repulsion to prevent this aggregation occuring.30 This balance 
of interactions results in a network structure forming throughout the continuous phase. 
The larger zeta potential of the larger nanogels at higher temperature appears to resist 
the formation of a shrunken gel unlike the smaller, lower zeta potential nanogels. 
Further heating of PNA65 and PNA160 resulted in complete phase separation resulting 
in aggregate formation for PNA65 above 38 °C when at 12 wt%, and for PNA160 
above approximately 37 °C for any concentration above 11 wt%. This morphology is 
likely due to the complete aggregation of the nanogel particles. As aggregates were 
only observable in PNA65 and PNA160, it may be due to these nanogels having the 
smallest zeta potential at elevated temperature (figure 4.3), which was not sufficient to 
overcome the driving force for the nanogels to aggregate.  
The phase behaviour of the four nanogel samples were then tested in PBS at 12 wt%, 
a concentration selected that showed phase changes for all four of the samples, 
allowing the effect of the PBS on the these phase changes to be observed, (figure 4.6, 
b). In the presence of PBS all samples exhibited at least 3 different phases. Samples 
PNA65 and PNA160 exhibited the same transitions as observed for the sample in water 
at 12 wt% but with lower transition temperatures. The larger nanogels PNA310 and 
PNA450 also displayed the liquid to swollen gel transition at lower temperatures in 
PBS compared to when dispersed in water, with the transition dropping from 25.5 to 
24.5 °C for both samples. Additionally, these nanogel samples displayed an additional 
phase transition that was not observed in water at 12 wt%, the formation of aggregates 
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at 32.5 °C. The difference in phase transitions of the nanogels in PBS was likely driven 
by two main factors: Firstly, the increased polarity of the solvent when PBS was used 
instead of water will reduce the temperature at which polymer-polymer interactions 
dominate. Secondly, the ions in the PBS will screen the charges of the sulphate groups 
which provided electrostatic repulsion of the nanogels when they were dispersed in 
water. Therefore, the transition from a liquid to a shrunken gel phase occurred at a 
lower temperature in PBS. As the temperature was increased further the shrunken gel 
formed a phase-separated aggregate, likely due to the lack of either steric or 
electrostatic stabilisation. This behaviour is similar to that shown by Hu et al. where a 
shrunken gel was formed, but if the electrostatic repulsion was removed the sample 
would phase separate and form an aggregate.16 In PBS the shrunken gel phase was 
found over a narrow temperature range, and only for PNA65 and PNA160. It is likely 
that when electrostatic repulsion has been heavily reduced in PBS, a shrunken gel can 
only occur when the particles still retain some supporting steric stabilisation below the 
LCST. Hence there is a transition to an aggregate when this is lost. When PNA310 and 
PNA450 were dispersed in PBS, the electrostatic repulsion between the particles was 
screened, and so all samples formed an aggregate as a 12 wt% PBS based dispersion. 
4.2.3. Rheology Studies 
Oscillatory rheology was also performed on the concentrated nanogel dispersions at 
12 wt% in water and PBS, (figure 4.6 c),‡‡ to compare the rheological properties of the 
dispersion with the visual phase behaviour in water, (figure 4.6 a), and PBS, 
(figure 4.6 b). The G’ (storage modulus) and G’’ (loss modulus) values were 
investigated as these values are the most relevant for studying the phase behaviour of 
the concentrated nanogel dispersions. A frequency of 1 Hz (6.28 rad s-1) was used for 
all measurements as used previously in literature for similar nanogel dispersions and 
rheological experimental setup,24,30 whilst an amplitude sweep was performed on each 
dispersion to find a suitable strain value within the linear viscoelastic range of each 
sample (figure A.4, Appendix) to perform a dynamic temperature sweep on each 
dispersion. 
                                                          
 
‡‡ Figure 4.6 duplicated on next page. 
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Figure 4.6 (Duplicate figure) – Comparison of nanogel phase behaviour and rheological properties in water and PBS at temperatures between 20 °C and 45 °C 
with a heating rate of 1 °C min-1 for the different nanogel samples with mean diameters from smallest (left) to largest (right), 65 nm, 160 nm, 310 nm and 450 
nm respectively. a) The phase diagrams of different nanogel samples dispersed in water at concentrations ranging from 2 wt% up to a maximum of 24 wt%. b) 
The phase diagrams of nanogel samples dispersed in PBS at 12 wt%. c) Rheological measurements of 12 wt% nanogels dispersions. Lines are a guide for the 
eye between the phase changes seen in the phase diagrams in water (dashed line) and PBS (dotted line) and the rheological data. 
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Characterising the nanogels by rheology provides information on the mechanical 
properties of the different phases. The temperature at which transitions were observed 
by the vial inversion test were generally accompanied by changes in the rheological 
data, with the four nanogel samples displaying differing rheological properties. In 
PNA65, G’’ is an order of magnitude larger than G’ below 30 °C (c.a. 1 and 0.1 
respectively) in both water and PBS, and has a tan δ >> 1, (figure A.5, Appendix), 
suggesting it existed as a viscous liquid, as seen in the phase study.61 Conversely, The 
G’ (storage modulus) is an order of magnitude greater than G’’ (loss modulus) for 
PNA160, PNA310 and PNA450 at 20 °C (c.a. 103 and 102) suggesting the formation 
of a gel in water and PBS,30 as seen in the phase study where a swollen gel was present 
for these nanogels dispersed at 12 wt%. As the temperature was increased G’ and G’’ 
gradually decrease, and the separation between G’ and G’’ reduces, corresponding to 
the decrease in size of the nanogel, (figure 4.3), resulting in nanogels less closely 
packing, as they begin to transition from a swollen gel to a liquid. The viscous 
properties of the material begin to dominate and so the material becomes more 
liquid-like. For PNA160, PNA310 and PNA450, before the swollen gel to liquid 
transition there was also a more gradual decrease of G’ and G’’ than after the transition 
where a slightly steeper gradient for G’ and G’’ can be observed, potentially providing 
a way to observe this transition rheologically. The exception to this is that in water, 
PNA160 behaves differently, with the moduli increasing after the transition at 30.5 °C. 
This is likely because a shrunken gel forms as the temperature continues to increase, 
as with PNA65 in water, which also shows an increase in moduli c.a. 5 °C before a 
shrunken gel was observed visually. Therefore the increase in moduli likely indicates 
the increasing interaction between nanogels which eventually leads to the formation 
of a shrunken gel network. The smallest nanogel, PNA65, had the properties of a 
viscous liquid until approximately 30 °C, while the three larger nanogels (PNA160, 
PNA310 and PNA450) displayed gel-like character between 20-25 °C, matching the 
data in the phase diagram where a swollen gel was observed by vial inversion. The 
initial values of G’ and G’’ are lower for PNA310 and PNA450 in PBS than water. 
This is likely due to PBS causing larger nanogels to deswell at low temperature.21 The 
reduced diameter means the nanogels were less closely packed, so that the swollen gel 
exhibits as reduced stiffness.  
As the temperature was increased above 30 °C in water and PBS, all samples displayed 
an abrupt increase in G’ and G’’ of at least two orders in magnitude for PNA65, 
PNA160 and PNA310 and one order of magnitude for PNA450 over a temperature 
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rise of less than 5 °C, when there is a corresponding formation of a shrunken gel or 
aggregate phase in the phase study. This was observed previously by Xu et al. in the 
formation of a shrunken gel,62  as well as in other studies.16,22,30 The rise in G’ and G’’ 
corresponds with the increasing attractive interaction between particles as they become 
more hydrophobic and transition from a liquid to either a shrunken gel or aggregate 
phase. In the case of PNA310 as an aqueous dispersion the sample remains a liquid at 
higher temperature. The dispersion is no longer viscoelastic and hence G’ and G’’ were 
not measurable above 35 °C (values < 0.1 Pa) and don’t show the dramatic rise in G’ 
and G’’ values. In PNA450 there is a less significant and more gradual increase in G’ 
and G’’ at high temperature for the aqueous dispersion, which was unexpected as no 
phase transition occurs. This may be due to shear induced aggregation of the largest 
particles.63 After performing the dynamic temperature sweep small aggregates were 
observed in the aqueous dispersion of PNA450, but not PNA310, 
(figure A.6, Appendix). Hence short range network formation due to particle-particle 
aggregation may occur, which alters the rheological properties of the dispersion, but 
is not observable in a vial inversion test. PNA 65, PNA160 and PNA310 also show an 
anomalous jump in G’ and G’’ (and intrinsic viscosity, figure A.7, Appendix) around 
the VPTT. This is due to shear induced chain entanglement, as observed by 
Howe et al.27  
From the rheology measurements of the samples, it can be concluded that it is possible 
to monitor the phase transitions of the concentrated nanogel dispersions by tracking 
the change in G’ and G’’ as temperature increases. Changes in phase behaviour are 
mirrored in the rheological moduli behaviour. In the temperature range of 20 to 30 °C, 
steric stabilisation dominates. Nanogels larger than c.a. 100 nm transition from a 
swollen gel to a liquid as G’ and G’’ values decrease, with G’ being larger than G’’. 
Nanogels less than c.a. 100 nm remain a viscous liquid in this temperature range with 
G’’ larger than G’, and no significant change in either value. Between 30 and 35 °C 
electrostatic stabilisation dominates. The moduli of small or large nanogels in PBS or 
water either rapidly increase if the dispersion solidifies, or decrease if a liquid is 
formed. Above 35 °C the moduli plateau for solidification, or is below the measurable 
range for a liquid. This is summarised in figure 4.9, where phase formation is 
dependent on temperature, as well as nanogel size (and hence structure) and ionic 
strength of the dispersion. The phases and phase transitions can be predicted by trends 
in how G’ and G’’ change with increasing temperature.  It is apparent from the phase 
studies and rheological data that all four nanogels are potentially suitable candidates 
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for an ISFI, however the size of a nanogel effects the overall suitability as an ISFI. All 
four nanogels showed either no solidification, or solidification above a temperature of 
35 °C at a sufficiently high concentration in water, well above the upper limit of room 
temperature (25 °C), avoiding premature solidification. Aggregation in PBS occurred 
at 32.5 °C for all four nanogels, sufficiently below body temperature to expect there 
to be no problem with non-aggregation at a depot site due to the deviations below core 
body temperature which are possible. PNA65 appears to be the most suitable nanogel 
for an ISFI, as at low temperature it was the only one of the three nanogels which 
remained a liquid at low temperature at a concentration of nanogel of 12 wt%, as 
reflected in its G’ and G’’ values at low temperature. This was most likely due to it 
homogeneous cross-linking leading to a much softer deformable particle than the other 
nanogels. This would make it much easier to formulate with drug and inject. PNA65 
also has the lowest zeta potential at elevated temperature, which may be useful for 
preventing charge induced biocompatibility issues associated with a high surface 
charge.64  
 
Figure 4.9 Schematic representation of the phase behaviour (A-C) and changes in rheological 
moduli (i-vi) of the concentrated nanogel dispersions. Stabilisation type shown in top box. 
Dependant on the nanogel size and ionic strength of the solvent, different pathways are taken 
through the phase data as the temperature increases. Phases: A1 - swollen gel, A2 – viscous 
liquid, A3 - liquid, B1 - shrunken gel B2 - low viscosity liquid, C - aggregate. Rheological 
moduli behaviour associated with each pathway: i) G’ > 10G’’ ii) G’ < 10G’’ iii) G’G’’(35°C) 
> 10G’G’’(30°C) iv) G’G’’ (45°C) < 10G’G’’(35°C) v) G’’ > 10G’ vi) G’G’’ < 0.1 Pa. 
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4.2.4. In Vitro Study Release Formulations 
Whilst PNA65 was the most appropriate nanogel for an ISFI from a phase transition 
and rheological perspective, there is also a need to know how nanogel size effects 
payload entrapment efficiency and drug release rate. In order to test this all four 
nanogels were loaded with varying amounts of 50% (w/w) lopinavir SDN payloads to 
conduct a sample and separate in vitro release experiment similar to the release 
experiment in Chapter 3. The release of drug from the aggregate into a surrounding 
PBS solution was quantified using HPLC, with release media completely replaced at 
each sample interval to avoid saturation of the release media by the poorly water 
soluble drug. Nanogel dispersions were prepared at 12 wt% for comparison with phase 
study and rheological data. Drug loading was tested at a nanogel:SDN ratio of 2:1, 1:1 
and 1:2, which corresponds to 33, 50 and 66 wt% of loaded SDN mass vs nanogel 
mass. Formulations can be seen in table 4.3.  
Table 4.3 Formulations of nanogel-drug for ISFI in vitro release study 
Formulation LPV 
SDN 
SDN 
Loading 
PNA65 PNA160 PNA310 PNA450 
 (mg) wt%a (mg) (mg) (mg) (mg) 
a) Saturation Study 
PNA450-66-S 136.4 66 - - - 68.2 
b) In vitro release study 
Free SDN 68.2 100 - - - - 
PNA65-33 34.1 33 68.2 - - - 
PNA65-50 68.2 50 68.2 - - - 
PNA65-66 136.4 66 68.2 - - - 
PNA160-33 34.1 33 - 68.2 - - 
PNA160-50 68.2 50 - 68.2 - - 
PNA160-66 136.4 66 - 68.2 - - 
PNA310-33 34.1 33 - - 68.2 - 
PNA310-50 68.2 50 - - 68.2 - 
PNA310-66 136.4 66 - - 68.2 - 
PNA450-33 34.1 33 - - - 68.2 
PNA450-50 68.2 50 - - - 68.2 
PNA450-66 136.4 66 - - - 68.2 
a wt% based on dry nanogel mass, (mass of SDN/(mass of SDN + mass of nanogel)*100. 
 
4.2.5. Saturation Study 
To ensure the saturation limit of drug in release media was avoided, a saturation study 
was conducted on the nanogel predicted to give the greatest release rate, and at the 
highest SDN loading tested, PNA-450-66-S (table 4.3, a). PNA450 was expected to 
show the greatest permeability and hence drug release rate, owing to it being the largest 
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nanogel, and so containing the largest pores between nanogels. In the saturation study 
1 ml of release media was removed from 200 ml of PBS at each sampling interval. It 
can be seen that the cumulative amount of drug released over time begins to plateau 
after approximately 30 hours, (figure 4.10). According to the European Pharmacopeia 
8.0 (5.17.1) and United States Pharmacopeia (USP37/NF32),65,66 sink conditions are 
reached when the volume of release media is at least three times saturation volume. 
Using the saturation study, a sampling interval of 24 hrs was selected for a 15 day 
in  vitro study of drug release from aggregate depots, as a compromise between 
realistic experimental parameters, and avoiding a saturation limit on the rate of drug 
release.  
 
Figure 4.10 Cumulative release of Lopinavir drug from PNA450-66-S (table 4.3) into 
200 ml of PBS, measured with HPLC in duplicate. 
4.2.6. In Vitro Release from Different Sized Nanogels 
With a greater SDN loading into the aggregates than chapter 3, it was expected that 
aggregate depots would be potentially more mechanically unstable and fracture upon 
or after formation. It is possible to retain fragments of depot matrix within a dialysis 
bag to prevent them from being lost in the sampling process, however a dialysis 
membrane can potentially hinder the diffusion of drug, with membrane permeation 
shown to control release rate.67 For this reason aggregates were retained in 150 µm 
mesh containers suspended in the release media to prevent loss of aggregate upon 
replacement of release media, (figure A.8, Appendix). At the start of the release period 
in the in vitro release study, sampling was performed after the first 1,2, and 5 hours to 
completely remove burst release drug from the release media. It can be seen in the 
LPV SDN control sample ‘Free SDN’, (table 4.3), that 100% release occurred after the 
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first sample point at 1 hr, and so there is no limitation imposed by the mesh container 
on release of drug into the release medium, (figure 4.11, a). The depots composed of 
different sized nanogels and different amounts of SDN loading all showed controlled 
release after a prolonged period of time. After 360 hours (15 days), the percentage of 
drug released ranged from a minimum of 14.6% for PNA65-33 to a maximum of 
67.8% for PNA160-66. This corresponds to a single order of magnitude difference in 
release rate of 4.9 and 40.3 µg hr-1 respectively, (figure 4.11, b). Applying the 
Ritger-Peppas equation,68 (Chapter 3, section 3.1.3), to the release data with the 
assumption that drug release occurs via Fickian diffusion as observed previously 
(Chapter 3, figure 3.9, c), shows that a single phase of release occurs from all depots, 
with the equation showing a good linear fit to the data, (figure 4.11, c). The associated 
dissolution constant values (k), and correlation coefficients (Rc) can be found in 
table  A.4, Appendix. This release behaviour concurs with the observation in 
chapter  3, that the polyNIPAM nanogels without allylamine comonomer form dense 
aggregates which completely entrap SDNs after any initial burst release during 
aggregate formation, so that drug is only released in dissolved form, rather than two 
release phases being present, where SDNs are released from the aggregate depot, 
followed by dissolved drug.  
During the release experiment, certain depots of higher drug loading started to fail 
mechanically and fracture. This can be seen visually in figure 4.12. This instability 
was categorised into (I) a stable depot which retains its shape with no fracturing, (II) 
a low number of fractures occur, where c.a. < 10% of the depot volume may separate 
into a small number of fragments, (III) a high number of fractures occur so that the 
depot separates into many fragments (c.a. >10% of the depot volume). The instability 
of some of the depots was reflected in the greater than expected release rate of the 
depots. This can be seen by comparing the dissolution constant (k) of depots which 
were mechanically stable (I) and those which fractured (III). PNA65 showed excellent 
stability, with no depot fracturing even at high loading of 66% LPV SDNs. This is 
reflected in the linear increase in dissolution constant (k) with greater SDN loading % 
(figure 4.13).  
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Figure 4.11 Release of LPV drug from aggregated nanogel discs over 360 hours; quantified 
by HPLC analysis, measurements performed in duplicate. An SDN control without nanogel, 
‘Free SDN’, was performed. (a) cumulative release (b) release rate (c) application of the 
Ritger-Peppas equation to the LPV release over 360 hours. 
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Figure 4.12 Images of in vitro release nanogel aggregate drug depots after 360 hours. The 
mechanical stability of the depots is categorised into (I) retains shape with no fracturing, (II) 
a low number of fractures into a small number of fragments, (III) a high number of fractures 
into many fragments. 
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Figure 4.13 Comparison of dissolution constant (k) for mechanically stable depots (PNA65) 
and depots which fracture during release at increased loading % (PNA160, PNA310, 
PNA450). Determined from duplicate HPLC measurments. 
The release rate can be tuned by changing the percentage of SDN loaded into the depot. 
Greater SDN loading is likely to introduce greater porosity into the release matrix, 
increasing the drug dissolution rate due to the increase in permeability of the depot. 
Theoretically as drug and excipient dissolves from the SDNs contained at the outer 
boundary of the depot over time, they are likely to be replaced with porous channels, 
to aid in the release of drug further within the depot, (figure 4.14). It is acknowledged 
that further detailed study into the structure of the aggregates is required to confirm 
this. In the case of PNA160, the depot only remained mechanically stable at 33% 
loading, with a great amount of fracturing (III) occurring with 50% and 66% loading. 
Hence a much greater increase in dissolution constant occurs for PNA160 at 50% and 
66% loading compared to PNA65, (figure 4.13). Similar behaviour is seen for PNA310 
and PNA450, which also became mechanically unstable above 33% loading. The 
dramatic increase in the diffusion constant can be explained by the fact that as the 
depot fractures into smaller fragments the drug has a shorter distance to diffuse, and 
greater surface area to diffuse from. The non-linear increase in dissolution constant for 
50% and 66% loading for PNA160, PNA310 and PNA450 can be attributed to an 
increase in the porosity of the material with greater drug loading combined with a 
varying and unknown degree of fracturing of the aggregate to enhance release rate.  
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Figure 4.14 Illustration of the dissolution of SDNs loaded into nanogel aggregates to introduce 
different amounts of porous channels into the matrix depending on SDN loading %. SDNs 
represented by red circles and nanogels by grey circles. a) Low loading and b) high loading of 
SDNs, i) start of release period and ii) after a period of release, where surface drug has 
dissolved and released from the aggregate depot, leading to porous channels which aid further 
drug release in the interior of the depot. 
 
With the indication that PNA65 nanogels were more deformable in section 4.2.2, the 
nanogels may have been able to deform around the payload or mesh together to form 
a more cohesive depot. Hence even with a high wt% of payload, the depot appeared to 
remain mechanically stable with no observed fracturing occurring. In regards to the 
larger nanogels, the likely existence of a highly cross-linked core,28 gives less 
deformable spheres which are not as cohesive in the presence of greater SDN loading, 
and so fracturing of the aggregate depot occurs. Focussing on the lowest loading of 
33%, where depots remained mechanically stable for all sizes of nanogel, it can be 
seen that the dissolution constant increase was linear with nanogel size when the 
dissolution constant was no longer affected by depot fracturing, (figure 4.15). Hence 
it is likely that smaller particles without a dense core underwent greater deformation 
upon packing to form an aggregate, reducing the inter-connectivity of pores in the 
aggregate, as well as containing smaller pores, lowering the permeability and hence 
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drug diffusion rate. Larger nanogels appear to form aggregates with greater porosity, 
providing another way to tune release rate from a nanogel release matrix by increasing 
the diffusion rate of drug from the depot. 
 
Figure 4.15 Comparison of dissolution constant (k) for mechanically stable (I) depots of 
different sized nanogels at a fixed SDN loading of 33%. Determined from duplicate HPLC 
measurments. 
 
The nanogels depots generally showed excellent control over burst release, even with 
increasing SDN loading %, with values as low as 1.5% burst release achieved, 
(figure 4.16). The burst release period was deemed to occur within the first hour, due 
to the rapid aggregation of the nanogels, with no dramatic increase in the cumulative 
% of drug released after the first hour (figure A.9., Appendix). Regardless of nanogel 
size, burst release was generally 4.8% or less for ≤50% SDN loading. When loading 
was increased to 66%, all sizes of nanogel were no longer capable of fully retaining 
the SDN payload, with burst release now in the range of 11.6% to 18.9% got an SDN 
loading of 66%. 
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Figure 4.16 Burst release (first 1 hour of release) (%) from aggregate depots of different 
sized nanogels (PNA65, PNA160, PNA310, PNA450) with different SDN loading (%). 
Determined from duplicate HPLC measurments. 
 
4.3. Conclusions 
In using nanogels of four different sizes, it was shown that differences occurred in the 
phase and rheology behaviour of concentrated dispersions of nanogels, the release rate 
of drug from SDN loaded depots of different sized nanogels, and depot mechanical 
stability over time. Increasing the SDS concentration in the synthesis to create smaller 
nanogels is documented to have an effect on the internal structure of the nanogel, hence 
the differences seen were due to a combination of nanogel size and internal structure 
associated with different sizes of nanogel. PNA65 showed the greatest difference to 
the other nanogels, which is highly likely due to previous studies observing a 
homogeneous internal structure for nanogels of this size, compared to the increasing 
core-shell natured structure of the other nanogels with increasing size. The phase and 
rheological measurements of the concentrated nanogel dispersions were in good 
agreement. The phase transition of all nanogels were appropriate for use as an ISFI at 
all concentrations tested. Solidification in water was not an issue, as it only occurred 
for PNA65 and PNA130, at a temperature of 35 °C, well above the upper limit of room 
temperature (25 °C). Aggregation also occurred at 32.5 °C well below a mean body 
temperature of 37 °C. PNA65 was found to be the most suitable, as unlike the other 
nanogels it did not display a swollen gel phase behaviour at higher dispersion 
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concentration, due to its greater deformability and soft sphere nature. As it remained a 
liquid at < 35 °C, it would be easier to formulate with drug, and also inject than the 
other nanogels. In the in vitro drug release study, all nanogels proved suitable, with 
sustained release of drug over time, and low burst release when the SDN payload was 
as high as 50 % loading. The release rate of drug could also be tuned in a linear fashion 
by changing the % loading of SDN, or the size of the nanogel used to form the depot. 
Again, PNA65 showed the greatest performance, as unlike the larger nanogels at 
higher % loading, PNA65 depots remained stable over time regardless of SDN 
loading %, with no fracturing of the depot. 
4.4. Materials and Methods  
4.4.1. Materials 
N-Isopropylacrylamide (NIPAM, ≥99%), N,N-methylenebis(acrylamide) (BIS, 99%), 
potassium persulfate (KPS, ≥99%), sodium chloride (NaCl, ≥99.5%), sodium 
phosphate dibasic dihydrate (Na2HPO4, ≥99%) potassium phosphate monobasic 
(KH2PO4, ≥99%), sodium phosphate dibasic dihydrate (Na2HPO4 · 2H2O, ≥99%), 
(orthophosphoric acid solution 50% (H3PO4, HPLC Grade), anhydrous sodium 
hydroxide pellets (NaOH, analysis grade), sodium dodecyl sulphate (SDS, ≥99%) 
were purchased from Sigma-Aldrich Company Ltd, Gillingham (Dorset) UK, a 
subsidiary of Merck KGaA, Darmstadt, Germany. Lopinavir (ABT-378) (LPV) was 
purchased from WuXi PharmaTech, Shanghai, China. Kolliphor TPGS was purchased 
from BASF, Ludwigshafen, Germany. Phosphate buffered saline tablets (Bioreagent), 
Acetonitrile (MeCN, HPLC grade), hydrochloric acid 37% (HCl, analytical grade), 
were purchased from Fischer Scientific UK, Loughborough, UK, a part of Thermo 
Fisher Scientific. Type I distilled water obtained from a water purification system with 
a resistivity of >18 MΩ cm−1 (PURELAB option R, Veolia). Spectra/por 2 (MWCO 
= 12-14 kDa) and spectra/por 3 (MWCO = 3.5 kDa) dialysis tubing was purchased 
from Spectrum Europe B.V., Breda, The Netherlands.  Chromafil Xtra PET 0.45 µm 
syringe filters were purchased from Hicrom Ltd. Theale, UK. 
4.4.2. Synthesis of PolyNIPAM Nanogels 
The polyNIPAM nanogels were synthesized by dispersion polymerisation. The 
composition used in the synthesis of each nanogel can be found in table M.4.1. The 
NIPAM monomer (7000 mg, 61.9 mmol), BIS cross-linker (700 mg, 4.5 mmol) and 
SDS surfactant (PNA450 = 30.0 mg, PNA310 = 78.8 mg, PNA160 = 260.2 mg, 
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PN60  = 939.1 mg) were dissolved in distilled water (470 mL) in a 1 L two-neck round 
bottom flask equipped with a stir bar and reflux condenser. This was then sealed and 
nitrogen was bubbled through the aqueous solution for 1 hour whilst stirring (400 rpm) 
to remove dissolved oxygen. The solution was then heated to 70 °C. Separately KPS 
initiator (280 mg) was dissolved in distilled water (30 mL) and degassed with N2 for 
1 hour before being transferred to the flask containing the monomers. The reaction was 
maintained under a N2 atmosphere for 4 hours at 70 °C before being cooled down to 
room temperature. The solution was then filtered through glass wool. To remove 
unreacted impurities, the nanogel suspension was dialyzed for 5 days using 
regenerated cellulose dialysis tubing (12-14 kDa MWCO for PNA400, PNA310 and 
PNA160 and 3.5 kDa MWCO for PNA60), (Spectrum Labs), replacing the distilled 
water every 12 hours. The purified suspension was then lyophilized (Virtis 
Benchtop  K with ultra-low temperature condenser) and stored in a desiccator. 
 
Table M.4.1 The composition used in nanogel synthesis. 
Sample NIPAM 
(mg) 
[SDS] 
(mg ml-1) 
BIS 
(mg) 
KPSa 
(mg) 
Waterb 
(ml) 
PNA65 7000 1.88 700 280 500 
PNA160 7000 0.52 700 280 500 
PNA310 7000 0.16 700 280 500 
PNA450 7000 0.06 700 280 500 
a KPS dissolved at 9.3 mg ml-1 in distilled water. 
bTotal volume of water, including addition of KPS dissolved in water. 
 
4.4.3. Characterisation of PolyNIPAM Nanogels 
Characterisation of the nanogels was carried out using dynamic light scattering (DLS) 
and laser Doppler electrophoresis (LDE). DLS and LDE was performed using a 
Malvern Zetasizer Nano ZS (running Malvern Zetasizer software V7.12) with 633 nm 
He-Ne laser and the detector positioned at 173°. Dialysed samples were diluted to 1 mg 
mL-1. The hydrodynamic diameter was recorded in the range (15-55 °C) using a 
thermal equilibration time of 600 seconds in 1 cm path length disposable polystyrene 
cuvettes. Measurements were repeated in triplicate to give a mean hydrodynamic 
diameter and polydispersity index (PdI). Zeta Potential measurements were performed 
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using DTS1070 folded capillary cells (Malvern, UK). The pH of the sample was 
measured before performing zeta potential measurements, and for all samples fell in 
the range pH 7 +/- 0.5. Capillary cells were flushed with ethanol and water prior to 
usage. The zeta potential measurement was made with a minimum of 10 and maximum 
of 40 runs, with a voltage of 150 V. The Smoluchowski approximation where 
f(Ka) = 1.5 was used. Due to the tendency of the nanogels to aggregate with increasing 
ionic strength solution when above 32°C, the measurements were conducted in the 
highest stable concentration of 0.001 M NaCl. This is despite the ISO 13099-2:2012 
and ASTM E2865-12 standard recommendation of 0.01 M NaCl to avoid potentially 
inducing electrode polarization, which causes voltage irregularities if solution 
conductivity is too low. Hence the zeta values give a relative qualitative comparison 
of zeta potential trends between the samples measured under the same conditions, 
rather than a quantitative value. 
4.4.4. Viscometery Measurements 
Lyophilized nanogels were dissolved in water for 24 hours on a sample tube roller. 
PNA450 required 30 minutes sonication in a sonication bath (S 100/H, Elmasonic) for 
complete dispersal. DLS was used to check complete dispersal of lyophilized nanogel 
was achieved, with particle size and PdI values equivalent to those before 
lyophilization during the nanogel synthesis, see table A.2. A Poulten Self U-Tube 
Ostwald Viscometer (V1618/02) was used to determine the relative viscosity of the 
dilute aqueous nanogel samples. All viscometry measurements were conducted at 
20 +/- 0.5 °C and performed in triplicate. 
4.4.5. Phase and Rheological Studies 
To form nanogels at different wt% in water and PBS (1X strength, pH 7.4) the 
lyophilized nanogels were first packed at the bottom of glass sample vials. Water or 
PBS was then added to the sample vials and the samples were held at 20 °C for 30 
minutes to allow the solvent to soak into the lyophilized nanogel material. The samples 
were then held at 27 °C for 24  hours to allow the nanogels to completely disperse. 
The samples were then added to a sonication bath (S 100/H, Elmasonic) for 30 minutes 
to remove any trapped air bubbles formed in the high concentration dispersions. This 
was repeated up to three times and the temperature of the bath was kept below 25 °C. 
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For phase studies the sample increasing in 2 wt % intervals from 2 wt % up to the 
maximum wt % at which each nanogel sample could be homogeneously dispersed 
were heated in 1 °C intervals and allowed to equilibrate for 5 minutes at each 
temperature. The phase of each sample was then observed by visual inspection and the 
vial inversion method:69 A liquid flowed down to the bottom of the vial; a swollen gel 
remained self-supporting and did not flow over 10 seconds; a shrunken gel remained 
self-supporting and adhered to the sides of the vial over 10 seconds with a small excess 
of water phase separating; an aggregate formed a pellet which was not self-supporting 
and with a large excess of water phase separated. When a phase transition occurred 
between two consecutive temperatures or wt % values the intermediate value was used. 
For example a phase transition between 10 wt % and 12 wt % is stated as occurring at 
11 wt %. For rheological studies a Thermo Fischer Haake MARS III rotational 
rheometer was used with a 35 mm parallel-plate head geometry to perform oscillatory 
rheology, A sample cover and solvent trap were used to prevent water evaporation 
from the sample. 12 wt% samples were loaded into syringes at 33 °C for placement on 
the rheology geometry as a liquid. The parallel-plate geometry was lowered onto the 
sample (0.5 mL) and cooled down to 20 °C for 10 minutes before commencing 
measurements to erase any loading and stress history. Amplitude sweeps were 
performed in the range of 0.1 to 100 % strain to find the linear viscoelastic range (LVE) 
for each sample, (figure A.4, Appendix) A strain in the LVE of each sample was 
selected for the proceeding measurements. This was 1 % for PNA450, PNA310 and 
PNA160, and 20 % for PNA65. A time sweep was then conducted for 600 seconds at 
the fixed strain values to ensure G’ and G’’ remained constant over time, to confirm 
that the sample remained stable under measurement conditions. A dynamic 
temperature sweep was then performed with a heating rate of 1 °C min-1 in the range 
of 20 °C to 45 °C. A frequency of 1 Hz (6.28 rad s-1) was used for all measurements 
as used previously in literature.24,30 
4.4.6. Lopinavir (LPV) Solid Drug Nanoparticle (SDN) Synthesis 
The LPV SDNs were prepared by emulsion-spray-drying as described by Giardiello et 
al.70 Briefly, a stock solution of LPV (200 mg mL−1 in dichloromethane (DCM)), 
polyvinyl alcohol (PVA grade 4–88, MW 57–77 000) (50 mg mL−1 in water), 
Kolliphor TPGS (50 mg mL−1 in water) were prepared. Three stock solutions were 
168 
 
 
CHAPTER 4 
mixed in the LPV: PVA : Kolliphor TPGS ratio of 60 : 192 : 48 (mL) in a 1 : 4 DCM 
to water mixture. Emulsification was conducted using a Hielscher UP400S ultrasonic 
processor equipped with a H14 Probe at 100% output (140 W) for 180 seconds, with 
immediate spray-drying using a benchtop spray-dryer (BUCHI Mini-290) with an air-
atomizing nozzle and compressed air as the drying gas. Spray-drying process 
conditions: 7 mL min−1 solution flow rate; 65 °C outlet temperature; 110 °C inlet 
temperature. Resultant powders were further dried under vacuum for 48 hours to 
remove residual DCM. SDN dispersions result from subsequent powder dispersion in 
water; for DLS characterisation, powders were dispersed in distilled water at 
2 mg mL−1 (1 mg mL−1 cf. LPV). 
4.4.7. In Vitro Release Study 
The in vitro drug release was performed using adaptations of the sample and separate 
method,71 as performed in previous work.72 A mass of 12 wt% (68.2 mg) of each 
lyophilised nanogel was dispersed to form a swollen self-supporting gel in 0.5 mL of 
PBS (pH 7.4, 0.137 M NaCl and 0.0027 M KCl) in a glass vial of internal diameter 
14 mm. To this 33, 50 or 66 wt% (34.1, 68.2 or 136.4 mg) of LPV SDNs (50% (w/w) 
loading of LPV) were vortexed. These were then heated to 37 °C for 1 hour to form 
shrunken discs with excess PBS expelled from the discs in the heating process, this 
was removed and used as the first release time point. These discs were transferred to 
150 µm mesh containers suspended in the release media in 250 mL glass sample jars 
with 200 mL of fresh PBS. Subsequent release samples were taken at pre-determined 
intervals by removing 200 mL from the vessel and replacing with 200 mL of fresh 
PBS at 37 °C to prevent a saturation limit with a large excess of solvent. Release 
vessels were kept at 37 °C ± 0.5 °C in a water bath. The amount of LPV released was 
quantified by HPLC analysis. A similar setup was used for the saturation study with 
PNA-450-66-S (table 4.3, a). However only 1 mL of release media was removed from 
200 ml of PBS at each sampling interval. 
4.4.8. HPLC Procedure 
The HPLC method is adapted from the method published by Giovanni Di Perri et al.73 
Briefly, HPLC grade acetonitrile (MeCN) (1.8 mL) was added to each release sample 
(4.2 mL) to create 30% (v/v) MeCN samples, followed by filtering through a 0.45 μm 
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PTFE syringe filter. 40 μL of the solution was injected into a HPLC-PDA system 
(PerkinElmer Series 200). The mobile phase was composed of solvent A (KH2PO4 
50 mM dissolved in HPLC grade water then pH adjusted with H3PO4 to reach 
pH 3.23) and solvent B (MeCN) with the gradient reported in Table M.2. 
Chromatographic separation was performed with an Agilent ZORBAX Eclipse Plus 
3.5 μm C18 column (100 × 4.6 mm ID, Santa Clara, CA) maintained at 25 °C in a 
column oven with a solvent flow rate of 0.5 mL min−1 giving a retention time of LPV 
of 9.6 ± 0.2 min. The PDA detector was set to 210 nm with a bandwidth of 2 nm. The 
concentration of LPV in the samples was calculated against known standards using the 
area under the chromatogram peaks. Three standards covering the concentration range 
of the HPLC method were used to verify the results, and samples were analysed in 
duplicate. 
Table M.2 The solvent gradient used in the HPLC method 
Time 
(min) 
Solvent A  
% (v/v) 
Solvent B  
% (v/v) 
Flow  
(mL min-1) 
0.0 70 30 0.5 
1.0 70 30 0.5 
3.0 30 70 0.5 
11.5 30 70 0.5 
12.0 70 30 0.5 
12.5 70 30 0.5 
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4.5. Appendix 
 
Figure A.1 PolyNIPAM nanogel hydrodynamic diameter vs concentration of sodium dodecyl 
sulphate (SDS) used in synthesis. Samples measured using DLS with the mean value of 
triplicate measurements used. 
 
 
 
 
Figure A.2 Photograph (digital image) of tyndall scattering in PNA160. Sample dispersed 
from 2 to 22 wt% from left to right in 2wt% increments. 
171 
 
 
CHAPTER 4 
 
Figure A.3 Swelling ratio vs temperature of different sized nanogels. Swelling ratio equals 
hydrodynamic diameter at given temperature divided by hydrodynamic diameter at 55 °C. 
Samples measured using DLS with the mean value of triplicate measurements used. 
 
 
 
Table A.1 Aggregation temperature in degrees Celsius (°C) of nanogels at 
1 mg ml-1 in NaCl solutions measured by DLS. A dash represents no aggregation in 
the temperature range measured (20 to 55 °C) 
[NaCl] (M) 1 0.1 0.01 0.001 0.0 
PN400 23  34  35  - - 
PN310 23  34  35  - - 
PN160 23  34  35  - - 
PN60 23  34  35  - - 
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Table A.3 k value for each nanogel sample 
Sample k (20 °C)a 
PNA450 0.091 
PNA310 0.106 
PNA160 0.134 
PNA65 0.282 
a k value determined from the fitting of the Bachelor equation 
(ƞrel=5.9(kc)2+2.5(kc)+1) to relative viscosity data at 20 °C. 
 
Table A.2 Hydrodynamic diameter and PdI of nanogels. All measurements made using DLS with aqueous 1 mg ml-1 samples measured in triplicate. 
 Synthesisa  Dispersalb  Sonicationc 
 PNA65 PNA160 PNA310 PNA450  PNA65 PNA160 PNA310 PNA450  PNA450 
Hydrodynamic Diameter (nm) 60 160 310 450  65 160 310 890  450 
PdI 0.13 0.03 0.01 0.02  0.13 0.02 0.01 0.63  0.03 
ameasured after synthesis and purification of nanogel. 
bmeasured after dispersion of lyophilised nanogel. 
cmeasured after 30 minutes sonication of aqueous dispersion in a sonication bath. 
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Figure A.4 Amplitude sweep for each nanogel sample as a 12 wt% aqueous dispersion. G’ (circle), G’’ (triangle), water (filled symbol), PBS (open symbol).
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Figure A.5 Dynamic temperature sweep Tan δ values for each nanogel in water (closed circle) 
and PBS (open circle). Tan δ (°) = 1 shown as black line.  
 
Figure A.6 Photographs (digital images) of aqueous samples at 50 °C after dynamic 
temperature sweep for a) PNA450 (visible solid aggregate particles present within liquid) b) 
PNA310 (liquid). (Top) original image and (bottom) enlarged image. 
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Figure A.7 Dynamic temperature sweep intrinsic viscosity values for each nanogel in water 
(closed circle) and PBS (open circle). 
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Figure A.8 Photograph (digital image) of PNA65-50 cylindrical aggregate nanogel depot held 
inside 150 µm pore size mesh contained suspended in 200 mL of release media (PBS, 1X 
strength, pH 7.4). 
Table A.4 Correlation coefficient (Rc) and dissolution constant (k) values. 
Formulation Rc k 
PNA65-33 2.08 0.9942 
PNA65-50 3.17 0.9988 
PNA65-66 5.97 0.9872 
PNA160-33 4.13 0.9995 
PNA160-50 14.69 0.9972 
PNA160-66 15.15 0.9837 
PNA310-33 5.56 0.9950 
PNA310-50 12.80 0.9813 
PNA310-66 11.82 0.9949 
PNA450-33 8.88 0.9971 
PNA450-50 8.31 0.9964 
PNA450-66 12.14 0.9964 
 
 
 
 
 
Figure A.9 Cumulative % release of LPV drug from aggregated nanogel discs over first 48 
hours. Burst release complete within one hour, with no further dramatic rise in total cumulative 
release. Determined using duplicate HPLC measurments. 
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5.1. Introduction 
The polyNIPAM nanogels developed for use as an ISFI in previous chapters show an 
inherent weakness; their lack of degradability. This final results chapter will explore 
the development of nanogels which are capable of undergoing degradation at a depot 
injection site in the body. 
5.1.1. Degradable Nanogels 
Biodegradable ISFIs solidify through different mechanisms such as thermoplastic 
setting pastes, in situ cross-linking, in situ polymer precipitation and in situ solidifying 
organogels.1 PolyNIPAM nanogels can solidify via in situ precipitation to form an 
aggregate, as we have demonstrated in previous work.2 In order for these solidified 
nanogels to be removed from the injection site through renal excretion after having 
served their purpose, the cross-linked polymer network must be degraded in vivo into 
low molecular weight polymers (~40 kDa or less),3 or smaller nanogels (~20 nm or 
less).4 The molecular weight of the polymer in a nanogel network can be degraded by 
either the scission of the backbone of the polymer or cleavage of bonds in the 
cross-linkers. The carbon-carbon backbone of polyNIPAM is extremely resistant to 
degradation, however, a range of studies have attempted to incorporate degradability 
into this backbone through strategies such as the insertion of degradable polymer 
blocks, and discrete insertion of main-chain degradable groups.5 The most appropriate 
technique for complete removal of a large mass of polymer from the body via a 
degradable backbone is the insertion of multiple main-chain degradable functionalities 
via a comonomer, due to the fact that it allows the polymer to degrade into significantly 
lower molecular weight polymers.6,7 In terms of free radical polymerisation (FRP), 
where a radical is generated and transferred from monomer to monomer as they are 
added to the end of a growing polymer chain, many ring opening comonomers are able 
to introduce a degradable polyester unit into the backbone.8 This has included the 
synthesis of enzymatically degradable linear polyNIPAM in toluene, where proteinase 
K was used in conjunction with comonomer 2-methylene-1,3-dioxepane, which 
introduces an ester into the polymer backbone.9 Ren and Agarwal also synthesised 
degradable polyNIPAM-co-ester polymers, however, the ring opening comonomer 
had a low reactivity, and polymerisation was conducted in anisole.10 Therefore, the 
degradable units were not distributed evenly throughout the polymer. Degradation 
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would lead to polymer fragments with a broad range of molecular weights, including 
those with a molecular weight greater than is required for renal excretion (~40 kDa) in 
vivo. Precipitation polymerisation is a common and simple method used to produce 
nanogels, however, this method is also highly sensitive to the solvent it is conducted 
in, as such the modification of this synthesis to create a nanogel structure in solvents 
other than water such as anisole may not be possible. This likely explains why 
polyNIPAM polymers which contain a degradable backbone via a ring opening 
comonomer have not reached widespread usage. There also currently appears to be no 
reports in literature of any other simple routes to synthesise polyNIPAM nanogels with 
a biodegradable polymer backbone. 
The second way in which nanogel degradation can occur in vivo is via the cross-links 
between the polymer chains which form the nanogel polymer network. A range of 
different degradable cross-linkers exist which can degrade in response to various 
conditions, and can also be incorporated successfully into a nanogel structure during 
synthesis. These include the synthesis of nanogels with glycolate ester based 
biodegradable cross-linking agents, which are able to degrade hydrolytically,11 ketal 
cross-linked nanogels which degrade in response to a low pH,12 enzymatic degradation 
using dextran based cross-linking agents,13 and many others.14–16 PolyNIPAM based 
degradable nanogels have previously been synthesised, for example with the inclusion 
of a cross-linking agent containing a vicinal diol.17 One form of biodegradable 
cross-linking agent which has been employed in numerous polyNIPAM nanogels is 
that of N,N’-bis(acryloyl)cystamine (BAC), which contains a biodegradable 
disulphide bond.18–21 BAC is similar in structure to the more commonly used non 
degradable cross-linking agent N,N′-methylenebis(acrylamide)(BIS), (figure 5.1, a). 
Disulphide bonds undergo reduction under physiologically relevant reducing 
conditions.20 The main disulphide bond reducing agent in the body is glutathione 
(GSH), which is found at a concentration of 2-20 µM in the extracellular environment, 
and 0.5-10 mM in the intracellular environment.22,23 Hence disulphide bonds rapidly 
cleave within the highly reductive environment of cells,24 but more slowly in 
extracellular fluid.25,26 In this process GSH is oxidised to form the dimer glutathione 
disulphide (GSSG), cleaving a disulphide bond into two thiols (figure 5.1, b),23 
potentially allowing the polymer network cross-linked by disulphide bonds in a BAC 
cross-linked nanogel to be slowly degraded in an extracellular environment, to 
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generate low molecular weight polymers which can be eliminated from the body. The 
reductant dithiothreitol (DTT), is often used for in vitro reduction of disulphide bonds, 
mimicking the role of GSH in the body,19,21,22 with reduction of the disulphide bond 
achieved via a thiol-disulphide exchange reaction driven by the formation of a six 
membered ring in DTT (figure 5.1, c).27,28  
 
Figure 5.1 Disulphide bond chemistry a) comparison of cross-linking agent chemical 
structure of i) N,N′-methylenebis(acrylamide)(BIS) and ii) N,N’-bis(acryloyl)cystamine 
(BAC), b) schematic showing reduction of nanogel disulphide bond into thiols by GSH, c) 
disulphide exchange reaction between nanogel disulphide bond and dithiothreitol (DTT). 
5.1.2. Obstacles to Degradation 
PolyNIPAM nanogels cross-linked with the degradable cross-linking agent 
(1,2-dihydroxylethylene)bisacrylamide (DHEA), have previously been reported to 
give incomplete degradation.17 It was hypothesised that non-degradable cross-linking 
is introduced through a chain transfer reaction. PolyNIPAM contains a hydrogen atom 
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on the tertiary carbon of the polymer main chain, which can be abstracted in a chain 
transfer reaction.17,27 In replacing the NIPAM monomer with 
N-isopropylmethacrylamide (NIPMAM), (figure 5.2), which is identical in structure 
except for a methyl group in place of the hydrogen atom on the tertiary carbon of the 
main polymer chain,29 fully degradable nanogels could be synthesised.17  
 
Figure 5.2 Chemical structure of a) poly(N-isopropylacrylamide) (polyNIPAM), b) Poly(N-
isopropylmethacrylamide) (polyNIPMAM) and c) a core-shell structure. 
 
PolyNIPMAM has an LCST between 38 to 44 °C (above body temperature),30,31 so it 
would be unable to aggregate in response to body temperature to form a depot, as the 
aggregation temperature of polyNIPMAM nanogels is around 46 °C.32 However by 
combining NIPMAM and NIPAM monomers, Fundueanu et al. recently showed that 
the LCST can be tuned by varying the copolymer composition. It was also found that 
a 60:40 mol% ratio of NIPAM to NIPMAM gave nanogels with a VPTT of 36.8 °C, 
just below body temperature.33 Weise et al. similarly showed that a 50:50 mol% ratio 
gave nanogels with a VPTT of 38 °C. They also synthesised a nanogel with a 
polyNIPAM core and polyNIPMAM shell structure (figure 5.2, c). The core-shell 
structure had a higher aggregation temperature (40 °C) than the copolymer nanogel 
composed of the same mol% of each monomer (36 °C).32 Therefore, aggregation 
temperature was more dependent on the VPTT of the polyNIPMAM shell than the 
polyNIPAM core. Hence it may be possible to synthesise a nanogel where the 
monomer in the core and shell are switched, to give a nanogel compromised of a 
polyNIPMAM core, and a polyNIPAM shell. The aggregation temperature of this 
nanogel would likely remain closer to polyNIPAM than polyNIPMAM, allowing 
aggregation at a temperature below 37 °C when at physiological ionic strength. 
Nanogels consisting of polyNIPMAM with the degradable cross-linking agent BAC 
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have also previously been synthesised by Gaulding et al.21 Again incomplete 
degradability was observed. This time it was attributed to the elevated temperature of 
synthesis (80 °C) allowing the disulphide bond of the BAC cross-linking agent to 
participate in various reactions, such as attack by a radical to form a thioether. These 
non-degradable cross-links also prevented the nanogel from fully degrading if a 
significant amount of the non-degradable cross-links present. However, fully 
degradable nanogels were synthesised by conducting low temperature redox-initiated 
polymerisation (50 °C) with the addition of N,N,N′,N′-tetra-methylethylenediamine 
(TEMED). This avoids unwanted reactions with the disulphide bond which occur at 
higher temperature.21 To summarise, both polyNIPAM, and BAC can potentially 
prevent nanogels fully degrading due to the chain transfer reactions which can occur. 
The non-degradable cross-links introduced by NIPAM polymerisation can be 
eliminated by replacing the monomer with NIPMAM, and the non-degradable 
cross-links introduced by BAC can be eliminated by conducting the reaction at a lower 
temperature. 
5.1.3. Monitoring Nanogel Degradation 
The degradation of nanogels has previously been monitored using a range of 
techniques including asymmetric flow field flow fractionation,17,21 dynamic light 
scattering,11,12 atomic force microscopy,27 scanning electron microscopy,20,34 
transmission electron microscopy19, visual turbidity21 and indirectly through enhanced 
drug or dye release.18,20  Monitoring degradation through dynamic light scattering is 
particularly useful, as degradation can be monitored in situ. Chen et al. and Leber et  al. 
showed that the count rate of a nanogel sample drops as the nanogel degrades.11,12 
Count rate is measured in kilo counts per second, and gives a measure of the fluctuation 
in scattered light intensity measured over time.35 The count rate is a function of particle 
size, concentration and particle to medium refractive index.36 Assuming the particles 
do not change in size or concentration, through processes such as aggregation or 
sedimentation, then a drop in count rate over time can be attributed to a change in 
particle to medium refractive index due to particle degradation, as polymeric material 
is lost from the particle and replaced by solvent. Zou et al. showed that the count rate 
of a degradable particle remained constant over time in a control sample, but gradually 
decreased in the presence of an enzymatic degradation species.37 
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5.1.4. Aims 
The main aim of this chapter is to synthesise polyNIPMAM core – polyNIPAM shell 
nanogels which are fully degradable whilst aggregating below 37 °C under 
physiological ionic strength, so as to be able to form a degradable aggregate drug 
delivery depot when injected into the body. This is not something which has previously 
been achieved, and would potentially give an ISFI which doesn’t suffer from burst 
release whilst also not requiring microsurgery for removal after having served its 
purpose. To achieve the main aim of this chapter the following objectives will be 
achieved: 
• Determine the mol% ratio of NIPMAM monomer used in the synthesis of the 
particle core and NIPAM monomer in the shell which minimises the 
polyNIPAM in the shell to reduce the amount of non-degradable cross-links 
introduced by NIPAM polymerisation, whilst retaining a polyNIPAM shell 
large enough to allow the particle to aggregate below 37 °C under 
physiological ionic strength. 
• Investigate the effect of the core-shell structure on the colloidal stability of the 
nanogels by testing both polyNIPAM and polyNIPMAM in the cores and shells 
and looking at the change in aggregation temperature of each nanogel. 
• Select the degradation conditions which allow slow degradation of the nanogel 
particle to gain further insight into how degradation occurs. The structure of 
nanogels changes with increasing temperature as they de-swell, so these 
degradation conditions will also be used to look at the effect of temperature on 
degradation rate of the nanogels. 
5.2. Results and Discussion 
5.2.1. Degradable Nanogel Synthesis and Characterisation 
To create a nanogel which was both degradable and able to aggregate below 37 °C at 
physiological ionic strength, a series of core-shell nanogels were produced with a 
polyNIPMAM core and polyNIPAM shell, (table 5.1). The mol% of NIPAM and 
NIPMAM used varied in order to minimise the polyNIPAM content in the shell with 
the aim of potentially reducing the amount of non-degradable cross-links introduced 
by NIPAM polymerisation, whilst retaining a polyNIPAM shell with a thickness great 
188 
 
 
CHAPTER 5 
enough to allow aggregation below 37 °C at physiological ionic strength, due to the 
underlying core with a higher aggregation temperature. The full composition of 
reactants used to create these nanogels can be found in (table M.5.1, Methods), The  
molar concentration ratio of monomer, cross-linker, and initiator was kept constant 
between samples and across core and shell stages of synthesis. These nanogels 
consisted of a decreasing mol% NIPMAM monomer used to create the core, compared 
to increasing mol% of NIPAM used for the synthesis of the shell. (The samples are 
named with the monomer in the core, followed by the monomer in the shell, followed 
by CS to represent the core-shell nature of the sample, and the ratio of mol% monomer 
used to create the core and shell. PNIPAM is abbreviated to PAM and PNIPMAM is 
abbreviated to MAM. For example “MAM/PAM CS 100/0”). The mol% of NIPMAM 
used decreased from 100, 70, 50, 30 to 15 mol% (MAM/PAM CS 100/0, MAM/PAM 
CS 70/30, MAM/PAM CS 50/50, MAM/PAM CS 30/70, MAM/PAM CS 15/85) 
respectively. In addition to these samples, a nanogel of 100 mol% NIPAM 
(PAM/MAM CS 100/0) was produced. A visual representation of the samples can be 
seen in figure 5.3. All nanogels showed a characteristic deswelling with increasing 
temperature (figure 5.4), and had a hydrodynamic diameter in the range of 86-208 nm 
at 25 °C, with no strong trends in nanogel size observed, (table 5.1). The PdI of all 
samples was also low (≤ 0.03), suggesting a single population of low dispersity 
samples were synthesised. The core-shell nanogels tended to be similar in size (149-
208 nm), and all the nanogel samples were larger than the nanogels consisting of 100 
mol% NIPAM, (PAM/MAM CS 100/0) (86 nm), despite the same total moles of 
monomer being used for each nanogel. This suggests the 100 mol% NIPAM nanogel 
may be more densely cross-linked and hence limited in the size it is able to swell to, 
or a smaller number of larger nanoparticles are formed when NIPMAM monomer is 
used in the synthesis.  
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Table 5.1 Composition and properties of core shell nanogels degradable into short polymer fragments produced using the monomers NIPAM 
and NIPMAM. 
Sample NIPMAM 
mol%a 
NIPAM 
mol%a 
Cross-linker 
Core/shell 
Hydrodynamic  
Diameterb  
(nm) 
PdI Swelling 
Ratioc 
Aggregation 
Temperature  
(°C) 
MAM/PAM CS 100/0 100 0 BAC/BAC 152 0.02 1.31 43 
MAM/PAM CS 70/30 70 30 BAC/BAC 201 0.02 1.36 41 
MAM/PAM CS 50/50 50 50 BAC/BAC 149 0.01 1.30 38 
MAM/PAM CS 30/70 30 70 BAC/BAC 167 0.02 1.21 37 
MAM/PAM CS 15/85 15 85 BAC/BAC 166 0.01 1.21 34 
PAM/MAM CS 100/0 0 100 BAC/BAC 86 0.03 1.19 34 
PAM/MAM CS 50/50 50 50 BAC/BAC 208 0.03 1.38 42 
PAM/MAM CS 50/50 BISd 50 50 BAC/BIS 208 0.01 1.76 41 
a mol% based on total moles of NIPMAM and NIPAM, excludes moles of cross-linker and initiator used (see table M.5.1, methods, for 
complete mol% composition of reactants) 
b Hydrodynamic diameter of an aqueous dispersion at 25 °C  and 1 mg ml-1 using DLS with the mean value of triplicate measurements. 
c Swelling ratio calculated using Hd (Hydrodynamic diameter). Hd (25 °C)/Hd (55 °C). 
d Control sample created using a core crosslinked with non-degradable N,N′-methylenebis(acrylamide) (BIS) crosslinker. 
 
 
Figure 5.3 Illustration of the core shell structure and monomer composition of the degradable nanogel samples. NIPAM monomer shown in grey, and 
NIPMAM monomer in purple. 
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Figure 5.4 Swelling ratio of nanogel samples with temperature. Swelling ratio calculated 
using Hd (Hydrodynamic diameter) of nanogel at given temperature (T). Hd (T)/Hd (55 °C). 
Hydrodynamic diameter provided by DLS measurements on a 1 mg ml-1 aqueous dispersion 
using the mean value of triplicate measurements. 
 
This range of nanogels all have a similar swelling ratio (1.19-1.36) at 25 °C with the 
exception PAM/MAM CS 50/50 BIS, with a decrease in swelling ratio as the mol% of 
PAM used in the synthesis increases (figure 5.5). Varga et al. showed for polyNIPAM 
nanogels, swelling ratio was linked to cross-linking density,38 and more recently this 
was shown to be applicable to polyNIPMAM nanogels.21 Particles with a higher 
cross-linking density are more constrained, and therefore have a lower swelling ratio. 
Nanogels with a greater PAM mol% hence can be considered to contain a higher 
overall cross-linking density due to their lower swelling ratio. In other studies, 
nanogels which were synthesised with PAM or MAM monomer contained a 
heterogeneous or homogeneous distribution of cross-linking, depending on the cross-
linking agent and polymerisation conditions used.21,39 PAM also undergoes 
polymerisation at a different rate to MAM, leading to a different reactivity ratio of 
monomer and cross-linking agent.40,41 Therefore the swelling ratio could be due to 
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differences in the distribution of the cross-linking with each of the two monomers 
giving a different internal nanogel structure. A study using a different cross-linking 
agent, (1,2-dihydroxylethylene)-bisacrylamide), showed that it was distributed more 
homogeneously through a polyNIPMAM than a polyNIPAM nanogel.17 Studies into 
the reaction kinetics, and internal structure of the nanogels would be required to 
provide further insight into the reason behind the increasing cross-linking density for 
nanogels synthesised with greater mol% of PAM monomer with BAC cross-linking 
agent compared to MAM monomer, and whether more homogeneous cross-linking 
occurs in the nanogel of one of the polymers over the other.  
 
Figure 5.5 Swelling ratio of nanogel compared to mol% of NIPAM (as a mol% of NIPAM 
and NIPMAM) used in synthesis. Swelling ratio calculated using Hd (Hydrodynamic 
diameter). Hd (25 °C)/Hd (55 °C) 
 
The aggregation temperature of the nanogels in PBS (1X strength, pH 7.4) was found 
by heating them in 1 °C intervals to determine the temperature at which the particles 
aggregated. This temperature was indicated by a dramatic rise in hydrodynamic 
diameter and sample dispersity value (figure A.1, Appendix).32 The aggregation 
temperature of 100 mol% MAM nanogel (MAM/PAM CS 100/0) was 43 °C, while 
for the 100 mol% PAM nanogel (PAM/MAM CS 100/0) it was 34 °C, (figure 5.6). 
For the samples of increasing mol% MAM used to create the nanogel core, the 
aggregation temperature also increases between these two temperature values. 
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Therefore despite polyNIPMAM being contained within the core of the particle, it still 
exerts some influence on the overall aggregation temperature as seen previsouly.32 
Some interpenetration exists between the core and shell of polyNIPAM core, 
polyNIPMAM shell nanogels,42 hence it is reasonable to assume this interpenetration 
exists when the monomer in the core and shell is switched around.  As the polyNIPAM 
shell collapses with temperature, the interpenetrating polyNIPMAM core is likely able 
to provide a degree of colloidal stability, shifting the aggregation temperature higher 
and towards that of polyNIPMAM particles (43 °C), compared to polyNIPAM 
particles (34 °C). There was no increase in aggregation temperature upon moving from 
a 100 mol% polyNIPAM nanogel (PAM/MAM CS 100/0) to a nanogel with a 15 mol% 
polyNIPMAM core (MAM/PAM CS 15/85), likely due to the shell being too thick for 
the interpenetrating core to provide any colloidal stability upon shell collapse.  
 
Figure 5.6 Aggregation temperature of nanogel and core-shell nanogels synthesised with 
NIPAM and NIPMAM monomers. 
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Two samples were synthesised in which the monomer used in the core and the shell 
was reversed compared to the previous samples. The first of these, 
(PAM/MAM CS  50/50), consisted of 50 mol% of NIPAM monomer to create the 
core, and 50 mol% NIPMAM for the shell, to assess the effect on the colloidal stability 
of the particle when the monomer in the core was switched to the shell and vice versa. 
The second (PAM/MAM CS 50/50 BIS) had the same mol% values, however, BIS 
was used in place of BAC in the synthesis of the core, to create a nanogel with only a 
degradable shell as a control sample (table 5.1, figure 5.3). These samples also showed 
a characteristic deswelling with rise in temperature (figure A.1, Appendix) and low 
PdI values (table 5.1). Comparing PAM/MAM CS 50/50 to MAM/PAM CS 50/50, 
having a shell consisting of polyNIPMAM as opposed to polyNIPAM gave an 
aggregation temperature 4 °C higher, (figure 5.6). This aggregation temperature 
(42 °C), for the PAM/MAM CS 50/50 sample was very close to that of the sample 
consisting of 100 mol% MAM monomer, MAM/PAM CS 100/0 (43 °C), despite a 
significant polyNIPAM core being present. The difference between 
PAM/MAM  CS 50/50 and MAM/PAM CS 50/50 is that the core, rather than shell 
collapses in PAM/MAM CS 50/50. This suggests that when the core collapses at 
elevated temperature, the nanogel shell allows the particle to remain colloidally stable, 
whereas when the shell collapses, the core can only provide limited colloidal stability 
to the nanogel. This is because steric stabilisation is provided be solvated polymer on 
the surface of the nanogel.43 So the aggregation temperature is unaffected by the 
polymer in the core becoming unsolvated. However, when the shell becomes insoluble 
and collapses into the core, the still solvated core is only able to somewhat penetrate 
through the collapsed shell to provide solvated polymer on the nanogel surface, hence 
the lower aggregation temperature. This behaviour of PAM/MAM CS 50/50 could find 
potential use in systemic drug delivery of poorly water-soluble drug, as polymeric 
hydrophobic core, hydrophilic shell vehicles which are colloidally stable at 
physiological temperature and ionic strength have previously used to encapsulate and 
deliver poorly water-soluble drugs.44–46 The sample MAM/PAM CS 30/70 has an 
aggregation temperature of (37 °C); with the main aim being to synthesise a nanogel 
which is able to aggregate under physiological conditions to form a drug delivery 
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depot, therefore nanogels synthesised with a 30 mol% or below NIPMAM core are 
able suitable for an aggregate drug delivery depot. 
The swelling ratio of the PAM/MAM CS 50/50 BIS (1.76) was significantly larger 
than any other sample (table 5.1), likely due to this being the only sample with a BIS 
cross-linking agent being incorporated into the core of the nanogel. BIS cross-linke 
has been shown to be incorporated inhomogeneously in polyNIPAM nanogel 
synthesis, changing the swelling ratio compared to homogeneous incorporation from 
a controlled feed.39 Therefore the reactivity ratio of NIPAM with BAC may have a 
different reactivity compared with BIS, due to the difference in swell ratio. To 
investigate this, the reaction kinetics of NIPAM with each cross-linking agent were 
investigated by monitoring the evolution of hydrodynamic diameter and PdI over the 
first five hours of the reaction. Samples PAM-BIS and PAM-BAC were synthesised 
using the same molar concentration of monomer, cross-linking agent and initiator as 
other samples (table M.5.1, methods), to create polyNIPAM nanogels cross-linked 
with BIS and BAC respectively. It can be seen in figure 5.7 that for PAM-BIS the 
hydrodynamic diameter of the particles remains constant, and the PdI remains low and 
constant, whereas in PAM-BAC, PdI decreases from an initially high value, and the 
hydrodynamic diameter increases and then begins to plateau over the first 5 hours of 
the reaction. This suggests that the PAM-BIS reaction is completed within the first 
hour, as seen previously,47 however the PAM-BAC reaction proceeds more slowly, 
with polymerisation and hence particle growth continuing for ~5 hours. This may have 
had some effect on the samples synthesised with NIPAM and BAC in the core of the 
nanogel, where ideally polymerisation of the core would have been conducted for a 
longer time period to ensure all of the monomer was converted into polymer before 
commencing polymerisation of the shell. The effect of this is there was likely a less 
defined transition from core to shell in the nanogels as some of the core monomer was 
left to join the polymerisation with the shell monomer.   
During the synthesis, precursor particles form, which both aggregate, and grow to 
achieve colloidally stable polymer particles.48,49 This process leads to an increase in 
particle size until the polymerisation is complete.47 The PdI of PAM-BAC is also 
initially high due to the existence of growing particles, precursor particles and 
oligomers, and aggregation between these species during synthesis.49–51 The PdI 
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stabilises (at a low value for monodisperse particles) when the polymerisation reaches 
completion, with no further precursor particles forming, or aggregation taking place 
between particles once they are colloidally stable. Hence it can be concluded that 
polymerisation of NIPAM proceeds more slowly with BAC than BIS. This gives 
particles of lower swelling ratio, and hence higher cross-link density, which is likely 
due to more homogeneous cross-linking occurring. 
 
Figure 5.7 Kinetic study of polyNIPAM nanogel synthesis with BIS (PAM-BIS) and BAC 
(PAM-BAC) cross-linking agents showing evolution of nanogel particle hydrodynamic 
diameter and PdI over time during the polymerisation reaction. Samples measured using 
DLS with the mean value of triplicate measurements used.  
 
5.2.2. Nanogel Degradation 
In order to completely degrade particles into short polymer fragments over a 
measurable time period, DTT was used in excess (150 mM, ~350 equivalents of DTT 
for each cross-link) at pH 10 to degrade the nanogel particles. It was found that all 
nanogels showed a high degree of degradability. DLS was used to measure the mean 
count rate in kilo counts per second (k.c.p.s.) of the sample before and after 
degradation, keeping the attenuator value and measurement position of the laser fixed 
for a specific sample before and after degradation. The mean count rate of each nanogel 
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was reduced to 0.9 – 6.7 % of its original value after degradation for all samples except 
PAM/MAM CS 50/50 BIS, which only degraded to 48.1% of its original count rate, 
due to its non-degradable core, (table 5.2).  
Table 5.2. Mean count rate reduction upon sample degradation of 1 mg 
ml-1 aqueous dispersion with 150 mM DTT at pH 10. 
Sample % of original count rate 
after degradation 
MAM/PAM CS 100/0 
MAM/PAM CS 70/30 
MAM/PAM CS 50/50 
MAM/PAM CS 30/70 
MAM/PAM CS 15/85 
PAM/MAM CS 100/0 
PAM/MAM CS 50/50 
PAM/MAM CS 50/50 BIS 
0.9 
1.8 
5.5 
1.0 
1.3 
1.2 
6.7 
48.1 
 
This is expected as only the shell can degrade, leaving a non-degraded core with a 
significant count rate. Previous work by Gaulding et al. showed that polyNIPMAM 
nanogels cross-linked with BAC were not fully degradable unless low temperature 
redox polymerisation was employed.21 With dispersion polymerisation conducted 
overnight at 80 °C leading to only partially degradable particles. Therefore, a lower 
temperature and reaction time of 70 °C and 4 hrs respectively appears to have 
significantly reduced the proposed chain transfer reactions which involve the 
di-sulphide bond. With polyNIPAM nanogels also showing a high degree of 
degradability, the proposed chain transfer reactions occurring from proton abstraction 
from the polymer backbone,17 may also have been reduced with a shorter reaction time. 
The polyNIPAM nanogel kinetic study samples PAM-BIS and PAM-BAC containing 
BIS and BAC cross-linking agent respectively were degraded with DTT at each 
timepoint in the reaction. PAM-BIS showed no degradation as expected, whilst 
PAM-BAC remained completely degradable in the first 5 hours of polymerisation, 
with a negligible measurable count rate after particle degradation (figure 5.8). It is 
clear that the causes of this underlying hindrance to complete nanogel degradation 
requires further investigation, to determine how a greater reaction duration and higher 
synthesis temperature reduce the amount of degradation that can occur within the 
particle. 
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Figure 5.8 During polyNIPAM nanogel synthesis sample was terminated at each time point 
and a normalised count rate was measured for kinetic study with BIS (PAM-BIS) and BAC 
(PAM-BAC) cross-linking agent. Each PAM-BAC and PAM-BIS sample was then degraded 
using the addition of 150 mM DTT to degrade the nanogel particles giving PAM-BIS-D and 
PAM-BAC-D. Samples measured using DLS with the mean value of triplicate measurements 
used. 
 
To study the degradation process more in depth, and the effect of temperature on 
degradation rate, the pH of the dispersion was lowered from pH 10 to pH 7 to give a 
much longer degradation period. The thiols of DTT have a pKa of 9.2 and 10.1 
respectively. Therefore at a pH lower than ~9, less of the of DTT exists in the active 
thiolate form which is able to initiate the di-sulphide exchange reaction and cleave the 
di-sulphide bonds contained within the nanogel. Hence degradation occurs more 
slowly at lower pH. This time dependence of degradation with pH can be seen visually 
in figure 5.9. Two turbid dispersions of MAM/PAM CS 50/50 at 1 mg ml-1 at pH 7 
were formed with 150 mM DTT. When a volume of NaOH solution was added which 
increased the pH to 10, and the sample was shaken, rapid degradation occurred, 
indicated by the significant change in turbidity of the solution. When the equivalent 
volume of water rather than NaOH solution was added, no change in turbidity was 
initially seen, due to the much slower rate of degradation at pH 7. Hence the decrease 
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in mean count rate with degradation of the sample could be monitored over a longer 
time period at pH 7 to gain an understanding of the degradation process. The time 
taken for complete degradation to occur could also be changed by changing the 
molarity of DTT present at pH 7. MAM/PAM CS 50/50 was degraded with 150, 15 
and 1.5 mM solutions of DTT. Complete degradation occurred within 16 hours with 
150 and 15 mM DTT solutions, however degradation took up to 46 hours with 1.5 mM 
DTT, (figure A.2, Appendix).  
 
Figure 5.9 Change in turbidity caused by degradation of MAM/PAM CS 50/50 at 1 mg ml-1 
with 150 mM DTT at a much faster rate at pH 10 than pH 7. a) Aqueous NaOH solution 
(0.1 M) (left) and water (right) added to dispersion, b) dispersion after shaking for 2 seconds.  
The degradation of MAM/PAM CS 50/50 over time was monitored using 150 mM 
DTT and a pH of 7, allowing a long enough degradation time to create a detailed 
degradation profile using DLS, (figure 5.10). The count rate of the sample decreased 
over a 14 hour period of degradation. In this period the PdI remained low and increased 
slightly at the end of the degradation period at ~11 hours. The hydrodynamic diameter 
of the particles continuously increased over the degradation period by 72%. This can 
be explained by the effects caused from cross-link scission in the nanogels. Previous 
work has showed that the size a nanogel is able to swell to is constrained by the density 
of cross-linking present.47,52 Therefore, as cross-links are broken over time, the 
polymer network is less restrained and so able to swell to a larger hydrodynamic 
diameter in the first 13 hours of degradation.17 After 13 hours, the scattering intensity 
became too low to continue measuring the hydrodynamic diameter, as essentially all 
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particles have now dissolved into oligomers with low scattering cross sections as all 
cross links are broken by the end of the degradation period.17 The count rate dropped 
in a similar manner to that seen for the degradation of particles in other work where 
the count rate gradually dropped to less than 35% of original value.12,37 The decrease 
can be explained by the fact that polymer chains were progressively lost from the 
particle over time, as cross-link scission occurred. This effect, combined with the 
swelling of the particle, reduced the refractive index difference between the particle 
and solvent, and hence the scattering intensity decreased, leading to a dramatic 
decrease in the count rate measured over 13 hours, to the point at which essentially all 
particles had degraded into oligomers. Finally, the PdI remained low throughout the 
degradation period, suggesting all nanogel particles degraded and swelled at the same 
rate. Towards the end of the degradation after ~12 hours the PdI increased, likely due 
to the complete disintegration of individual particles into smaller fragments and finally 
oligomers at slightly different times. Again, the scattering intensity was too low to 
continue measuring PdI after ~13 hours of degradation to give reliable data (count rate 
below measurable range) as it was likely no particles were left to scatter enough light 
for sample measurements, so at this point, measurements were simply being made on 
low levels of contamination in the sample, such as from dust. 
 
Figure 5.10 Degradation of MAM/PAM CS 50/50 at pH 7, 25 °C, with 150 mM DTT. 
Count Rate, PdI and hydrodynamic diameter were monitored over time. Samples measured 
using DLS with the mean value of triplicate measurements used. 
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Due to the deswelling behaviour of polyNIPAM/polyNIPMAM nanogels in response 
to increasing temperature, it was expected that this would influence the rate of 
degradation of the nanogels, as the particles become a denser polymer network with 
increasing temperature. The degradation of MAM/PAM CS 50/50 with DTT at pH 7 
was monitored with sealed cuvettes at different temperatures, (figure 5.11). Upon 
increasing the temperature from 10 to 25 °C, normalised count decreased over a shorter 
time frame indicating that the rate of degradation had increased, with degradation time 
reduced from 1.6 to 0.6 days (figure 5.11, a). However, when temperature was 
increased from 25 to 40 °C, the rate of count rate decrease over time was dramatically 
lower, which indicates the degradation rate decreased dramatically at higher 
temperature, (figure 5.11, b), with an increase in degradation time from 0.6 to 4 days 
on moving from 25 to 32.5 °C. This can be explained by the fact that at low temperature 
(10 to 25 °C) polyNIPAM/polyNIPMAM nanogels remain hydrophilic in nature, 
containing a high degree of water,53 with little change in swelling as the temperature 
increases, (figure A.1, Appendix). Therefore the increase in degradation rate with 
temperature can be attributed to a faster thiol-disulphide exchange reaction rate 
occurring at higher temperature.54 The degradation rate decreased above 25 °C, as 
polyNIPAM/polyNIPMAM nanogels start to dramatically deswell as the temperature 
increases towards the LCST of the polymers contained in MAM/PAM CS 50/50 
(figure 5.4),30,55 and a decrease in water content occurs as the nanogel environment 
becomes more hydrophobic in nature. This creates an environment where the 
disulphide bonds are less solvent accessible, so that they are more difficult to reduce 
with DTT.56 Ainavarapu et al. showed that the reduction of solvent inaccessible di-
sulphide bonds in 100 mM DTT was very slow compared to solvent accessible di-
sulphide bonds.57 Hence the degradation rate of the MAM/PAM CS 50/50 decreases 
when increasing the temperature above 25 °C. A similar effect would be expected for 
GSH in vivo, as GSH is also a highly water soluble reducing agent which resides in an 
aqueous environment like DTT.58  
201 
 
 
CHAPTER 5 
 
Figure 5.11 Time dependence of count rate for MAM/PAM CS 50/50 at pH 7, with 
degradation conducted in 150 mM DTT at different temperatures, a) 10, 20 and 25 °C, 
(linear time scale) b) 25, 30, 32.5 and 40 °C (logarithmic time scale). Samples measured 
using DLS with the mean value of triplicate measurements used. 
At 40 °C no decrease in count rate was seen in the first day, suggesting little or no 
degradation occurs at this temperature on this timescale. Therefore, a sample was held 
at 40 °C in an incubator and transferred at specific times into the measuring chamber 
of the DLS equipment preheated to the same temperature to measure over a longer 
time period. The count rate began to decrease over the first 18 days, dropping to 81% 
of its initial value, (figure 5.11, b), suggesting degradation slowly takes place. The loss 
of polymer and increase in swelling with disulphide bond scission on the surface of 
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the particle likely slowly exposes disulphide bonds further into the interior of the 
particle over time, so that at 40 °C the particles are degraded very slowly. DTT is not 
stable for a long time in reduced form,56 however by conducting the degradation at pH 
7, the reducing activity of DTT was likely prolonged, due to only a small fraction of 
the DTT being present in reduced form at a given time. However, although DTT was 
present in excess, it is likely that DTT would still lose it reducing power over the 18 
days the experiment was conducted. Hence although it’s likely that degradation takes 
place slowly at 40 °C, this requires further investigation, where DTT is replaced 
continuously or at given timepoints, and stabilised, for example with egtazic acid to 
reduce the loss of reducing power.59 A nanogel control would also need to be 
performed in a future study to ensure nanogels were not undergoing sedimentation at 
elevated temperature over an extended time period. 
The dramatic effect on degradation rate with temperature enable nanogels to be 
created, which in the short term remain relatively stable in a highly water soluble 
reducing agent at 40 °C, but rapidly degrade at 25 °C. This can be demonstrated by 
initiating degradation for two samples of MAM/PAM CS 50/50 at 25 °C (I) and 40 °C 
(II) respectively, (figure 5.12). After 0.66 days, for the sample at 25 °C (I), the count 
rate has dropped to 2.9% of its original value and the hydrodynamic diameter has 
increased as the particle has swollen and disintegrated. In the same period of time, the 
sample at 40 °C (II.a) has maintained its starting count rate and particle hydrodynamic 
diameter, suggesting no significant degradation has occurred. When this sample is then 
cooled to 25 °C (II.b), the count rate and hydrodynamic diameter change at the same 
rate as sample (I). The degradation process is effectively ‘switched on’ by the 15 °C 
drop in temperature. 
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Figure 5.12 Time dependence of count rate and hydrodynamic diameter for MAM/PAM CS 
50/50 at pH 7, with degradation conducted in 150 mM DTT at 25 °C (I), or at 40 °C (II.a), 
followed by a reduction in temperature to 25 °C (II.b). Samples measured using DLS with 
the mean value of triplicate measurements used. 
 
5.3. Conclusion 
The degradable cross-linking agent BAC, which contains a disulphide bond was 
successfully utilised in the synthesise of degradable nanogels based on NIPAM and 
NIPMAM. Single monomer nanogels, and core-shell nanogels of the two different 
monomers were produced. For core-shell nanogels the aggregation temperature was 
shown to be dependant not only on the LCST of the respective monomers, but also to 
be more sensitive to the LCST of the shell than the core. A nanogel was also 
synthesised which contained a collapsed hydrophobic core, whilst also remaining 
colloidally stable under physiological conditions due to its higher LCST shell 
(PAM/MAM CS 50/50). This may be useful for the delivery of poorly water-soluble 
drug. All the nanogels synthesised were shown to be essentially completely 
degradable, despite previous published work by others sometimes leading to only 
partially degradable nanogels when BAC cross-linking agent, or NIPAM monomer 
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were employed using a longer reaction time or higher temperature. The effect of 
temperature and reaction time on the formation on non-degradable cross-links in the 
synthesis requires a more in-depth study. It was shown that the degradation process 
could be monitored over time using DLS to measure sample mean count rate, particle 
hydrodynamic diameter, and PdI. The particles swell and appear to degrade at a 
constant rate to one another over the degradation period. Temperature was also shown 
to have a great effect on the rate of particle degradation, with degradation occurring in 
less than a day at 25 °C under reducing conditions, but over a week at 40 °C. The exact 
rate of degradation at 40 °C is yet to be determined. With the reduction in normalised 
count rate from 100% to 80% in 2 weeks, the degradation rate appears to be increasing 
and it would be expected that degradation into polymer fragments would eventually 
occur fully. This may allow the depot to provide long-term sustained release of drug 
before being degraded and removed from the body, however this requires further 
investigation.   
 
5.4. Materials and Methods 
5.4.1. Materials 
N-Isopropylacrylamide (NIPAM, ≥99%), N-isopropylmethacrylamide (NIPMAM, 
97%),  N,N-methylenebis(acrylamide) (BIS, 99%), potassium persulfate (KPS, 
≥99%), sodium chloride (NaCl, ≥99.5%), anhydrous sodium hydroxide pellets 
(NaOH, analysis grade), sodium dodecyl sulphate (SDS, ≥99%) were purchased from 
Sigma-Aldrich Company Ltd, Gillingham (Dorset) UK, a subsidiary of Merck KGaA, 
Darmstadt, Germany. Phosphate buffered saline tablets (Bioreagent), hydrochloric 
acid 37% (HCl, analytical grade), were purchased from Fischer Scientific UK, 
Loughborough, UK, a part of Thermo Fisher Scientific. N,N′-Bis(acryloyl)cystamine 
(BAC, 98%) was purchased from Alfa Aesar, Lancashire, UK, a subsidiary of Thermo 
Fisher Scientific, Waltham (Massachusetts), USA. 1,4-Dithiothreitol (DTT, 97%) was 
purchased from Manchester organics Ltd., Runcorn, UK, a subsidiary of Navin 
Fluorine International Ltd., Mumbai, India. Type I distilled water obtained from a 
water purification system with a resistivity of >18 MΩ cm−1 (PURELAB option R, 
Veolia). Spectra/por 2 (MWCO = 12-14 kDa) dialysis tubing was purchased from 
Spectrum Europe B.V., Breda, The Netherlands.  
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5.4.2. Synthesis of Degradable PolyNIPAM Nanogels 
The polyNIPAM nanogels were synthesized by dispersion polymerisation. The 
composition used in the synthesis of each nanogel can be found in table M.5.1. For the 
synthesis of the core, the NIPAM or NIPMAM monomer, BIS or BAC cross-linking 
agent and SDS surfactant were dissolved in distilled water in a 250 mL two-neck round 
bottom flask equipped with a stir bar and reflux condenser. This was then sealed and 
nitrogen was bubbled through the aqueous solution for 1 hour whilst stirring (400 rpm) 
to remove dissolved oxygen. The solution was then heated to 70 °C. Separately KPS 
initiator was dissolved in distilled water and degassed with N2 for 1 hour before being 
transferred to the flask containing the monomers. The reaction was maintained under 
a N2 atmosphere for 1 hours at 70 °C before further addition of the shell monomer, 
cross-linking agent and SDS which were separately sealed and degassed with nitrogen 
for 1 hour whilst stirring (400 rpm), and further KPS initiator. After a further 3 hours 
at 70 °C the solution was cooled down to room temperature. Where only a core was 
synthesized, the reaction was simply conducted for 4 hours to give the same total 
reaction time. To remove unreacted impurities, the nanogel suspension was dialyzed 
for 5 days using regenerated cellulose dialysis tubing (12-14 kDa MWCO, Spectrum 
Labs), replacing the distilled water every 12 hours. The purified suspension was then 
lyophilized (Virtis Benchtop K with ultra-low temperature condenser) and stored in a 
desiccator. 
For the kinetics study, the same reaction conditions were used, however samples were 
taken from the reaction at specific time intervals and terminated by immediately 
cooling the sample to 0 °C in and ice bath whilst simultaneously bubbling air into the 
solution. 
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Table M.5.1 Nanogel reactants composition. 
 Monomera 
(93 mol%) 
 BAC 
(5 mol%) 
 KPSb 
(2 mol%) 
 SDS 
 
 Waterd 
Sample NIMAM NIPAM  Core Shell  Core Shell  Core Shell  Core Shell 
 mol% mol%  mol% mol%  mol% mol%  mg mg  mL mL 
MAM/PAM CS 
100/0 
93 0  5 -  2 -  80 -  140 - 
MAM/PAM CS 
70/30 
65.1 27.9  3.5 1.5  1.4 0.6  56 24  98 42 
MAM/PAM CS 
50/50 
46.5 46.5  2.5 2.5  1 1  40 40  70 70 
MAM/PAM CS 
30/70 
27.9 65.1  1.5 3.5  0.6 1.4  24 56  42 98 
MAM/PAM CS 
15/85 
13.9 79.1  0.75 4.25  0.3 1.7  12 68  21 119 
PAM/MAM CS 
100/0 
0 93  5 -  2 -  80 -  140 - 
PAM/MAM CS 
50/50 
46.5 46.5  2.5 2.5  2.5 2.5  40 40  70 70 
PAM/MAM CS 
50/50 BIS 
46.5 46.5  2.5 2.5  2.5c 2.5  40 40  70 70 
PAM-BAC  93  5 -  2 -     140 - 
PAM-BIS  93  5 -  2 -     140 - 
a 34.7 mmol of total monomer used in synthesis  
b 9.38 mg/ml aqueous solution 
c 2.5 mol% BIS 
d 160 ml reaction volume, which includes a total addition of 20 ml aqueous KPS. 
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5.4.3. Characterisation of Degradable PolyNIPAM Nanogels 
Dynamic light scattering (DLS) measurements were performed at 25 °C with a 1 mg 
ml-1 nanogel dispersion using an equilibration time of 600 seconds, unless otherwise 
stated, with a Malvern Zetasizer Nano ZS (running Malvern Zetasizer software V7.12) 
(Malvern Instruments, Malvern, UK) with 633 nm He–Ne laser and the detector 
positioned at 173°. 1 cm path length disposable polystyrene cuvettes were used for 
measurements. Measurements were repeated in triplicate to give a mean Z-average 
diameter and polydispersity index (PdI) value. Adjustments of dispersion pH were 
made with NaOH and HCl solutions, and dispersion pH measurements were made with 
a HI-11310 pH Edge Electrode (HANNA Instruments, Bedfordshire, UK). 
5.4.4. Nanogel Degradation Studies 
Nanogels were degraded as a 1 mg ml-1 pH 10 aqueous dispersion using 150 mM DTT 
where immediate degradation was required, pH adjustments were made using 0.1M 
NaOH solution. DLS was used to measure the mean count rate of a degraded and 
non-degraded sample at the same attenuator value and measurement position. For long 
term monitoring of degradation, a 1 mg ml-1 pH 7 aqueous dispersion of the nanogels 
was used with 150 mM of DTT unless otherwise stated. The attenuator value was fixed 
at a value found to be suitable for the dispersion at the start of the degradation, and the 
measurement position of the laser was fixed at 4.65 mm (centre of the cuvette). For 
degradation over 6 hours, or at elevated temperatures, the measurement cuvette was 
sealed to prevent solvent evaporation over time. For the measurement on the sample 
held in a cuvette at 40 °C, which was transferred between an incubator and a DLS 
measuring chamber for measurements, the DLS sample chamber was preheated to 
40 °C for 10 minutes.
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5.5. Appendix 
 
 
Figure A.1 Stability of nanogel samples in PBS (1X strength, pH 7.4) with increasing 
temperature. Aggregation temperature reached when dramatic increase in hydrodynamic 
diameter observed. Hydrodynamic diameter provided by DLS measurements on a 1 mg ml-1 
PBS dispersion. 
 
 
 
Figure A.2 Reduction in count rate over time of MAM/PAM CS 50/50 as a 1 mg ml-1 pH 7 
aqueous dispersion in the presence of different concentrations of DTT. 
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6.1. Conclusions 
The main aim of this research was to investigate polyNIPAM nanogels for use as an 
in situ forming implant (ISFI). Three different solidification concepts were explored, 
and it was found that solidification to form a drug depot could be achieved using the 
combined dual stimulus of physiological temperature and ionic strength to trigger the 
aggregation of nanogel particles in a concentrated polyNIPAM nanogel dispersion to 
form a solid drug depot at the injection site. The nanogels were also able to rapidly 
and responsively aggregate at the injection site after being injected through a standard 
18G needle, resulting in a small burst release compared to other ISFI systems. This 
dual triggered solidification of polyNIPAM nanogels is a novel ISFI technology. 
Further research then expanded on this nanogel based ISFI to gain a greater 
understanding and further optimisation for its use as an ISFI. The system was able to 
meet the aims set out in the research objectives (Chapter 1, section 1.6), which could 
potentially allow it to be developed towards a commercially and clinically viable ISFI, 
whilst also potentially offering better performance than other ISFIs. The nanogel 
system was able to efficiently entrap a hydrophobic drug or solid drug nanoparticle 
(SDN) payload with a burst release as low as 0.5% of the cumulative release 
achievable. A high drug loading was also possible, with depots remaining 
mechanically stable with up to 66 wt% loading with SDNs. Drug release from the 
depot was also maintained for over 120 days in the in vitro release. This release rate 
could also be tuned, depending on the ratio of polyNIPAM and 
polyNIPAM-co-allylamine nanogel used in the depot formulation, or the size of the 
polyNIPAM nanogels used. The nanogels also presented no cytotoxicity in the limited 
preliminary studies conducted. Finally, nanogels created with a biodegradable 
di-sulphide cross-linking agent were demonstrated to be degradable in a physiological 
environment.  
Using polyNIPAM in its nanogel form also gave four important advantages for this 
ISFI. These are (1) the colloidal stability of nanogels can be tailored by their synthesis 
conditions, as such, so they can be synthesised so that they are no longer colloidally 
stable above the VPTT at increased ionic strength. This allows triggered aggregation 
to occurs via the dual triggers of the temperature and ionic strength of the depot 
injection site, (2) the large surface area of polyNIPAM nanogels compared to bulk 
hydrogels allows rapid aggregation at the depot site, entrapping the payload, and 
avoiding the larger burst release seen in the slow gelation of other ISFI systems, 
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(3) Incorporation of a comonomer in the nanogel synthesis allows easy tuning of the 
release rate of drug, (4) sheer thinning behaviour of the nanogel allows easy injection 
of the material. A short summary of each results chapter can be found below. 
6.1.1. Chapter 2 
Chapter 2 explored three concepts for in situ solidification of a polyNIPAM nanogel 
dispersion. These concepts were pH enhanced thermally triggered gelation to form a 
shrunken gel, charge based colloidal gel network formation, and dual temperature and 
ionic strength triggered aggregation. The comonomers allylamine and acrylic acid 
were successfully incorporated into the nanogel synthesis to give pH responsive and 
oppositely charged nanogels required for pH or charge based gelation. 
Polyvinylpyrrolidone (PVP) stabilised nanogels were used for these two gelation 
concepts in order to prevent aggregation of the nanogels at physiological temperature 
and ionic strength. However, PVP also appeared to disrupt the interactions between 
nanogels which allowed solidification via these mechanisms. Conversely, in the dual 
temperature and ionic strength triggered aggregation concept, PVP allowed 
aggregation of concentrated polyNIPAM nanogel dispersions when heated in the 
absence of the ionic strength trigger, which was undesirable. However, a concentrated 
dispersion of surfactant free nanogels and nanogels synthesised with sodium dodecyl 
sulphate (SDS) were shown to responsively aggregate only under the dual-stimuli of 
physiological ionic strength and temperature.  This behaviour allowed the rapid 
formation of an aggregate depot for drug delivery, as required to act as an ISFI. Hence 
the aggregation concept using surfactant free and SDS based nanogels were used in 
subsequent chapters for further testing and development as an ISFI. 
6.1.2. Chapter 3 
In Chapter 3, surfactant free polyNIPAM and polyNIPAM-co-allylamine nanogels of 
approximately 550 nm hydrodynamic diameter were successfully synthesised and 
characterised. As a concentrated dispersion these nanogels could be injected through 
an 18G needle into subcutaneous tissue and a subcutaneous tissue mimic to rapidly 
form an aggregate depot. They were also found to entrap a model payload of oil red 
dyed polystyrene particles upon aggregating to form a depot. The depot was found to 
vary in density and water content depending on the ratio of polyNIPAM to 
polyNIPAM-co-allylamine nanogels used. Poorly water soluble drug lopinavir (LPV) 
in either its powder or  SDN form were loaded into the depot for in vitro release studies. 
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This gave a tuneable drug release rate with polyNIPAM-co-allylamine nanogels giving 
a greater release rate. Sustained release from the depots was also possible for over 
120 days, with burst release as low as 0.5% for LPV, and 3.4% for the SDN form of 
the drug. Release was also shown to occur through Fickian diffusion of drug through 
the depot matrix. Finally no cytotoxicity was seen in ATP and MTT assays conducted 
on the nanogels. 
6.1.3. Chapter 4 
Chapter 4 focused on polyNIPAM nanogels of four different hydrodynamic diameters 
(65, 160, 310 and 450 nm). These were synthesised using dispersion polymerisation 
with different concentrations of SDS. As a dilute dispersion in water all the nanogels 
showed the same swelling ratio in response to temperature, and the same aggregation 
temperature in higher ionic strength phosphate buffered saline (PBS). As a 
concentrated dispersion it was shown that dramatic changes in the phase transitions 
and rheological properties were seen for different nanogel sizes at different 
temperatures and dispersion concentrations in water and PBS. Swollen gel, shrunken 
gel, liquid and  phase separated (aggregate) phases were all possible under specific 
combinations of temperature, solvent and dispersion concentration. The smallest 
nanogels PNA65 showed the most unusual phase and rheological behaviour, which 
was highly likely due to its different internal structure compared to the larger nanogels. 
Previous studies have shown a homogeneous internal structure for nanogels of this size 
(around 65 nm), compared to the increasing core-shell natured structure of the other 
nanogels with increasing size. When LPV SDNs were loaded into the nanogel depots 
in an in vitro release study, the release rate of drug from the nanogel depot was also 
tuneable by changing the size of the nanogel used to form the depot. The release rate 
of drug could also be tuned in a linear fashion by changing the % loading of SDN, or 
the size of the nanogel used to form the depot. All sizes of nanogel also gave a low 
burst release of <5% with a 50 wt% payload of LPV SDNs, and a sustained release of 
drug over the 15 days of the release experiment. The 65 nm diameter nanogels 
(PNA65) were found to be the most suitable of the different sized nanogels for an ISFI, 
as a depot with a 66 wt% loading of LPV SDN’s remained mechanically stable across 
the entire release period. Unlike the other nanogels, at a temperature below 35 °C and 
a high dispersion concentration these nanogels also remained a liquid rather than a 
swollen gel, which is easier to formulate with drug and inject through a needle. 
216 
 
 
CHAPTER 6 
6.1.4. Chapter 5 
Biodegradable nanogels were successfully synthesised using the cross-linking agent 
N,N’-bis(acryloyl)cystamine (BAC), which contains a degradable di-sulphide bond. 
These nanogels were synthesised using the monomers NIPAM or 
N-isopropylmethacrylamide (NIPMAM). Single monomer nanogels, and core-shell 
nanogels of the two different monomers were produced. The aggregation temperature 
of the core-shell nanogels was dependant on the ratio of each monomer used in the 
synthesis, as well as which monomer was used in the core and shell of the nanogel, 
with aggregation temperature being more sensitive to the LCST of the monomer used 
in the shell than the core. A nanogel was also synthesised which under physiological 
conditions contained a collapsed hydrophobic core, whilst also remaining colloidally 
stable due to its higher LCST shell (PAM/MAM CS 50/50). This may be useful for 
the delivery of poorly water-soluble drug. Degradation of the particles with the 
reductant dithiothreitol (DTT) was monitored over time using dynamic light scattering 
to monitor the mean count rate, hydrodynamic diameter and PdI of the sample. All 
nanogels synthesised were essentially fully degradable, despite only partial 
degradation seen in previous studies with different reaction times and temperatures.1,2 
This is likely due to shorter reactions times and lower temperatures, which is 
something that could be investigated further in the future. The degradation rate was 
shown to be strongly dependent on the temperature dependent swelling behaviour of 
the nanogels. Full degradation occurred in less than a day at 25 °C under reducing 
conditions, but over a week at 40 °C. Higher temperature causes the nanogels to 
deswell, so that the di-sulphide bonds are less accessible to water soluble reductants. 
This gives a much lower rate of degradation at a higher temperature, which would be 
required if a nanogel depots was to medicate a patient over a period of months. 
6.2. Future Work 
There are several areas where the research and development conducted could be 
expanded upon further. In Chapter 2, PVP appeared to prevent the colloidal 
interactions which allow the solidification of polyNIPAM nanogels triggered by a 
change in pH to form a shrunken gel, or through oppositely charged nanogels 
self-assembling into a gel. Versions of these nanogels could be synthesised without 
PVP, and despite the loss of colloidal stabilisation at physiological ionic strength 
without the steric stabilisation provided by PVP, may still be able to solidify into a gel 
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without aggregating. This would give alternative methods of solidification and a solid 
phase with different properties. The ISFI would consist of a shrunken gel like phase, 
potentially giving different drug release rates and biocompatibilities to the aggregate 
phase of an ISFI based on a nanogel aggregate depot.  
In Chapter 3 the delivery of the poorly water soluble drug LPV and the SDN form of 
the drug were demonstrated. Release of other drug payloads could be tested. This could 
include the combination of two or more drugs, as required in combination therapies 
such as those used to treat cancer,3 and HIV.4,5 Release of other nanomedicine delivery 
vehicles could also be tested.6,7 The release of hydrophilic drug, which would have a 
much lower affinity for the depot, and so potentially a much greater release rate could 
be explored. The biocompatibility of the nanogels could also be tested to a greater 
extent than the cytotoxicity assays performed in this chapter. The biocompatibility of 
implantable biomaterials covers a range of aspects which must be considered beyond 
simply looking at the biocompatibility of the biomaterial in question without 
considering the effects of injection and implantation. Inflammation, wound healing, 
and foreign body response should be considered alongside cytotoxicity of the 
biomaterials.8 Inflammation response has previously been observed in polyNIPAM in 
bulk hydrogel, reaching a peak after 30 days,9 so this could cause potential 
biocompatibility issues, which would need to be assessed in vivo. This inflammation 
response may be due to polyNIPAM having a more hydrophobic nature above the 
VPTT, as the more hydrophobic a polymer is, the more monocytic adhesion occurs,10 
which can induce inflammation and other unwanted effects.11 However, it is important 
to remember that although polyNIPAM is often described as hydrophobic above its 
LCST, it’s actually more accurate to consider it as partially dehydrated, as many 
studies have shown it is still surrounded by 20-50 wt% water.12 Hence it shouldn’t be 
assumed that the hydrophobicity of aggregates will cause biocompatibility issues. Due 
to the nanogels being nanoparticulate, phagocytosis may also occur, with particles in 
the size range of the polyNIPAM nanogels previously being demonstrated to be 
internalised by cells.13 This phagocytic activity could be investigated.14 
It was assumed in Chapter 4 that nanogels of different sizes synthesised with SDS had 
heterogeneous or homogeneous cross-linking density based on their size, as previously 
reported in literature.15–22 This could be confirmed using characterisation techniques 
such as small angle x-ray scattering,23 or multi angle light scattering,2 to determine the 
radius of gyration of the nanogels, giving the density distribution within the nanogels. 
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This could help substantiate the idea of the smallest nanogel (PNA65) having a low 
homogeneous cross-linking density, rather than a higher cross-linked core. This would 
help reinforce the proposal of the smaller nanogel particles having greater 
deformability and the associated difference in phase and rheological data. It is likely 
this was the cause of observations such as PNA65 existing as a liquid rather than 
swollen gel phase at high dispersion concentration and low temperature. Also the fact 
PNA65 had greater mechanical stability as a depot, where the smaller nanogels 
potentially deform around the payload to form a cohesive network unlike the larger 
less deformable nanogels. As the different sized nanogels showed different rates of 
release of hydrophobic drug, likely due to the size of the porous water filled pores in 
the matrix,24–26 it would also be useful to be able to measure the porosity and size of 
the pores to provide further evidence for the theory underpinning this observation. This 
could be done through techniques such as cryogenic SEM, AFM and mercury intrusion 
porosimetry.27 
In Chapter 5 BAC cross-linked nanogels were demonstrated to be fully degradable 
with the reduction agent DTT at different temperatures. However, a degradation 
experiment closer to in vivo conditions would be more desirable. The degradation on 
nanogels with GSH at 37 °C could be monitored in an aqueous dispersion using DLS 
to determine the timescale of degradation of nanogels under these conditions. More 
importantly, weight loss from an aggregate depot could be monitored over time, and 
an in vitro release experiment in the presence of a reducing agent could be conducted 
to find the effect of the degradation on the release rate of drug over time. The rate of 
polymer degradation could then be factored into a mathematical model which has 
previously been used to describe drug release from cylindrical depots based on both 
diffusion and degradation.28 The degraded fragments of polymer created from the 
nanogel degradation could also be analysed, to find the average molecular weight and 
branching of the degraded polymer fragments to determine how complete the 
degradation of the nanogels is. Analysis could be performed using a technique such as 
size exclusion (gel permeation) chromatography.29 Finally the degradable nanogels 
could be tested for specific applications. For example the concentration of the 
reductant GSH is often higher in tumour tissue,30 and so if the ISFI was injected at the 
site of a tumour, this might allow a responsive faster rate of local release of drug at the 
site of the tumour. This is because the tumour would be creating a higher concentration 
of GSH to enable faster degradation of the depot, and hence a higher drug release rate. 
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